dabigatran has been researched along with Stroke in 1227 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (1.30) | 29.6817 |
| 2010's | 909 (74.08) | 24.3611 |
| 2020's | 302 (24.61) | 2.80 |
| Authors | Studies |
|---|---|
| Cavillon Decaestecker, M; Decaestecker, K; Ferret, L; Gautier, S; Tsogli, ES; Verdun, S | 1 |
| Abdulsattar, W; Al-Abdouh, A; Alom, M; Assaly, R; Ayesh, H; Beran, A; Hamouda, D; Khuder, SA; Mhanna, M; Sajdeya, O; Srour, O | 1 |
| An, J; Duan, L; Huang, CW; Lee, MS; Sim, JJ | 1 |
| Barnett-Griness, O; Gronich, N; Kotler, A; Saliba, W; Stein, N | 1 |
| Ashton, V; Bunz, TJ; Coleman, CI | 1 |
| Attia, J; Bagepally, BS; Chaikledkaew, U; Chaiyakunapruk, N; McKay, G; Nathisuwan, S; Noviyani, R; Sritara, P; Thakkinstian, A; Youngkong, S | 1 |
| Everington, T; Husted, M; McKeague, L; Sly, D | 1 |
| Amin, AN; Auladell-Rispau, A; Barrios, V; Escobar, C; Lip, GYH; Requeijo, C; Salazar, J; Santero, M | 1 |
| Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Hernandez, I; Keshishian, A; Russ, C; Tsai, WL; Yuce, H | 1 |
| Durand, M; Renoux, C; Sinyavskaya, L | 1 |
| Guo, CL; Lee, APW; Shahzada, TS | 1 |
| Chu, H; Du, X; Feng, M; Fu, G; He, B; Liu, J; Wang, B; Wang, Z; Yu, Y; Zhuo, W | 1 |
| Brüggenjürgen, B; Gao, X; Marston, XL; Unverdorben, M; Wang, R; Ye, X; Yeh, YC; Zimmermann, L | 1 |
| Dong, W; Jiang, M; Nie, X; Zhou, H | 1 |
| Caldarola, P; Cipriani, M; Colivicchi, F; Corda, M; De Luca, L; De Nardo, A; Di Fusco, SA; Di Lenarda, A; Francese, GM; Gabrielli, D; Gulizia, MM; Mocini, D; Napoletano, C; Navazio, A; Oliva, F; Riccio, C; Roncon, L; Tizzani, E; Urbinati, S; Valente, S | 1 |
| Alvarez, P; Chaudhury, P; Desai, MY; Hanna, M; Kanj, M; Mentias, A; Moudgil, R; Nakhla, M | 1 |
| Chern, AKC; Choi, EK; Chutinet, A; Hanafy, DA; Jiampo, P; Lee, YS; Oh, YS; Trivedi, P; Zhai, D | 2 |
| Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C | 1 |
| Alioğlu, E; Altın, C; Bilgin, N; Çetin, N; Dalgıç, O; Ekmekçi, C; Kocabaş, U; Özpelit, ME; Pekel, N; Topaloğlu, C; Tülüce, K; Tunçer, E; Türk, UÖ; Türkoğlu, Eİ; Yavuz, V; Yüksel, K | 1 |
| Groll, A; Haefeli, WE; Meid, AD; Wirbka, L | 1 |
| Hill-McManus, D; Hughes, DA | 1 |
| de Vries, TI; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; Visseren, FLJ; Westerink, J | 1 |
| An, Y; Ieko, M; Kumano, O; Suzuki, S; Yamazaki, M; Yasaka, M | 1 |
| Aakerøy, R; Ellekjær, H; Hegstad, S; Helland, A; Kristoffersen, AH; Schjøtt, J; Spigset, O; Stokes, CL; Tomić, M | 1 |
| Babálová, L; Bolek, T; Dluhá, J; Hajaš, G; Kubisz, P; Kurča, E; Mokáň, M; Nosáľ, V; Petrovičová, A; Samoš, M; Sivák, Š; Škorňová, I; Stančiaková, L; Staško, J | 1 |
| Ciminata, G; Deidda, M; Geue, C; Kreif, N; Langhorne, P; Wu, O | 1 |
| Lomakina, V; Sozio, SJ; Tekle, J | 1 |
| Barnes, GD; Connors, JM; Cuker, A; Dawwas, GK | 1 |
| Gerner, ST; Kallmünzer, B; Macha, K; Plechschmidt, J; Schwab, S; Siedler, G; Stoll, S; Strasser, E; Wang, R | 1 |
| Bereznicki, LR; Bezabhe, WM; Kefale, AT; Peterson, GM | 1 |
| Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; Gurusamy, VK; Halperin, JL; Huisman, MV; Lip, GYH; Lohmann, R; Lu, S; Ma, CS; Rothman, KJ; Teutsch, C | 1 |
| Diener, HC; Dubner, SJ; Gurusamy, VK; Halperin, JL; Huisman, MV; Kotalczyk, A; Lip, GYH; Ma, CS; Marler, S; Rothman, KJ; Teutsch, C | 1 |
| da Silva, RMFL | 1 |
| Celestino Sobral Filho, D; de Barros Guimarães, AA; do Rego Barros, MC; Lima Filho, AIN | 1 |
| Murray, KT; Ray, WA | 1 |
| Gu, HQ | 1 |
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E; Tryggvason, G | 1 |
| Bowrin, K; Briere, JB; Cabeza, AIP; Escobar Cervantes, C; Gasche, D; Genís Gironès, M; Llorac Moix, A; Martí-Almor, J; Millier, A; Tardu, J; Toumi, M | 1 |
| Bang, OY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, MY; On, YK; Park, YJ; Ryu, J; Suh, HS | 1 |
| Cho, MS; Choi, KJ; Kang, DH; Kim, DH; Kim, J; Kim, M; Kim, SJ; Lee, S; Lee, SA; Nam, GB; Song, JM | 1 |
| Chan, ECY; Soh, XQ; Tan, DS | 1 |
| Atreja, N; Deitelzweig, S; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Luo, X; Schuler, P; Yuce, H; Zhang, Y | 1 |
| Alkhameys, S; Barrett, R | 1 |
| Csajka, C; Daali, Y; Fontana, P; Gaspar, F; Guidi, M; Reny, JL; Terrier, J | 1 |
| Chandrasegaram, A; Peters, CD | 1 |
| Ageno, W; Angiolillo, DJ; Barnes, GD; Bhatt, DL; Bikdeli, B; Connors, JM; Eikelboom, JW; Fanikos, J; Goldhaber, SZ; Jimenez, D; Kirtane, AJ; Krumholz, HM; Lip, GYH; Lippi, G; Lopes, RD; Mehran, R; Monreal, M; Parikh, SA; Piazza, G; Sadeghipour, P; Siegal, DM; Talasaz, AH; Weitz, JI; Zahedi Tajrishi, F | 1 |
| Bladin, CF; Brueckmann, M; Chutinet, A; Cronin, L; Del Brutto, VJ; Diener, HC; Easton, JD; Estol, CJ; Granger, CB; Grauer, C; Kleine, E; Lyrer, P; Molina, CA; Sacco, RL; Schellinger, PD; Toyoda, K | 1 |
| Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR | 1 |
| Asiimwe, A; Brobert, G; Morgan Stewart, H; Russell, B; Vora, P | 1 |
| Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Uchiyama, S; Wakayama, J; Yamashita, T; Yasaka, M | 1 |
| Chang, A; Harper, P; Stephens, M | 1 |
| Akhmatkhanova, LK; Cheboksarov, DV; Khamidova, LT; Klychnikova, EV; Kokov, LS; Kovaleva, EA; Muslimov, RS; Petrikov, SS; Ramazanov, GR; Rybalko, NV; Shamalov, NA | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, Q; Yu, M; Zong, L | 1 |
| Archontakis-Barakakis, P; Batsidis, A; Giamouzis, G; Giannakoulas, G; Giannopoulos, S; Kalaitzoglou, D; Kokkinidis, DG; Li, W; Lip, GYH; Manolopoulos, A; Ntaios, G; Palaiodimos, L; Tzelves, L | 1 |
| Ajao, A; Connolly, JG; Cosgrove, A; Eworuke, E; Kolonoski, J; Mohamoud, M; Shapira, O; Zhang, R | 1 |
| Anguita, M; Badimón, L; Bertomeu-Martínez, V; Cequier, Á; Esteve-Pastor, MA; Lip, GYH; López-Gálvez, R; Marín, F; Muñiz, J; Otero, D; Rivera-Caravaca, JM; Roldán-Rabadán, I; Ruiz-Ortiz, M | 1 |
| Al Kasasbeh, M; Al-Abdouh, A; Barbarawi, M; Barbarawi, O; Corcoran, J; Mhanna, M; Obeidat, K; Pickett, CC | 1 |
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E | 2 |
| Amin, A; Dina, O; Hines, DM; Keshishian, A; Le, H; Liu, X; Rosenblatt, L; Vo, L; Zhang, Q | 1 |
| Chaudhury, P; Desai, MY; Harb, S; Johnston, D; Kapadia, S; Menon, V; Mentias, A; Michael, M; Nakhla, S; Saad, M; Saliba, W; Svensson, L; Wazni, O | 1 |
| Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Guitard-Dehoux, D; Hanon, O; Jacoud, F; Mahé, I; Marant-Micallef, C; Née, M; Steg, PG; Van Ganse, E | 1 |
| Bansal, A; Eisele, CD; Jain, R; Julian, K; Mausteller, KG; Patel, P | 1 |
| Bai, Z; Chen, H; Cheng, G; Ning, H; Yang, N; Zhao, Y; Zou, M | 1 |
| Arora, P; Jayasekare, R; Muehrcke, M; Russell, M | 1 |
| Ktenopoulos, N; Lionaki, S; Rallidis, LS; Sagris, M; Theofilis, P | 1 |
| Burgos-Gonzalez, A; Huerta, C; Peñalver, MJ; Pulido, J; Sordo, L; Soriano, LC | 1 |
| Baker, L; Bartels, DB; Beier, L; Diener, HC; Dubner, SJ; França, LR; Halperin, JL; Huisman, MV; Lip, GYH; Lu, S; Lyrer, P; Ma, CS; Marler, S; Paquette, M; Rothman, KJ; Senges, J; Teutsch, C; Zint, K | 1 |
| Beyene, K; Chan, AHY; Gong, J; Hayes, M; Munevar Aquite, O; Schauer, C; Wei, H | 1 |
| Bani Hani, Z; S H Abrahim, M; Sofola-James, O | 1 |
| Björnsson, ES; Hreinsson, JP; Ingason, AB | 1 |
| Bielecka, B; Gorczyca-Głowacka, I; Wożakowska-Kapłon, B | 1 |
| Arioli, D; Athanasiou, A; Ballestri, S; Capitelli, M; Cappi, C; Coluccio, V; Di Girolamo, M; Marietta, M; Marrazzo, A; Romagnoli, E | 1 |
| Ali, AK; Duffield, S; Gatto, N; Gibbs, L; Govil, P; Jaksa, A; Jonsson, P; Kent, S; Kincaid, L; Patrick, AR; Rowark, S; Sharma, M | 1 |
| Belhassen, M; Cotte, FE; Dalon, F; Danchin, N; Gollety, S; Hanon, O; Jacoud, F; Mahé, I; Nolin, M; Steg, G; Van Ganse, E | 1 |
| Amado, DK; Borges-Junior, FA; Brucki, SMD; Calderaro, D; Caramelli, B; Caramelli, P; Cardozo, FAM; Escalante-Rojas, MC; Gualandro, DM; Magalhães, IR; Matheus, MG; Nitrini, R; Pastana, AF; Rodrigues, ACO; Spera, RR; Tavares, CAM; Yu, PC | 1 |
| Baborikina, A; Haritoncenko, I; Karelis, G; Kikule, I | 1 |
| Badve, SV; Deague, J; Dundon, BK; Hammett, C; Joseph, JE; Kerr, PG; Lo, S; Perkovic, V; Tran, HA; Wong, A | 1 |
| Kalka, I; Kornowski, R; Rossman, H; Segal, E; Talmor-Barkan, Y; Witberg, G; Yacovzada, NS | 1 |
| Arora, J; de Lusignan, S; Delanerolle, G; Emanuel, S; Fan, X; Feher, M; Field, BC; Heiss, C; Hobbs, FR; Joy, M; Kar, D; Pollock, KG; Sandler, B; Sheppard, JP; Williams, J | 1 |
| Ha, N; Hess, R; Mouland, E; Renner, E; Sutter-Long, D | 1 |
| Curis, E; Delrue, M; Foulon-Pinto, G; Gaussem, P; Gouin-Thibault, I; Guen, JL; Jourdi, G; Ketz, F; Lafuente-Lafuente, C; Lecompte, T; Mullier, F; Pautas, E; Puymirat, E; Rivière, L; Siguret, V; Tall, F | 1 |
| Anastassopoulou, A; Doobaree, IU; Fay, M; Gusto, G; Khachatryan, A; Manu, M; Mughal, F; Spentzouris, G; Zawaneh, Y | 1 |
| Borhani-Haghighi, A; Ghafari Darab, M; Goudarzi, Z; Hayatbakhsh, A; Jafari, M; Karimzadeh, I; Keshavarz, K; Vazin, A | 1 |
| Bortman, LV; Di Girolamo, G; Giorgi, MA; Gonzalez, CD; Mitchell, F; Naveiro, S; Pérez Morales, J | 1 |
| Atreja, N; Deitelzweig, S; Jenkins, A; Jiang, J; Kang, A; Keshishian, A; Lip, GYH; Schuler, P; Sun, X; Yuce, H | 1 |
| Ansell, J; Freedman, D; Siegal, DM | 1 |
| Matre, NB; McLaughlin, EM; Naik, KD; Rozycki, AJ; Whitson, BA | 1 |
| Chai-Adisaksopha, C; Hantrakool, S; Hantrakun, N; Niprapan, P; Norasetthada, L; Piriyakhuntorn, P; Punnachet, T; Rattanathammethee, T; Rattarittamrong, E; Tantiworawit, A; Thiankhaw, K; Wongcharoen, W | 1 |
| Atreja, N; Dhamane, AD; Di Fusco, M; Emir, B; Ferri, M; Gutierrez, C; Keshishian, A; Russ, C; Yuce, H | 1 |
| Aktan, A; Arslan, B; Aslan, B; Demir, M; Ertaş, F; Günlü, S; Güzel, T; Kılıç, R; Özbek, M | 1 |
| Ágústsson, AS; Björnsson, ES; Guðmundsdóttir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Önundarson, PT; Pálsson, DA; Reynisson, IE; Rumba, E | 1 |
| Björck, F; Jansson, M; Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Aigami, T; Fujii, S; Fukudo, M; Ishigo, T; Katano, S; Koyama, M; Takada, R; Yano, T | 1 |
| Cohen, D; Lavon, O | 1 |
| Malý, J; Moudallel, S; Rydant, S; Steurbaut, S; van den Eynde, C | 1 |
| Lee, B; Mahawish, KM; Shiu, S | 1 |
| Ashton, V; Berger, JS; Bookhart, B; Boudreau, J; Germain, G; Laliberté, F; Lefebvre, P; Lejeune, D; Weir, MR | 1 |
| Bindler, RJ; Caverley, ZR; Mendelson, S; Soh, P | 1 |
| Chaiyakunapruk, N; Nathisuwan, S; Nelson, RE; Nonthasawadsri, T; Syeed, MS | 1 |
| Frol, S; Kermer, P; Oblak, JP; Šabovič, M | 1 |
| Aronow, HD; Hume, AL; Lawal, OD; Matson, KL; Shobayo, F; Taveira, TH; Wen, X; Zhang, Y | 1 |
| Chan, EW; Knapp, MRJ; Li, HL; Wei, L; Wong, ICK; Yan, VKC | 1 |
| Andrade, JG; Fordyce, CB; Holmes, DN; Levin, A; Piccini, JP; Yao, RJR | 1 |
| Desai, NR; Dhruva, SS; Graham, DJ; Inselman, JW; Lee, JY; Ngufor, C; Noseworthy, PA; Polley, E; Ross, JS; Shah, ND; Siontis, KC; Yao, X | 1 |
| Altın, C; Aslan, O; Bilgel, ZG; Boyraz, B; Çakal, S; Çayırlı, S; Çoner, A; Coşgun, MS; Dal, A; Dalgıç, O; Demir, M; Doğduş, M; Erdoğan, A; Ergin, I; Genç, Ö; Güler, A; Güvendi Şengör, B; İbişoğlu, E; İlkay Yüce, E; Kaplan, M; Karabulut, D; Karabulut, U; Keskin Meriç, B; Kıvrak, T; Kocabaş, U; Murat, B; Murat, S; Naki Tekin, DD; Özçalık, E; Özdemir, I; Özgeyik, M; Özyurtlu, F; Şahin, Ş; Şen, T; Tüner, H; Urgun, ÖD; Uzman, O; Yavuz, V | 1 |
| Nakano, Y; Sairaku, A | 1 |
| De Backer, TL; Grymonprez, M; Ikram, MA; Lahousse, L; Petrovic, M; Steurbaut, S | 1 |
| Bae, YJ; Hwang, HJ; Jin, ES; Sohn, IS | 1 |
| Andreone, V; Anticoli, S; Barbarini, L; Biguzzi, S; Caggiula, M; Candelaresi, P; Caso, V; Cenciarelli, S; Colangeli, E; Concari, L; Cordici, F; De Angelis, MV; Dell'Aera, C; Diana, F; Digiovanni, A; Eusebi, P; Fortunata Musolino, R; Gentile, M; Giammello, F; Giannandrea, D; Giorli, E; La Gioia, S; Longoni, M; Mangiardi, M; Matteo, E; Migliaccio, L; Mosconi, MG; Muto, M; Naccarato, M; Paciaroni, M; Petruzzellis, M; Pronello, E; Ricci, S; Rizzo, F; Romoli, M; Ruggiero, M; Sacco, S; Scura, GM; Sepe, FN; Sessa, M; Toni, D; Zedde, ML; Zini, A | 1 |
| Al Qaraghuli, F; Fiedler-Kelly, J; Gonzalez, D; Powell, JR; Weiner, D | 1 |
| Chen, X; Dai, H; Du, X; Gu, P; Guan, C; Huang, N; Huang, X; Li, R; Lin, X; Liu, X; Liu, Y; Lv, M; Wu, T; Xu, W; Zhang, J; Zhang, M; Zhang, W; Zheng, Q; Zhu, Z | 1 |
| Ameriso, SF; Pujol Lereis, VA | 1 |
| Hayat, A; Själander, A; Wallvik, J | 1 |
| Ho, LT; Huang, CF; Jeng, JS; Kuo, CH; Lin, SY; Liu, YB; Peng, YF; Tang, SC; Tsai, LK | 1 |
| Alves da Silva, P; Caldeira, D; Pinto, FJ | 1 |
| Kwon, HM; Lee, YS; Moon, HS; Nam, KW; Won, SH | 1 |
| Achanta, A; Bhalodia, NJ; Cheng, J; Coons, JC; Deri, CR; Heiney, H; Iasella, CJ; Marchionda, O; Stahl, K; White, EM | 1 |
| Blanchon, T; Conte, C; Gosselin, L; Hanslik, T; Lapeyre-Mestre, M; Launay, T; Rossignol, L; Saint-Salvi, B; Sarazin, M; Souty, C; Steichen, O; Turbelin, C; Vilcu, AM | 1 |
| Apolinario, M; Firth, C; Keddis, MT; Lim, ES; Shamoun, F; Zhang, N | 1 |
| Chung, CP; Daugherty, JR; Dickson, AL; Dupont, WD; Hung, AM; Murray, KT; Ray, WA; Smalley, W; Stein, CM; Zimmerman, E | 1 |
| Ilc, S; Mavri, A | 1 |
| Atreja, N; Bell, G; Cato, M; Cheng, D; DeKoven, M; Divino, V; Hernandez, I; Hines, DM; Hood, DW; Kariuki, W; Russ, C; Xie, L | 1 |
| Brinkmann, M; Diener, HC; Eschenfelder, CC; Gröschel, K; Grosse, GM; Hüsing, A; Kuklik, N; Michalski, D; Nabavi, D; Poli, S; Royl, G; Sparenberg, P; Stang, A; Weimar, C; Weissenborn, K | 1 |
| Chen, J; Ma, F; Xu, W; Zhang, J | 1 |
| Bechler, K; Callahan, A; Shah, N; Xu, Y | 1 |
| Chen, K; Chen, X; Chen, Z; Ju, J; Li, Q; Ma, D; Tian, W; Wang, T; Wang, X; Xu, H; Zhang, J | 1 |
| Alt, E; Bessette, LG; Kim, DH; Mahesri, M; Najafzadeh, M; Schneeweiss, S; Shin, H; Wang, SV | 1 |
| An, J; Cheetham, TC; Lang, DT; Lee, MS; Luong, T; Reynolds, K | 1 |
| Brunetti, ND; D'Angelo, A; De Gennaro, L; Derosa, G; Gaudio, G; Gavazzoni, M; Maffioli, P; Maggi, A; Pasini, G; Raddino, R; Rizzo, M | 1 |
| Eikelboom, JW; Weitz, JI | 2 |
| Baiardi, G; Cafaro, A; Cangemi, G; Caviglia, MC; Mattioli, F; Poeta, MG; Stella, M | 1 |
| Yin, E | 1 |
| Chan, YH; Fong, KY; Lip, GYH; Tan, VH; Yeo, C | 1 |
| Chilbert, MR; Goriacko, P; Jacobs, D; Saber, M; Sinnet, M; Woodruff, AE | 1 |
| Gao, J; Miao, L; Shi, D; Shi, J; Song, L; Yu, H; Zhu, C | 1 |
| Ago, T; Kitayama, J; Ogata, T; Okata, T; Wakisaka, Y; Yoshioka, T | 1 |
| Cera, M; Comi, G; Cozzani, G; Della Bella, P; Gaspardone, C; Godino, C; Leo, G; Maisano, F; Margonato, A; Mattiello, P; Melillo, F; Montorfano, M; Nemola, G; Parlati, AL; Russi, A; Salerno, A; Sparasci, FM; Tresoldi, M; Vetrugno, L; Zangrillo, A | 1 |
| Gu, ZC; Lin, HW; Liu, BL; Ma, EL; Pan, MM; Wang, J; Wang, X; Wu, B; Zhang, C | 1 |
| Assouline, S; Cohen, C; Cohen, S; Dhanjal, TS; Dib, JC; Dievart, F; Durand, P; Garban, T; Guedj-Meynier, D; Guenoun, M; Hoffman, O; Lellouche, N; Lequeux, B; Ouazana, L; Parrens, E; Pradeau, V; Sabouret, P; Schwartz, J; Sharareh, A; Villaceque, M | 1 |
| Alghamdi, B; Alhuwail, A; Alkhathami, S; Alkredees, M; Almalki, T; AlNasser, M; Alotaibi, W; Alqahtani, B; Alsaeed, O; Alsalem, T; Alshahrani, F; Alshreem, A; Alzahrani, Y; Asiri, A; Assiri, A; Ayoub, M; Bakkari, A; Basndwah, H; Ibrahim, ARN; Khudari, A; Mustafa, M; Sultan, H; Tawhari, F; Zaitoun, M | 1 |
| Berry, SD; Daiello, LA; Hayes, KN; Kiel, DP; Kim, DH; Lee, Y; Zhang, T; Zullo, AR | 1 |
| Al-Hussainy, N; Kragholm, KH; Lip, GYH; Lundbye-Christensen, S; Pareek, M; Riahi, S; Therkelsen, SK; Torp-Pedersen, C | 1 |
| Huang, KC; Lee, JK; Lin, DS; Lin, TT; Lo, HY | 1 |
| Chang, YM; Chen, CH; Hsieh, MT; Lin, PY; Lin, SH; Liu, CH; Sung, PS; Wang, CM | 1 |
| Albendín Iglesias, H; Arregui Montoya, F; Bailén Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Lova Navarro, A; Manzano-Fernández, S; Pascual Figal, DA | 1 |
| Balabanova, Y; Brobert, G; Fatoba, S; García Rodríguez, LA; Martín-Pérez, M; Roberts, L; Ruigomez, A; Schaefer, B; Suzart-Woischnik, K; Vora, P | 1 |
| Casajuana, M; Giner-Soriano, M; Morros, R; Roso-Llorach, A; Vedia, C | 1 |
| Beauchesne, LM; Bouma, BJ; Khairy, P; Macle, L; Mongeon, FP; Mulder, BJM; Schwerzmann, M | 1 |
| Bernard, MA; Blin, P; Dallongeville, J; Droz-Perroteau, C; Dureau-Pournin, C; Fauchier, L; Lassalle, R; Moore, N; Sacher, F | 1 |
| Blin, P; de Pouvourville, G; Karam, P | 1 |
| Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ | 1 |
| Eschler, CM; Exadaktylos, AK; Funk, GC; Lindner, G; Maier, V; Walter, P; Woitok, BK | 1 |
| Lai, TH; Lai, YJ; Lin, YT | 1 |
| Diener, HC; Dubner, SJ; França, LR; Halperin, JL; Huisman, MV; Lip, GYH; Lu, S; Ma, CS; Nieuwlaat, R; Olshansky, B; Paquette, M; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; França, LR; Halperin, JL; Huisman, MV; Lip, GYH; Lu, S; Ma, CS; Mazurek, M; Paquette, M; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Chao, TF; Chen, SA; Chen, TJ; Chiang, CE; Liao, JN; Lip, GYH | 1 |
| Jansson, M; Norrving, B; Renlund, H; Själander, A; Själander, S; Sjögren, V | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Kanorskii, SG | 2 |
| Bartels, DB; Gopalakrishnan, C; Gurusamy, VK; Huybrechts, KF; Landon, J; Schneeweiss, S; Zint, K | 1 |
| Kaneko, N; Ohtani, T; Sintoku, R; Yajima, T | 1 |
| Goyal, N; Mowla, A; Sadighi, A; Seiffge, DJ; Shahjouei, S; Tsivgoulis, G; Wang, M; Zand, R | 1 |
| Lip, GYH; Mujovic, N; Potpara, TS | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Chu, YB; Dong, SJ; Gupta, P; Li, YH; Wu, B; Zhai, SD; Zhang, YJ | 1 |
| Drabik, L; Potpara, T; Undas, A | 2 |
| Ghanima, W; Halvorsen, S; Jonasson, C; Rutherford, OW; Söderdahl, F | 2 |
| Abdalla, Y; Abraham, A; Althaus, K; Becks, G; Berrouschot, J; Berthel, J; Bode, FJ; Burghaus, L; Cangür, H; Daffertshofer, M; Diener, HC; Edelbusch, S; Eggers, J; El-Sabassy, H; Eschenfelder, CC; Gerlach, R; Grond, M; Gröschel, K; Große-Dresselhaus, F; Günther, A; Haase, CG; Haensch, CA; Harloff, A; Heckmann, JG; Held, V; Hieber, M; Kauert, A; Kermer, P; Kern, R; Kerz, T; Köhrmann, M; Kraft, P; Kühnlein, P; Latta, J; Leinisch, E; Leithner, C; Lenz, A; Mäurer, M; Müllges, W; Neumann-Haefelin, T; Nolte, CH; Obermann, M; Partowi, S; Patzschke, P; Poli, S; Pulkowski, U; Purrucker, J; Rehfeldt, T; Ringleb, PA; Rossi, R; Röther, J; Sarnowksi, BV; Sauer, O; Schackert, G; Schäfer, N; Schellinger, PD; Schneider, A; Schuppner, R; Schwab, S; Schwarte, O; Seitz, RJ; Senger, S; Shah, YP; Sindern, E; Sparenberg, P; Steiner, T; Szabo, K; Urbanek, C; Weissenborn, K; Wienecke, P; Witt, K; Wruck, R; Wunderlich, S | 1 |
| Boissier, E; Bourcier, R; Dargazanli, C; Desal, H; Gory, B; Kyheng, M; L'Allinec, V; Labreuche, J; Lapergue, B; Mazighi, M; Roy, M; Sibon, I | 1 |
| Chaiyakunapruk, N; Dilokthornsakul, P; Hollingworth, W; Jahan, NK; Kongpakwattana, K; Lai, NM; Nathisuwan, S; Ng, SS | 1 |
| Aimo, A; De Caterina, R; Petricciuolo, S | 1 |
| Buda, S; Degli Esposti, L; Perrone, V; Piovaccari, G; Saragoni, S | 1 |
| Bao, Y; Hua, W; Jin, Q; Ke, M; Lin, C; Ling, T; Pan, W; Quan, J; Wei, Y; Wu, L; Xie, Y; Zhang, N | 1 |
| Huang, Y; Liang, H; Rong, G; Wang, H; Wang, L | 1 |
| Hsu, JY; Huang, HK; Lin, SM; Liu, PP; Loh, CH; Peng, CC; Wang, JH | 1 |
| Alvarez, P; Asleh, R; Briasoulis, A; Chrischilles, E; Gao, Y; Inampudi, C; Leira, EC; Vaughan-Sarrazin, M | 1 |
| Brown, J; Diaby, V; Kim, S; Lingineni, K; Pham, PN; Schmidt, S; Wang, CY | 1 |
| Dias, FA; Pontes-Neto, OM; Seiffge, DJ | 1 |
| Barber, PA; Ranta, A; Wu, TY | 1 |
| Chaturvedi, S; Mehndiratta, P | 1 |
| Benavente, OR; Buck, B; Butcher, KS; Coutts, SB; Field, TS; Gioia, LC; Hart, RG; Hill, MD; Klahr, AC; Miller, J; Ng, K; Sharma, M; Sheridan, P; Siddiqui, M; Sivakumar, L | 1 |
| Atarashi, H; Fukaya, T; Inoue, H; Koretsune, Y; Okumura, K; Taniguchi, A; Uchiyama, S; Yamashita, T; Yasaka, M | 2 |
| Ishigaku, Y; Kamada, A; Maeda, T; Narumi, S; Natori, T; Oi, K; Oura, K; Shimizu, M; Terayama, Y; Tsuda, K; Yoshida, M | 1 |
| Božič-Mijovski, M; Detkova, N; Frol, S; Gradišek, P; Gregorič, M; Kosi, IE; Mavri, A; Nedog, V; Stecher, A; Uštar, KK; Vene, N; Žerjav, U | 1 |
| Beharry, J; Campbell, BCV; Drew, R; Fink, JN; Kleinig, TJ; Parsons, MW; Waters, MJ; Wilson, D; Wu, TY | 1 |
| Dąbrowska-Kugacka, A; Daniluk, P; Lasocka, Z; Lewicka, E; Nabiałek-Trojanowska, I; Zarzycka, E; Zaucha, JM | 1 |
| Ho, KH; Leng, G; van Hove, M | 1 |
| Benczur, B; Bergler-Klein, J; Ciernik, M; Gotcheva, N; Medvedchikov, A; Napalkov, D; Põder, P; Simic, D; Skride, A; Tang, W; Trusz-Gluza, M; Vesely, J; Vinereanu, D; Vishnepolsky, T; Vrabec, M | 1 |
| Acar, RD; Akgün, T; Camm, AJ; Emren, V; Kanat, S; Karacağlar, E; Kepez, A; Kul, Ş; Özel, E; Şimşek, E; Tülüce, K; Türk, UÖ; Yakar Tülüce, S | 1 |
| Liu, X; Xu, ZX; Yu, P; Yuan, P; Zhu, WG | 1 |
| Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y | 1 |
| Alrohimi, A; Buck, B; Butcher, K; Dowlatshahi, D; Kalashyan, H; Ng, K; Shamy, M; Sharma, M; Shuaib, A; Sivakumar, L; Stotts, G; Thirunavukkarasu, S | 1 |
| Bauersachs, J; Berliner, D; Flierl, U; Schäfer, A | 1 |
| Brooks, MM; Glynn, NW; Hernandez, I; Saba, S; Yang, L; Zhang, Y | 1 |
| Berteotti, M; Casciaro, MA; Ettorre, E; Godino, C; Lip, GYH; Marcucci, R; Melillo, F; Menafra, V; Menichelli, D; Pastori, D; Perticone, F; Pignatelli, P; Saliola, M; Sciacqua, A; Violi, F | 1 |
| Böhm, M; Brueckmann, M; Eikelboom, JW; Ezekowitz, M; Fräßdorf, M; Hijazi, Z; Hohnloser, SH; Mahfoud, F; Schmieder, RE; Schumacher, H; Wallentin, L; Yusuf, S | 1 |
| Ashurov, AB; Khagush, AL; Kiseleva, MV; Novikova, TN; Plotnikova, MO; Podoprigora, EA; Sayganov, SA | 1 |
| Bar, M; Bernstein, RA; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Gdovinová, Z; Granger, CB; Grauer, C; Kleine, E; Kleinig, TJ; Lyrer, P; Martins, S; Meyerhoff, J; Milling, T; Pfeilschifter, W; Poli, S; Reif, M; Rose, DZ; Sacco, RL; Šaňák, D; Schäbitz, WR | 1 |
| Balusson, F; Bouget, J; Lacut, K; Maignan, M; Nowak, E; Oger, E; Pavageau, L; Roy, PM; Scailteux, LM | 1 |
| Chan, EW; Cheung, CL; Lam, JKY; Lau, WCY; Lee, ACH; Lip, GYH; Man, KKC; Sing, CW; Siu, CW; Wong, ICK | 1 |
| Ahmed, N; Barbarini, L; Escudero-Martinez, I; Fryze, W; Gdovinova, Z; Karlinski, M; Kobayashi, A; Krastev, G; Lesko, N; Mazya, M; Paiva Nunes, A; Pasztoova, K; Peeters, A; Sobolewski, P; Teutsch, C; Toni, D; Vilionskis, A | 1 |
| Liu, X; Sun, Y; Xu, Y | 1 |
| Hironobe, N; Kihara, Y; Matsumura, H; Nakano, Y; Onohara, Y; Sairaku, A | 1 |
| Arellano-Rodrigo, E; Barrios, V; Donado, E; Escobar, C; Fernández-Dueñas, J; Garrido, RR; Gómez-Doblas, JJ; Rodríguez, JP; Sánchez, JU | 1 |
| Andersen, PS; Bruun, NE; Bundgaard, H; Butt, JH; Fosbøl, EL; Gerds, TA; Gislason, GH; Iversen, K; Køber, L; Larsen, AR; Olesen, JB; Petersen, A; Skov, RL; Torp-Pedersen, C; Verhamme, P | 1 |
| Douketis, J; Kaplovitch, E; Shaw, JR | 1 |
| García-Sempere, A; Hurtado, I; Peiró, S; Rodríguez-Bernal, CL; Sanfélix-Gimeno, G; Santa-Ana-Téllez, Y | 1 |
| Belhassen, M; Cotté, FE; Dalon, F; Danchin, N; Falissard, B; Gollety, S; Hanon, O; Jacoud, F; Lefevre, C; Mahé, I; Nolin, M; Steg, PG; Van Ganse, E | 1 |
| Fomin, VV; Kogay, VV; Listratov, AI; Napalkov, DA; Skripka, AI; Sokolova, AA | 1 |
| Abdullaev, SP; Mirzaev, KB; Sychev, DA | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, AL; Keshishian, AV; Li, X; Lip, GYH; Luo, X; Mardekian, J; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Bergler-Klein, J; Chuquiure-Valenzuela, E; Diener, HC; Dubner, SJ; Halperin, J; Huisman, MV; Lip, GYH; Lu, S; Ma, CS; Paquette, M; Riou França, L; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Aakjaer, M; Andersen, M; De Bruin, ML; Gardarsdottir, H; Heeke, A; Huerta, C; Klungel, OH; León-Muñoz, LM; Merino, EM; Montero, D; Rottenkolber, M; Schmiedl, S; Souverein, PC; van den Ham, HA | 1 |
| Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J | 1 |
| Afriyie, A; Berger, SE; Deshpande, S; Di Fusco, M; Earley, A; Kang, A; Lopes, RD; Mantovani, LG; Russ, C | 1 |
| Edwards, JK; Lund, JL; Poole, C; Simpson, RJ; Stürmer, T; Webster-Clark, M | 2 |
| Darius, H | 2 |
| Katus, HA; Kraft, M; Nietfeld, J; Schlund, D; Schmidt, C; Thomas, D; Wiedmann, F | 1 |
| Co, COC; Domingo, AMC; Iboleon-Dy, MAM; Ilano, KCS; Laxamana, LC; Macrohon-Valdez, MCZ; Mojica, CV; Yu, JRT | 1 |
| Ahn, JH; Cha, TJ; Choi, EK; Choi, JI; Han, S; Hwang, J; Hwang, KW; Kim, DK; Lee, SR; Lee, YS; Park, HS; Park, JS; Shin, DG | 1 |
| Jin, H; Wang, L; Zhi, H; Zhou, W; Zhu, K | 1 |
| Cao, ZC; Dong, Y; Huang, ZC; Jia, HY; Li, CQ; Liu, TL; Liu, XY; Sun, JJ | 1 |
| Corica, B; Proietti, M; Romiti, GF | 1 |
| Frol, S; Hudnik, LK; Oblak, JP; Šabovič, M; Sernec, LP | 1 |
| Bazan-Socha, S; Dropiński, J; Pacholczak-Madej, R; Undas, A; Zaręba, L | 1 |
| Bao, HH; Cheng, XS; Ding, CC; Hu, LH; Li, MH; Zhan, BM; Zhou, W | 1 |
| Caprini, JA; Clark, NP; Douketis, J; Kaplovitch, E; Li, N; MacDougall, K; Schulman, S; Spyropoulos, AC; Tafur, AJ | 1 |
| Chan, EW; Chan, KWK; Chen, JY; Choi, CW; Fan, K; Feng, Y; Hai, JJ; Huang, D; Jim, MH; Lam, CC; Lam, H; Lau, YM; Lee, KL; Ng, A; Siu, CW; Tam, CCF; Tan, N; Wong, CK; Wong, YTA; Yan, BP; Yiu, KH; Yung, CY; Yung, SYA; Zhou, M | 1 |
| Eikelboom, JW; Eriksson, N; Ezekowitz, MD; Granger, CB; Hijazi, Z; Lindbäck, J; Lopes, RD; Oldgren, J; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Aucella, F; Barcellona, D; Brunori, G; Forneris, G; Genovesi, SC; Grandone, E; Gresele, P; Marietta, M; Poli, D; Testa, S; Tripodi, A | 1 |
| Basic-Jukic, N; Furic-Cunko, V; Juric, I | 1 |
| Ahn, SH; Cho, HJ; Choi, HY; Choi, JK; Han, SW; Heo, JH; Jung, YH; Kang, YJ; Kim, WJ; Kim, YD; Kwon, JH; Lee, KY; Nam, HS; Park, HJ; Park, JH; Seo, JH; Sung, SM | 1 |
| Moullaali, TJ; Parry-Jones, AR; Ziai, WC | 1 |
| Jang, E; Joung, B; Kim, D; Kim, JY; Kim, TH; Lee, MH; Lip, GYH; Pak, HN; Sung, JH; Uhm, JS; Yang, PS; Yu, HT | 1 |
| Fanning, L; Lau, WCY; Man, KKC; Mongkhon, P; Wong, ICK; Wong, KHTW | 1 |
| Andreoli, L; Barcellona, D; Cafolla, A; De Micheli, V; Denas, G; Falanga, A; Fierro, T; Gerosa, M; Ghirarduzzi, A; Gresele, P; Hoxha, A; Martinelli, I; Pengo, V; Prisco, D; Silvestri, E; Testa, S; Tincani, A; Tosetto, A | 1 |
| Gerasimenko, AS; Gorbatenko, VS; Shatalova, OV | 1 |
| Atić, A; Hadžibegović, I; Hulak Karlak, V; Jurin, I; Lucijanić, M; Magličić, A; Šakić, Z; Starčević, B | 1 |
| Ali, H; Balla, C; Bonitta, G; Briani, M; Cappato, R; Chiarito, M; Furlanello, F; Giustozzi, M; Lodigiani, C; Lupo, P; Riva, L; Stefanini, G | 1 |
| Bertoletti, L; Cucherat, M; Durieu, I; Grange, C; Grenet, G; Gueyffier, F; Kilo, R; Laporte, S; Lega, JC; Mainbourg, S; Mismetti, P; Nony, P; Provencher, S | 1 |
| Hardy, LJ; Khan, AA; Lau, YC; Lip, GYH; Philippou, H; Shantsila, E | 1 |
| Bereznicki, LR; Bezabhe, WM; Curtain, C; Peterson, GM; Radford, J; Salahudeen, MS; Wimmer, BC | 1 |
| Carney, G; Durand, M; Eltonsy, S; Filion, KB; Fisher, A; Jun, M; Kuo, IF; Matteau, A; Pang, M; Paterson, JM; Quail, J; Renoux, C; Schnitzer, ME | 1 |
| Dvorackova, S; Jirsova, E; Kolar, J; Kubena, AA; Mala-Ladova, K; Maly, J; Steurbaut, S; Zimcikova, E | 1 |
| Bang, OY; Choi, HY; Han, S; Jang, SW; Kang, S; Kim, YH; Lee, JM; Lee, MY; On, YK; Park, YJ; Suh, HS; Won, MM | 1 |
| Ishizawa, K; Mitsuboshi, S; Niimura, T; Zamami, Y | 1 |
| Medlicott, NJ; Reith, DM; Simpson, BH; Smith, AJ | 1 |
| Avorn, J; Gagne, JJ; Kesselheim, AS; Rome, BN | 1 |
| Lee, EM; Tan, VH; Tan, YC; Tiew, WJ; Wong, VL | 1 |
| Bernardini, F; Marchetti, G; Romoli, M; Urbinati, S | 1 |
| Chao, TF; Chen, SJ; Chen, TJ; Jiang, YR; Liao, JN; Tsai, CT | 1 |
| Brahmbhatt, B; Devani, K; Radadiya, D; Reddy, C | 1 |
| Vauzelle, C | 1 |
| Cui, C; Cui, X; Li, D; Liu, Y; Wei, H | 1 |
| Hung, CS; Li, HJ; Lin, FJ; Lin, SY; Wang, CC | 1 |
| Ghaznavi, Z; Jackevicius, CA; Lu, L; Warner, AL | 1 |
| Lorenzoni, V; Pirri, S; Turchetti, G | 1 |
| Chen, W; Jiang, S; Lv, C; Lv, M; Wu, L; Wu, T; Zhang, J | 1 |
| Chen, S; Dong, Y; He, J; Lip, GYH; Liu, C; Wu, D; Ye, Z; Zhu, W | 1 |
| Arita, T; Nagahama, T; Nagai, K; Otsuka, T; Suzuki, S; Tanaka, T; Yagi, N; Yamashita, T | 1 |
| Di Fusco, M; Friend, K; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Thomas, L; Yuce, H | 1 |
| Cappelleri, JC; Deitelzweig, S; Di Fusco, M; Gutierrez, C; Kang, A; Keshishian, A; Mokgokong, R; Savone, M | 1 |
| Altay, S; Aşkın, L; Beşli, F; Çakmak, HA; Canpolat, U; Gedikli, Ö; Pehlivanoğlu, S; Şahin, M; Sinan, ÜY; Ünlü, S; Yanık, A | 1 |
| Ashton, R; Buck, J; Fromings Hill, J; Ghosh, B; Lee, G; Martin, A; Orlowski, A; Springate, C | 1 |
| Chen, HY; Chou, KJ; Huang, CW; Lee, PT; Lin, PC; Ou, SH; Su, YC | 1 |
| Aguiar de Sousa, D; Bendszus, M; Caria, J; Coutinho, JM; Dentali, F; Diener, HC; Ferro, JM; Huisman, H; Jansen, O; Kobayashi, A; Miede, C; Neto, LL | 1 |
| Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH | 1 |
| Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, SR; Lip, GYH; Oh, S | 1 |
| Ashton, V; Berger, JS; Jung, Y; Kharat, A; Laliberté, F; Lefebvre, P; Lejeune, D; Moore, KT | 1 |
| Böhm, M; Brueckmann, M; Connolly, S; Eikelboom, JW; Ewen, S; Ezekowitz, M; Millenaar, D; Schumacher, H; Slawik, J; Ukena, C; Wallentin, L; Yusuf, S | 1 |
| Chang, RY; Hu, YF; Huang, CY; Lee, CW; Lee, TM; Liu, ME; Yeh, HI | 1 |
| Cannegieter, SC; Huisman, MV; Klok, FA; Lijfering, WM; Rosendaal, FR; Teichert, M; van der Meer, FJM; van Rein, N; Zielinski, GD | 1 |
| Duvanova, SP; Filimonov, KM; Gorbunova, EV; Makarov, SA; Mamchur, SE | 1 |
| Antz, M; Camm, AJ; Collins, R; Cornu, P; Desteghe, L; Haeusler, KG; Heidbüchel, H; Oldgren, J; Potpara, T; Reinecke, H; Roldan-Schilling, V; Rowell, N; Sinnaeve, P; Steffel, J; Vanassche, T | 1 |
| Dong, YX; Gao, LJ; Li, WW; Ma, CM; Wang, N; Xia, YL; Xiao, XJ; Yang, MH; Yin, XM; Yu, XH; Zhang, RF | 1 |
| Benczur, B; Bergler-Klein, J; Ciernik, M; Gotcheva, N; Medvedchikov, A; Napalkov, D; Põder, P; Simić, D; Skride, A; Tang, W; Trusz-Gluza, M; Vesely, J; Vinereanu, D | 1 |
| Anoopkumar-Dukie, S; Badrick, T; Bernaitis, N | 1 |
| Deitelzweig, S; Dhamane, AD; Jiang, J; Kang, A; Keshishian, A; Klem, C; Lip, GYH; Luo, X; Mardekian, J; Rosenblatt, L; Yuce, H | 1 |
| Alatawi, Y; Alghamdi, BS; Alshehri, FS; Balabagno, AO; Chen, Y; Durmanova, V; Evangelista, LS; Hromadka, T; Javor, J; Ji, Q; Jiao, J; Kralova, M; Kurdi, M; Labban, S; Li, X; Li, Y; Lv, Q; Minarik, G; Ocenasova, A; Pagsibigan, JS; Parnicka, Z; Reznakova, V; Shawkatova, I; Shen, ZJ; Tian, X; Tu, S; Tuazon, JA; Vaseckova, B; Wang, XY; Wang, Z; Xue, Y; Zeng, LX; Zhang, S; Zhang, ZH; Zuo, C | 1 |
| Dasgupta, K; Godin, R; Nedjar, H; Rahme, E; Tagalakis, V | 1 |
| Anderson, A; Eworuke, E; Gassman, A; Hou, L; Huang, TY; Moeny, D; Waldron, P; Wong, HL; Zhang, R | 1 |
| Akpan, IJ; Cuker, A | 1 |
| Bradley, SM; Gosch, KL; Hess, PL; Jani, SM; Maddox, TM; Michael Ho, P; Varosy, PD; Virani, SS | 1 |
| Cook, BM; Kanaan, DM; Kelly, J; Malloy, R | 1 |
| Atar, D; Rubboli, A | 1 |
| Bennie, M; Forslund, T; Hallas, J; Haug, U; Hellfritzsch, M; Hjemdahl, P; Karlstad, Ø; Kjerpeseth, LJ; Klungel, OH; Kollhorst, B; Komen, JJ; Mantel-Teeuwisse, AK; Mueller, T; Olesen, M; Pottegård, A; Schink, T; Voss, A; Wettermark, B | 1 |
| Cui, X; Guo, M; Thai, S; Wang, T; Wei, J; Xu, W; Zhao, Y; Zhou, J | 1 |
| Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M | 1 |
| Diener, HC; Dubner, SJ; Hall, C; Halperin, JL; Huisman, MV; Kalejs, O; Lip, GYH; Lyrer, P; Ma, CS; Rothman, KJ; Teutsch, C; van der Wall, SJ; Zhai, D; Zint, K | 1 |
| Chaudhry, UA; Ezekowitz, MD; George, WT; Gracely, EJ; Harper, G; Harper, GR; Wolfe, CM | 1 |
| Abdelgawwad, K; Brescia, CW; Coleman, CI; Costa, OS; O'Donnell, B; Sood, N; Vardar, B | 1 |
| Al-Khalili, F; Ehrenstein, V; Ghanima, W; Gislason, G; Halvorsen, S; Hohnloser, SH; Jenkins, A; Johnsen, SP; Linder, M; Madsen, M; Sulo, G; Tell, GS | 1 |
| Abenhaim, L; Benichou, J; Davy, JM; Dialla, O; Ferrières, J; Grimaldi-Bensouda, L; Le Heuzey, JY; Leys, D; Martinez, M; Nighoghossian, N; Nordon, C; Smadja, D; Touzé, E | 1 |
| Ma, S; Mei, H; Wang, J | 1 |
| Caughey, GE; Li, RJ; Shakib, S | 1 |
| Jiang, H; Jiang, Y; Lv, J; Ma, H; Zeng, H | 1 |
| Chen, CY; Chu, CC; Huang, YL | 1 |
| Cornu, P; Dupont, A; Moudallel, S; Steurbaut, S | 1 |
| Atripaldi, U; Bottino, R; Cattaneo, D; Clementi, E; Giannetti, L; Laezza, N; Russo, V | 1 |
| Ikusaka, M; Ishizuka, K; Mori, T; Yokokawa, D | 1 |
| Ader, J; Desai, NR; Jones, PG; Reinhardt, SW; Spertus, JA; Tang, Y | 1 |
| Chen, J; Chen, M; Fang, Z; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J | 1 |
| Biss, B; Brouwer, MA; Calkins, H; Gerstenfeld, EP; Grimaldi, M; Guiver, K; Hohnloser, SH; Nordaby, M; Okumura, K; Schilling, R; Serota, H; Verma, A; Willems, S | 1 |
| Ammann, P; Blum, S; Conen, D; Di Valentino, M; Erne, P; Kühne, M; Moschovitis, G; Osswald, S; Schläpfer, J; Shah, D; Sticherling, C; Tabord, A; Vogt, C; Zimny, M | 1 |
| Chan, EW; Cheung, CL; Lam, JK; Lau, WC; Lee, AC; Lip, GY; Man, KK; Sing, CW; Siu, CW; Wong, IC | 1 |
| Burden, AM; de Boer, A; de Vries, F; Ebbelaar, C; Schalekamp, T; Souverein, P; Stolk, LM; Ten Cate-Hoek, A | 1 |
| Connolly, SJ; Eikelboom, JW; Hirsh, J; Quinlan, DJ; Weitz, JI | 1 |
| Bhave, PD; Chrischilles, E; Girotra, S; Giudici, M; Hodgson-Zingman, D; Mazur, A; Palamaner Subash Shantha, G; Vaughan Sarrazin, MS | 1 |
| Bissig, D; Manjunath, R; Ng, KL; Richman, DP; Traylor, BR | 1 |
| Colquhoun, D; Freedman, B; Ortiz, M; Simons, LA; Waterhouse, BJ | 1 |
| Chan, KA; Chen, HM; Lai, CL; Liao, MT; Lin, TT | 1 |
| Bai, Y; Lip, GYH; Shantsila, A | 1 |
| Arias-Jaramillo, DR; Gaviria-Mendoza, A; Machado-Alba, JE | 1 |
| Barkun, AN; Dorreen, A; Huynh, T; Martel, M; Miller, CS | 1 |
| Schwartz, JB | 1 |
| Alexander, JH; Lopes, RD; Vora, AN | 1 |
| Lim, WS; Zhao, YJ | 1 |
| Graham, DJ; Kelman, JA; Wernecke, M | 1 |
| He, J; Nordling, MM; Tireli, D; Wienecke, T | 1 |
| Bonde, AN; Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Olesen, JB; Sindet-Pedersen, C; Staerk, L | 1 |
| Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E | 1 |
| Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M | 1 |
| Abdalla, Y; Althaus, K; Berrouschot, J; Cangür, H; Daffertshofer, M; Diener, HC; Edelbusch, S; Eschenfelder, CC; Grond, M; Gröschel, K; Haase, CG; Harloff, A; Held, V; Kauert, A; Kermer, P; Kraft, P; Lenz, A; Müllges, W; Obermann, M; Partowi, S; Purrucker, J; Ringleb, PA; Rossi, R; Röther, J; Schäfer, N; Schneider, A; Schuppner, R; Seitz, RJ; Szabo, K; Wruck, R | 1 |
| Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
| Cei, M; Dentali, F; Giorgi-Pierfranceschi, M; Mastroiacovo, D; Mumoli, N; Tamborini-Permunian, E; Vitale, J | 1 |
| Angeli, F; Brueckmann, M; Connolly, SJ; Di Pasquale, G; Ezekowitz, MD; Kleine, E; Lip, GYH; Mazzotta, G; Reboldi, G; Verdecchia, P; Wallentin, L; Yusuf, S | 1 |
| Abugattas de Torres, JP; Brugada, P; Chierchia, GB; Choudhury, R; Coutino-Moreno, HE; de Asmundis, C; De Regibus, V; Iacopino, S; Longobardi, M; Mugnai, G; Storti, C; Stroker, E; Takarada, K | 1 |
| Alamiri, K; Novak, JE; Yee, J | 1 |
| Benavente, O; Butcher, K; Coutts, SB; Field, TS; Gioia, L; Hill, MD; Ng, KH; Sharma, M | 1 |
| Bowen, JM; Burke, N; Campbell, K; Holbrook, A; Jegathisawaran, J; Tarride, JE | 1 |
| Gersh, BJ; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F | 1 |
| Ansell, J; Fonarow, GC; Gersh, BJ; Hylek, E; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Shrader, P; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Aiello, A; Aspromonte, N; Colivicchi, F; Di Fusco, SA; Santini, M; Tubaro, M | 1 |
| Amin, A; Baser, O; Dina, O; Keshishian, A; Le, H; Liu, X; Mardekian, J; Rosenblatt, L; Trocio, J; Vo, L; Zhang, Q | 1 |
| Andrews, G; Annavarapu, S; Costantino, ME; Gandhi, PK; Ghate, SR; Moretz, C; Reynolds, SL; Sander, S; Sheer, R; Wang, C | 1 |
| Arora, P; Gandhi, P; Gilligan, AM; Henriques, C; Sander, S; Smith, DM; Song, X; Wang, C | 1 |
| Alberts, MJ; Bunz, TJ; Coleman, CI; Peacock, WF | 1 |
| Fosbøl, EL; Gadsbøll, K; Gislason, GH; Gundlund, A; Køber, L; Lamberts, M; Olesen, JB; Staerk, L; Vinding, NE | 1 |
| Sugiyama, T | 1 |
| Chan, EW; Lau, WCY; Wong, ICK | 1 |
| Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM | 1 |
| Jolobe, OM | 1 |
| Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ | 1 |
| Jolobe, OMP | 1 |
| Lip, GYH; Rivera-Caravaca, JM | 1 |
| Lip, GYH; Makaritsis, K; Michel, P; Ntaios, G; Papavasileiou, V; Vemmos, K | 1 |
| Gersh, BJ; Hargraves, I; Montori, VM; Noseworthy, PA; Shah, ND; Yao, X | 1 |
| Cossey, TC; Grotta, JC; Reddy, ST; Savitz, SI | 1 |
| Alonso, A; Norby, FL | 1 |
| Alla, F; Billionnet, C; Maura, G; Pariente, A | 1 |
| Valent, F | 1 |
| Cao, Q; Jacobs, MS; Jansman, FGA; Postma, MJ; Tieleman, RG; van Hulst, M; van Leent, MWJ | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Spencer, C; Ziemann, U; Zuern, CS | 1 |
| Gandhi, P; Gilligan, AM; Henriques, C; Sander, S; Smith, DM; Song, X; Wang, C | 1 |
| Fogerty, AE; Oertel, LB | 1 |
| Agosti, S; Casalino, L; Rocci, E; Rota, E; Zaccone, G | 1 |
| Golaszewski, SM; Pikija, S; Sebastian Mutzenbach, J; Sellner, J; Sztriha, LK | 1 |
| An, SJ; Kim, CK; Kim, TJ; Ko, SB; Nam, KW; Oh, K; Yoon, BW | 1 |
| Curtice, T; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Luo, X; Mardekian, J; Menges, B; Trocio, J | 1 |
| Brown, JD; Shewale, AR; Talbert, JC | 2 |
| Bonde, AN; Fosbøl, EL; Gerds, TA; Gislason, GH; Lamberts, M; Lip, GYH; Olesen, JB; Ozenne, B; Staerk, L; Torp-Pedersen, C | 2 |
| Deger, KA; Gandhi, P; Kansal, AR; Peng, S; Qiao, N; Ustyugova, A; Wang, C | 1 |
| Hernandez, I; Saba, S; Zhang, Y | 2 |
| Borne, RT; Hess, PL; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Masoudi, FA; O'Donnell, C; Turakhia, MP; Varosy, PD | 1 |
| Alonso, A; Bengtson, LGS; Chamberlain, AM; Chen, LY; Lutsey, PL; MacLehose, RF; Norby, FL; Rapson, I | 1 |
| Chenoweth, JA; Holmes, JF; Johnson, MA; Nishijima, DK; Shook, L; Sutter, ME | 1 |
| Diener, HC; Dubner, SJ; Halperin, JL; Huisman, MV; Lip, GYH; Lu, S; Ma, CS; Nieuwlaat, R; Paquette, M; Riou França, L; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Baldi, M; Ciconte, G; Conti, M; Pappone, C; Saviano, M; Vicedomini, G | 1 |
| Bansal, VK; Choi, MJ; Herzog, CA; Jaar, BG; Kramer, H; Mehta, R; Rocco, MV; Sarnak, MJ | 1 |
| Akyüz, A; Başaran, Ö; Berilgen, R; Çelik, O; Çetin, N; Coşar, S; Dereli, Y; Doğan, T; Doğan, V; Emren, SV; Enhoş, A; Ergene, O; Gürsul, E; İnci, S; Karaca, I; Karaca, Ö; Köseoğlu, C; Levent, F; Onrat, E; Otlu, YÖ; Özdemir, İH; Özmen, Ç; Sümerkan, M; Zoghi, M | 1 |
| Babiarz, A; Bodys, A; Budnik, M; Filipiak, KJ; Gawałko, M; Kapłon-Cieślicka, A; Kochanowski, J; Opolski, G; Peller, M; Scisło, P; Uliński, R; Żochowski, M | 1 |
| Collings, SL; Evans, D; Hack, G; Johnson, ME; Lefèvre, C; Maguire, A; Stynes, G | 1 |
| Alla, F; Billionnet, C; Gagne, JJ; Maura, G; Pariente, A | 1 |
| Chaturvedi, S; Diener, HC; Hohnloser, SH; Molina, CA; Selim, MH | 1 |
| Kanai, Y; Matsuda, H; Mitaki, S; Oguro, H; Onoda, K; Tahara, N; Takayoshi, H; Yamaguchi, S | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Lane, DA; Oldgren, J; Proietti, M; Roldan, V; Wallentin, L; Yusuf, S | 1 |
| Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M | 1 |
| Cheetham, TC; Gagne, JJ; Go, AS; Goulding, MR; Graham, DJ; Houstoun, M; Izem, R; Mott, K; Reichman, ME; Singer, DE; Southworth, MR; Sung, SH; Toh, S; Zhang, R | 1 |
| Grove, EL; Hellfritzsch, M; Pottegård, A | 1 |
| Beshir, SA; Chee, KH; Lo, YL; Sim, S; Yap, LB | 1 |
| Anguita, M; Asunción Esteve-Pastor, M; Bertomeu, V; Cequier, A; Marín, F; Martínez-Sellés, M; Muñiz, J; Raña Míguez, P; Roldán, I; Ruiz Ortiz, M | 1 |
| Akitsu, K; Fujino, T; Ikeda, T; Koike, H; Koike, M; Shinohara, M; Suzuki, T; Yao, S; Yuzawa, H | 1 |
| Ahn, Y; Cho, JG; Cho, JY; Hong, YJ; Hyun, DY; Jeong, MH; Kim, JH; Kim, KH; Kim, MC; Kim, Y; Lee, KH; Lee, N; Oh, SS; Park, HJ; Park, HW; Park, JC; Sim, DS; Won, J; Yoon, HJ; Yoon, NS | 1 |
| Engebretsen, EH; Myrstad, M; Tveit, A; Vandvik, I | 1 |
| Cao, F; Henk, HJ; Mardekian, J; Odell, K; Patel, C; Price, K; Sands, GH; Singh, P; Singhal, S; Tan, W; Trocio, J; Tuell, K; Vo, L | 1 |
| Bahrmann, P; Christ, M | 1 |
| Ishikawa, T; Moroi, J; Nakase, T | 1 |
| Levanov, AN; Sinitsina, II; Sychev, DA; Tsomaya, IV; Vardanyan, AV | 1 |
| Elder, J; Fu, AC; Jain, R; Lim, J; Sander, SD; Tan, H; Wang, C | 1 |
| Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM | 1 |
| Cheng, HM; Hsu, CC; Hsu, PF; Huang, CJ; Sung, SH; Tu, ST; Yu, BH | 1 |
| Boo, YL; Hoo, FK; Koh, KW; Kolanthaivelu, J; Ng, YP; P'ng, HS; Roslan, A; Yap, LB; Yap, SH | 1 |
| De Maistre, E; Derex, L; Gouin-Thibault, I; Gruel, Y; Sie, P; Susen, S; Touzé, E | 1 |
| Jesus, PAP; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG | 1 |
| Gil, M; Webster, E | 1 |
| Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S | 1 |
| Fischer, MA; Franklin, JM; Gagne, JJ; Glynn, RJ; Huybrechts, KF; Schneeweiss, S; Wang, SV | 1 |
| Gil-Guillén, V; Gracia-Diez, C; Hermida-Campa, E; Márquez-Contreras, E; Márquez-Rivero, S; Martell-Claros, N; Sanchez-López, E | 1 |
| Cannon, CP; Lip, GYH; Oldgren, J | 1 |
| Karnieg, T; Wang, X | 1 |
| Dekkers, T; Kramers, C; Lafeber, M | 1 |
| Baduashvili, A; Evans, AT | 1 |
| Asmar, J; Bizouard, G; Collings, SL; Duhot, D; Fauchier, L; Johnson, ME; Lefèvre, C; Maguire, A; Mouquet, F; Stynes, G; Vannier-Moreau, V | 1 |
| Jones, WS; Piccini, JP | 1 |
| Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S | 1 |
| Chan, SC; Chan, ST; Fong, CS; Fong, WC; Kwok, VW; Lo, WT; Ng, KF; Wong, GC | 1 |
| Choudhry, NK; Gagne, JJ; Najafzadeh, M; Schneeweiss, S; Wang, SV | 1 |
| Bączek, M; Gorczyca, I; Jelonek, O; Kośmider, P; Wożakowska-Kapłon, B | 1 |
| Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S | 1 |
| Kyle, A; McBain, L | 1 |
| Balsam, P; Bednarski, J; Maciejewski, K; Opolski, G; Ozierański, K; Peller, M; Praska-Oginska, A; Szepietowska, K; Tymińska, A; Zaboyska, I; Zaleska, M; Żukowska, K | 1 |
| Arteaga, C; Combes, E; Foucher, S; Mallecourt, C; Renard, A; Wilhlem, L | 1 |
| Ago, T; Kitazono, T; Makihara, N; Morita, T; Ohya, Y; Takaba, H; Wakisaka, K | 1 |
| Ashley, J; Sood, MM | 1 |
| Chi, NF; Chien, LN; Chien, SC; Ko, Y; Wang, Y | 1 |
| Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L | 1 |
| Escobar, C; Martí-Almor, J; Martínez-Zapata, MJ; Pérez Cabeza, A | 1 |
| Harper, P; Pollock, D; Stephens, M | 1 |
| Fang, CW; Hsiao, YJ; Lin, FY; Lu, CH; Tsai, LK; Tsai, YT; Yen, PS | 1 |
| Brich, J; Geisen, U; Harloff, A; Heck, D; Hieber, M; Hollasch, H; Mächtel, M; Niesen, WD | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; Elsaesser, A; Halperin, JL; Huisman, MV; Lip, GYH; Lu, S; Ma, CS; Paquette, M; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Bunz, TJ; Coleman, CI; Martinez, BK; Sood, NA | 1 |
| Armeni, M; Bendini, MG; Caldarone, E; D'Emidio, S; Fusco, A; Leggio, M; Lombardi, M; Mazza, A; Mereu, D; Severi, P | 1 |
| Haas, K; Heuschmann, PU; Khan, S; Purrucker, JC; Rizos, T; Siedler, T; Veltkamp, R; Wolf, M | 1 |
| Kamble, S; Kawabata, H; Lip, GYH; Mardekian, J; Masseria, C; Pan, X; Phatak, H | 1 |
| Garzon, J; Jaramillo, L; Mendoza, L; Mendoza-Sanchez, J; Quiroga, A; Rangel, L; Silva, F | 1 |
| Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y | 1 |
| Belenkov, YN; Khabarova, NV; SHakaryants, GA | 1 |
| Banach, M; Covic, A; Lopatowska, P; Malyszko, J; Mlodawska, E; Sobkowicz, B; Tomaszuk-Kazberuk, A | 1 |
| Baser, O; Di Fusco, M; Friend, K; Gupta, K; Hamilton, M; Jones, WS; Keshishian, A; Li, X; Lopes, RD; Luo, X; Mardekian, J; Masseria, C; Pan, X; Steffel, J | 1 |
| Černík, D; Herzig, R; Jakubíček, S; Kunáš, Z; Mikulík, R; Ostrý, S; Reif, M; Rohan, V; Šaňák, D; Tomek, A; Veverka, T | 1 |
| Andrews, GA; Annavarapu, S; Arora, P; Gandhi, PK; Li, Y; Moretz, C; Sander, SD; Wang, C | 1 |
| Burke, C; Collins, R; Coughlan, T; Egom, EE; McAuliffe, C; McHugh, J; Moore, D; Morrissey, E; O'Brien, J; Pharithi, RB; Ranganathan, D; Ryan, D; Vaughan, M | 1 |
| Bittinger, L; Curtis, C; Pol, D; Ramkumar, S | 1 |
| Durand, M; Johnson, S; Matteau, A; Sinyavskaya, L | 1 |
| Bereczki, D; May, Z; Pásztor, M; Szakács, Z | 1 |
| Bangdiwala, SI; Berwanger, O; Biccard, BM; Botto, F; Chaudhry, NK; Connolly, SJ; de Nadal, M; Devereaux, PJ; Duceppe, E; Eikelboom, JW; Erb, J; Franzosi, MG; Guyatt, G; Hoeft, A; Iglesias, PP; Kearon, C; Magloire, P; Mayosi, B; Meyhoff, CS; Neary, J; Pettit, S; Rahate, PV; Rao, M; Rao-Melacini, P; Rodseth, R; Sessler, DI; Sharma, M; Srinathan, SK; Szczeklik, W; Tandon, V; Villar, JC; Vincent, J; Xavier, D; Yusuf, S | 1 |
| Grutters, JPC; Maas, AHEM; Rolden, HJA; van der Wilt, GJ | 1 |
| Andersson, NW; Lund, M; Melbye, M; Pasternak, B; Svanström, H | 1 |
| Bohn, J; Cosgrove, A; Desai, RJ; Gagne, JJ; Jin, Y; Karami, S; Kennedy, A; Kim, C; Kim, J; Major, JM; Niman, A; Ouellet-Hellstrom, R; Toh, S; Wang, SV; Wyss, R | 1 |
| Chang, Y; Crowther, M; Holbrook, A; Larsen, TB; Levine, MAH; Li, G; Lip, GYH; Mbuagbaw, L; Sun, X; Tang, J; Thabane, L; Witt, DM | 1 |
| Dobrev, D; Fender, AC | 1 |
| Chrapek, M; Janion-Sadowska, A; Papuga-Szela, E; Undas, A; Łukaszuk, R | 1 |
| Campbell, BC; Coote, S; Davis, SM; Donnan, GA; Easton, D; Jones, B; Ng, F; Ng, JL; Parsons, M; Pesavento, L; Rodrigues, E; Yan, B; Zhao, H | 1 |
| Krug, K; Laux, G; Peters-Klimm, F; Schwill, S; Szecsenyi, J; van Lieshout, J; Wensing, M | 1 |
| Caponi, C; Cenciarelli, S; Gallina, A; Giannandrea, D; Marando, C; Marsili, E; Mastrocola, S; Mazzoli, T; Mengoni, A; Padiglioni, C; Ricci, S; Romoli, M; Sacchini, E | 1 |
| Bai, Y; Carmo, J; Esteve-Pastor, MA; Lip, GYH; Marín, F; Orenes-Piñero, E; Proietti, M; Rivera-Caravaca, JM; Roldán, V; Romanazzi, I; Romiti, GF | 1 |
| Avnery, O; Battat, E; Derazne, E; Dotan, SG; Ellis, MH; Hammerman, A | 1 |
| Earl, KM; Jamali, F; Leblanc, K; Semchuk, W; Weitz, JI | 1 |
| Ariansen, I; Ellekjær, H; Furu, K; Kjerpeseth, LJ; Selmer, R; Skovlund, E | 1 |
| Ando, D; Hosoki, S; Koga, M; Takagi, M; Toyoda, K; Yamagami, H | 1 |
| Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kitazawa, H; Okabe, M; Sato, T; Takahashi, M | 1 |
| Domanovits, H; Frossard, M; Gremmel, T; Niessner, A; Pabinger, I; Sengölge, G; Steinlechner, B; Sycha, T; Wolzt, M | 1 |
| Kido, K; Ngorsuraches, S | 1 |
| Bowrin, K; Briere, JB; Coleman, C; Fauchier, L; Folkerts, K; Levy, P; Millier, A; Taieb, V; Toumi, M; Wu, O | 1 |
| Aljohani, MM; Alsager, OA; Chinnappan, R; Cialla-May, D; Eissa, S; Popp, J; Weber, K; Zourob, M | 1 |
| Dannenberg, L; Kelm, M; Petzold, T; Polzin, A; Wolff, G; Zeus, T | 1 |
| Deng, JF; Yip, L | 1 |
| Franchino-Elder, J; Gilligan, AM; Henriques, C; Sainski-Nguyen, A; Sander, S; Smith, DM; Song, X; Wang, C; Wilson, K | 1 |
| Agnelli, G; Aita, A; Angeli, F; Becattini, C; Cavallini, C; Conti, S; Giustozzi, M; Molini, G; Turturiello, D; Vedovati, MC; Verdecchia, P | 1 |
| Fang, CW; Hsiao, YJ; Tsai, LK; Tsai, YT | 1 |
| Chu, F; Derry, K; Hailey, L; Meyer, D | 1 |
| Lip, GYH | 1 |
| Hiremath, JS; Trailokya, A | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Huang, RJ; Jin, C; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Andersen, M; Braunschweig, F; Forslund, T; Hjemdahl, P; Komen, JJ; Mantel-Teeuwisse, AK; von Euler, M; Wettermark, B | 1 |
| An, GV; Belenkov, YN; Khabarova, NV; SHakaryants, GA | 1 |
| Aoki, J; Kanamaru, T; Kimura, K; Matsumoto, N; Mishina, M; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Sekine, T; Shimoyama, T; Suda, S; Suzuki, K | 1 |
| Ansell, JE; Blanco, R; Fonarow, GC; Freeman, JV; Gersh, BJ; Go, AS; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Naccarelli, G; Peterson, ED; Piccini, JP; Pokorney, SD; Reiffel, JA; Singer, DE; Thomas, LE; Washam, JB | 1 |
| Chang, SH; Chu, PH; Kuo, CF; Tseng, HJ; Wang, CL; Wen, MS; Wu, VC | 1 |
| Braunschweig, F; Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wallén, H | 1 |
| Abdulsattar, Y; Kamble, S; Lip, GYH; Mardekian, J; Masseria, C; Petkun, W; Phatak, H; Tepper, PG | 1 |
| Alcusky, M; Fisher, M; Goldberg, RJ; Hume, AL; Lapane, KL; McManus, DD; Tjia, J | 1 |
| Alvarez-Madrazo, S; Bennie, M; Mueller, T; Robertson, C; Wu, O | 1 |
| Abouelfath, A; Bénichou, J; Blin, P; Cottin, Y; Droz, C; Dureau-Pournin, C; Lassalle, R; Mismetti, P; Moore, N | 1 |
| Chu, HM; Fang, RY; Fu, GH; Gao, F; Liu, J; Yu, YB | 1 |
| Cannegieter, SC; Huisman, MV; Klok, FA; Lijfering, WM; Rosendaal, FR; Teichert, M; Zielinski, GD | 1 |
| Cheon, K; Cho, HJ; Choi, HY; Han, SW; Heo, JH; Jung, YH; Kim, YD; Lee, HS; Lee, KY; Nam, HS; Park, HJ; Park, JH | 1 |
| Fanaroff, AC; Ohman, EM | 1 |
| Hirakawa, T; Ishida, K; Koretsune, Y; Kuroki, D; Ono, Y; Sumida, T; Urushihara, H; Yamashita, T; Yasaka, M | 1 |
| Jala, S; O'Brien, E | 1 |
| Baker, CL; Dhamane, AD; Dina, O; Lin, J; Lingohr-Smith, M; Mardekian, J; Menges, B; Nadkarni, A; Rosenblatt, L; Russ, C | 1 |
| Ahmad, A; Evans, A; Oh, K; Petrini, M; Rush, T; Schwartzman, E; Tang, W; Thompson, D; Villines, TC | 1 |
| Bonde, AN; Fosbøl, EL; Gislason, GH; Køber, L; Lamberts, M; Olesen, JB; Rørth, R; Torp-Pedersen, C; Vinding, NE | 1 |
| Gottsäter, A | 1 |
| Wallentin, L | 1 |
| Oldgren, J | 1 |
| Frol, S; Pretnar Oblak, J; Sabovic, M | 1 |
| Baser, O; Deitelzweig, S; Friend, K; Gupta, K; Hamilton, M; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Masseria, C; Nadkarni, A; Pan, X | 1 |
| Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M | 1 |
| Cipriano, LE; Hachinski, V; Lee, SAW; Ruiz Vargas, E; Sposato, LA | 1 |
| Akamatsu, Y; Hayashi, T; Kameyama, M; Karibe, H; Narisawa, A | 1 |
| Chen, CL; Chen, HM; Chen, LA; Chen, PL; Chou, PC; Fang, CW; Hsieh, CY; Li, YH; Lu, CM; Shih, YS; Sun, MC; Tsai, YT; Tsao, CR; Yeh, JT | 1 |
| Jeng, JS; Kuo, CH; Lin, SY; Shen, LJ; Tang, SC; Tsai, LK; Yeh, SJ | 1 |
| Guo, X; Liu, Y; Sun, Z; Xu, Y; Zhang, Y | 1 |
| Joung, B; Kim, JY; Kim, TH; Kim, YH; Lee, MH; Pak, HN; Park, J; Shim, J; Uhm, JS; Yu, HT | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Arakawa, K; Endo, T; Fukui, K; Himeno, H; Ishikawa, T; Kikuchi, S; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okuda, J; Sakamaki, K; Sawada, R; Shigemasa, T; Shimizu, M; Sugano, T; Takamura, T; Tamura, K; Tsukahara, K; Tsunematsu, T | 1 |
| Banchelli, F; Boriani, G; D'Amico, R; Guazzaloca, G; Magrini, N; Malavasi, VL; Manotti, C; Marietta, M; Pattacini, C; Pavesi, P; Quintavalla, R; Sinigaglia, T; Urbinati, S; Voci, C | 1 |
| Chaudhury, P; Mentias, A; Shantha, G; Vaughan Sarrazin, MS | 1 |
| Bosch, F; Cerdá, M; Cerezo-Manchado, JJ; Fernández, M; Johansson, E; Martínez, F; Rodríguez, S; Santamaría, A; Varela, A | 1 |
| Huang, Y; Que, D; Wang, L; Wu, S; Xie, S; Xu, Y; Yau, TO | 1 |
| Rubboli, A | 1 |
| Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R | 1 |
| Young, M | 1 |
| Chao, AC; Chen, CF; Chou, PS; Ho, BL; Hu, HH; Lin, RT; Lin, SF; Lin, YJ | 1 |
| Bartels, DB; Franklin, JM; Gopalakrishnan, C; Huybrechts, KF; Kulldorff, M; Schneeweiss, S; Zint, K | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Jesus, P; Monteiro, JMC; Oliveira Filho, J; San-Martin, DL; Silva, BCG; Souza, IFB | 1 |
| Ariano, C; De Vecchis, R | 1 |
| Chan, YH; Chang, SH; Chen, SW; Kuo, CF; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Cha, MJ; Choi, EK; Kim, HM; Kwon, JM; Lee, SY; Oh, S; Park, CS | 1 |
| Breuer, L; Engelhorn, T; Kallmünzer, B; Macha, K; Marsch, A; Schwab, S; Siedler, G; Strasser, EF | 1 |
| Arcadi, FA; Calabrò, RS; Casella, C; Genovese, C; Giorgianni, R; Marino, S; Naro, A; Portaro, S | 1 |
| Brown, JD; Pham, PN | 1 |
| Basic, E; Hohnloser, SH; Nabauer, M | 1 |
| Amin, A; Baker, CL; Carda, E; Dhamane, A; Dina, O; Keshishian, A; Mardekian, J; Nadkarni, A; Rosenblatt, L; Russ, C; Yuce, H | 1 |
| Gawarikar, Y; Patel, R; Ting, A; Venkat, AR | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GYH; Mauri, L; Miede, C; Montalescot, G; Nordaby, M; Oldgren, J; Ozkor, M; Steg, PG; Ten Berg, JM; Vardas, P | 1 |
| Pickett, JD | 1 |
| Cha, MJ; Choi, EK; Joung, B; Kang, KW; Kim, C; Kim, H; Kim, J; Kim, JB; Kim, TH; Lee, JM; Lee, YS; Park, HW; Park, J; Park, JK; Shim, J; Uhm, JS | 1 |
| Medlicott, NJ; Reith, D; Simpson, BH; Smith, A | 1 |
| Alings, M; Connolly, SJ; Dorresteijn, JAN; Eikelboom, JW; Peters, RJG; Stam-Slob, MC; van der Graaf, Y; van der Leeuw, J; Visseren, FLJ | 1 |
| Caughey, G; Duszynski, K; Kalisch Ellett, LM; Kerr, M; Pratt, NL; Ramsay, E; Roughead, EE; Shakib, S | 1 |
| Herkes, G; Loh, CH | 1 |
| Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S | 1 |
| Chan, YH; Chang, SH; Chao, TF; Kuo, CT; Lee, HF; Lip, GYH; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Balachander, N; Deitelzweig, S; Dhamane, AD; Di Fusco, M; Garcia Reeves, AB; Kang, A; Keshishian, A; Li, X; Lip, GYH; Luo, X; Mardekian, J; Nadkarni, A; Pan, X; Rosenblatt, L; Yuce, H | 1 |
| Dina, O; Gupta, K; Keshishian, A; Mardekian, J; Nadkarni, A; Shank, TC; Trocio, J; Zhang, Q | 1 |
| Batiushin, MM | 1 |
| Chen, YT; Lin, HJ | 1 |
| Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L | 1 |
| Hinotsu, S; Kano, MR; Kitamura, Y; Koyama, T; Miller, MW; Ogawa, A; Ohshima, A; Sendo, T; Tanaka, HY; Zamami, Y | 1 |
| López-López, JA; Thom, H; Welton, NJ | 1 |
| Camm, AJ | 1 |
| Dieterich, M; Dietrich, D; Feil, K; Feuerecker, R; Jandl, M; Kellert, L; Klein, M; Küpper, C; Lücking, M; Marziniak, M; Poppert, H; Thanbichler, F; Topka, H; Wunderlich, S; Zerkaulen, I | 1 |
| Dawson, J; Fearon, P; Marshall, S; Quinn, TJ | 1 |
| Clark, WM; Horowitz, BZ; Javedani, PP; Lutsep, HL | 1 |
| Akwaa, F; Spyropoulos, AC | 1 |
| Galanis, T; Merli, GJ | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM | 2 |
| Hernández, M; Suárez, C | 1 |
| Masjuan, J | 3 |
| Dalmau, FG | 1 |
| Berger, R; Chase, M; Ganetsky, M; Salhanick, SD | 1 |
| Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Christory, F; Connolly, SJ; Dan, GA; Hatala, R; Huber, K; Kher, A; Kiss, RG; Klun, NV; Meier, B; Merkely, B; Pieske, B; Potpara, T; Stępińska, J; Vinereanu, D; Widimský, P | 1 |
| Callréus, T; Due, KM; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Higashiya, S; Hina, K; Hirohata, S; Kamikawa, S; Kawamura, H; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H | 1 |
| Attia, JR; Pearce, R | 1 |
| Eikelboom, JW; Hankey, GJ | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Chevalier, J; de Pouvourville, G; Giroud, M | 1 |
| Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV | 1 |
| Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N | 1 |
| Harris, K; Mant, J | 1 |
| Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD | 1 |
| Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP | 1 |
| Darius, H; Sommer, S | 1 |
| Atay, JK; Barnes, GD; Coatney, J; Ehle, M; Fanikos, J; Froehlich, JB; Goldhaber, SZ; Piazza, G | 1 |
| Ahmad, Y; Lip, GY | 3 |
| Bergman, E; Braun, OÖ; Smith, JG; Svensson, P; van der Pals, J; Wieloch, M | 1 |
| Gallego, P; Lip, GY; Roldan, V | 1 |
| Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Suzuki, M; Tanaka, Y; Yagishita, A; Yokoyama, Y | 1 |
| Micieli, A; Singh, SM; Wijeysundera, HC | 1 |
| Heidenreich, PA | 1 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Bender, M | 1 |
| Bauer, KA | 1 |
| Bereczki, D; Béres-Molnár, KA; Folyovich, A; Vadasdi, K; Varga, V | 1 |
| Aisenberg, J; Desai, J; Granger, CB; Weitz, JI | 1 |
| Klein, HH | 1 |
| Chen, JH; Connolly, SJ; Dans, AL; Ezekowitz, MD; Hori, M; Kim, SS; Koyanagi, M; Lau, CP; Liu, LS; Omar, R; Pais, P; Reilly, PA; Tan, RS; Tanomsup, S; Wallentin, L; Watanabe, M; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Toth, PP | 1 |
| Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Verheugt, FW | 1 |
| Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Brueckmann, M; Budaj, AJ; Chen, JH; Connolly, SJ; Dans, AL; Darius, H; Di Pasquale, G; Duffy, CO; Eikelboom, J; Ezekowitz, MD; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, L; Nanas, J; Oldgren, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Pogue, J; Raev, D; Reilly, PA; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Themeles, E; Toivonen, L; Vinereanu, D; Wallentin, L; Wang, SQ; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Breuer, L; Köhrmann, M; Ringwald, J; Schwab, S | 1 |
| Han, SY; Lee, PY; Miyahara, RK | 1 |
| Gong, IY; Kim, RB | 1 |
| Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Finsterer, J; Stöllberger, C | 4 |
| Diener, HC | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Gommans, J; Harper, P; Jayathissa, S | 1 |
| Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Eikelboom, JW; Robinson, M; Schulman, S; Shortt, B | 1 |
| Bhimani, AA; Hong, M | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Ellis, CR; Kaiser, DW | 1 |
| Aguilar, MI; Freeman, WD; Kuo, RS | 1 |
| Bosnyák, E; Csécsei, P; Deli, G; Fehér, G; Szapary, L | 1 |
| Bertoletti, L; Da Costa, A; Durupt, S; Epinat, M; Laporte, S; Lega, JC; Mismetti, P | 1 |
| Dalen, JE | 1 |
| Fanikos, J | 1 |
| Eder, V; Haring, HP; Müller, P; Nesser, HJ; Nußbaumer, K; Sonnberger, M; Topakian, R; Trenkler, J; Windpessl, M | 1 |
| Alvrtsyan, H; Francis, K; Matchar, D; Miyasato, G; Rao, Y; Sanchez, H; Sander, S; Siu, K; Walker, D; Yu, C; Zalesak, M | 1 |
| Wanat, MA | 1 |
| Baglin, T | 1 |
| Stiefelhagen, P | 1 |
| Barry, M | 2 |
| Lip, GY; Potpara, TS | 2 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Lip, GY; Van Gelder, IC; Van Veldhuisen, DJ | 1 |
| Rosenfeld, JV; Schaerf, NB; Thomas, PA | 1 |
| Hylek, EM | 1 |
| Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU | 1 |
| Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M | 1 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Amara, W; Guedeney, P; Iusuf, A | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
| Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ | 1 |
| Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S | 1 |
| Damgaard, D; Simonsen, CZ; Steiner, T; Tietze, A | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Clemens, A; Fraessdorf, M; Friedman, J | 1 |
| Waks, JW; Zimetbaum, PJ | 1 |
| Eikelboom, JW; Kapral, MK; McGrath, ER; O'Donnell, MJ | 1 |
| Cove, CL; Hylek, EM | 1 |
| Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB | 1 |
| Wood, P | 1 |
| Darko, W; Miller, CD; Probst, LA; Sidman, E | 1 |
| Faust, AC; Kawalsky, D; Smith, MB | 1 |
| Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Omote, Y; Yamashita, T; Yunoki, T | 1 |
| Manning, JA | 1 |
| Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L | 1 |
| Bastovansky, A; Finsterer, J; Paul, G; Stöllberger, C | 1 |
| Kitazono, T | 1 |
| Laffan, M; Shapiro, S | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S | 1 |
| Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A | 1 |
| Barillari, G; Cheng, JW | 1 |
| Butcher, K; Kate, M; Shuaib, A; Szkotak, A; Witt, A | 1 |
| Diener, HC; Weber, R | 1 |
| Bajorek, B; Wang, Y | 1 |
| Schulman, S | 1 |
| Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX | 1 |
| Hanon, O | 1 |
| Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F | 1 |
| Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H | 1 |
| Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L | 1 |
| Aronow, WS; Chatterjee, S; Ghosh, J; Nairooz, R; Sardar, P; Wetterslev, J | 1 |
| Acket, B; Bagheri, H; Bourrel, R; Lavezzi, O; Molinier, A; Montastruc, JL | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Aburakawa, Y; Kimura, T; Kuroda, K; Suzuki, Y; Yahara, O; Yoshida, K | 1 |
| Ackermann, D; Bartels, DB; Clemens, A; Diener, HC; Dubner, SJ; Halperin, JL; Huisman, MV; Lip, GY; Ma, CS; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 2 |
| Brunetti, L; Chen, C; White, J | 1 |
| Antoniazzi, S; Berdaï, D; Clementi, E; Conti, V; Salvo, F | 1 |
| Chang, CH; Chen, JH; Lin, LJ; Yang, YH | 1 |
| Henry, BL; Kumar, R; Smith, RE | 1 |
| Cordova, EG; del Aguila, D; Salazar, CA | 1 |
| Harder, S; Meyer Dos Santos, S | 1 |
| Amorosi, SL; Armstrong, S; Da Deppo, L; Garfield, S; Stein, K | 1 |
| Inaishi, J; Mano, Y; Nogawa, S; Okada, S; Yoshizaki, T | 1 |
| Iung, B; Vahanian, A | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brannath, W; Schmidt, S | 1 |
| Bonner, E; Finsterer, J; Stöllberger, C | 1 |
| Dogné, JM; Douxfis, J; Laloux, P; Larock, AS; Mullier, F; Spinewine, A | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| Foley, J; Kirchhof, P; Lip, GY | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Akasheva, DU; Tkacheva, ON | 1 |
| Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J | 1 |
| Diogo, C; Duarte, J; Nzwalo, H; Pestana, P; Rita, H; Sobral, S; Sousa E Costa, J | 1 |
| Zateĭshchikov, DA; Zotova, IV | 1 |
| Expósito, V; Fernández-Fresnedo, G; Seras, M | 1 |
| Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD | 1 |
| Lévy, S | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Vora, A | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P | 1 |
| Cowell, RP | 1 |
| Kihara, Y; Nakano, Y; Sairaku, A | 1 |
| AbuDagga, A; Fu, AC; Kwong, WJ; Stephenson, JJ; Tan, H; Weintraub, WS | 1 |
| Kmietowicz, Z | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Amirehsani, KA; Scott, KA | 1 |
| Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF | 1 |
| Garg, P; Morris, P; Morris, PD; Saraf, K; Sheridan, P; Storey, R | 1 |
| Mitchell, AR; Page, PL; Thomas, R | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Aslan, O; Ozdemir, M; Senol, H; Ugur-Yildiz, M; Yaylali, YT; Yildirim, S; Yurtdas, M | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Alonso Cánovas, A; Cruz, A; DeFelipe-Mimbrera, A; Guillán, M; Masjuan, J; Matute, C; Sainz de la Maza, S; Vera, R | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Steurer, J | 1 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Hernández Olmedo, M; Suárez Fernández, C | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 2 |
| Lane, DA; Lip, GY; Senoo, K | 1 |
| Cordeiro, G; Cunha, L; Duque, C; Pego, J; Sargento-Freitas, J; Silva, F | 1 |
| Bennell, MC; Krahn, M; Micieli, A; Pham, B; Singh, SM; Wijeysundera, HC | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Bernstein, RA; Eikelboom, J; Huisman, MV; Kamphuisen, P; Levy, JH; Pollack, CV; Sellke, FW; Steiner, T; Weitz, JI | 1 |
| Demulder, A; Safouris, A; Triantafyllou, N; Tsivgoulis, G | 1 |
| Connolly, SJ; Wallentin, L; Yusuf, S | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Cairns, JA; Connolly, S; Cox, JL; Dorian, P; Gladstone, D; Healey, JS; Ivers, N; Leblanc, K; Macle, L; McMurtry, MS; Mitchell, LB; Nattel, S; Stiell, IG; Verma, A | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Kovács, T | 1 |
| Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Aita, A; Angeli, F; Bartolini, C; De Filippo, V; di Giacomo, L; Martone, S; Molini, G; Reboldi, G; Valecchi, F; Verdecchia, P | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 2 |
| Eikelboom, JW; Hart, RG | 1 |
| Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY | 1 |
| Gierek, D; Lasek-Bal, A; Urbanek, T | 1 |
| Gonschior, AK; Heinrich-Nols, J; Kansal, AR; Noack, H; Sorensen, SV; Sunderland, T; Zheng, Y | 1 |
| Deitelzweig, SB; Jing, Y; Makenbaeva, D; Swindle, JP | 1 |
| Andreu-Cayuelas, JM; Gallego, P; Lip, GY; Manzano-Fernández, S; Marín, F; Orenes-Piñero, E; Roldán, V; Valdés, M; Vicente, V | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Okumura, K; Owada, S; Sasaki, K; Sasaki, S; Tomita, H | 1 |
| Brueckmann, M; Connolly, SJ; Douketis, JD; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Healey, JS; Noack, H; Oldgren, J; Reilly, P; Spyropoulos, AC; Wallentin, L | 1 |
| Ansell, M; Sood, V; Syyed, N | 1 |
| Beliavskaia, OO; Vavilova, TV | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Amin, A; Deitelzweig, S | 1 |
| Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J | 1 |
| Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Einecke, D | 4 |
| Shchendrygina, AA | 1 |
| Beauchesne, M; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Tousignant, A; Turgeon, M | 1 |
| Cantillon, D; Coleman, CM; Kanj, M; Khalaf, S; Mould, S; Saliba, W; Wazni, O | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Ferreira, J; Mirco, A | 1 |
| Beyer-Westendorf, J; Daschkow, K; Ebertz, F; Endig, H; Förster, K; Gelbricht, V; Köhler, C; Michalski, F; Pannach, S; Sahin, K; Tittl, L; Weiss, N; Werth, S | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Bovi, P; Cappellari, M | 1 |
| Abdollah, H; Baranchuk, A; Enriquez, A; Michael, K; Redfearn, D; Simpson, C | 1 |
| Brookhart, MA; Fang, G; Farley, JF; Gehi, AK; Lauffenburger, JC; Rhoney, DH | 1 |
| Müller, P; Windpessl, M | 1 |
| Hsieh, CY; Hsu, JC; Lu, CY; Yang, YH | 1 |
| Lane, DA; Wood, K | 1 |
| Aisha, B; Eng, DT; Hashim, MI; Hussin, A; Kaur, S; Koh, KW; Muhammad, Z; Omar, R; Rebo, R; Rusani, BI; Shanmugam, R; Sivalingam, L; Umadevan, D; Yap, LB | 1 |
| Hilpert, U | 1 |
| Ameri, AA | 1 |
| Saliba, W | 1 |
| Hernandez, I | 1 |
| Singh, SM; Wijeysundera, HC | 1 |
| Fujino, T; Ikeda, T; Kabuki, T; Kiuchi, S; Kobayashi, K; Yamazaki, A; Yamazaki, J; Yamazaki, Y | 1 |
| Caldeira, D; Costa, J; Ferreira, JJ; Gonçalves, N; Pinto, FJ | 1 |
| Brambatti, M; Brueckmann, M; Clemens, A; Connolly, SJ; Darius, H; Ezekowitz, MD; Healey, JS; Noack, HH; Oldgren, J; Wallentin, L; Yusuf, S | 1 |
| Brookhart, MA; Ellis, AR; Girman, CJ; Jonsson Funk, M; Simpson, RJ; Stürmer, T; Wyss, R | 1 |
| Ganetsky, M | 1 |
| Ageno, W; Riva, N | 1 |
| Crawford, B; Morimoto, T; Ueda, S; Wada, K | 1 |
| Marietta, M | 1 |
| Alonso-Coello, P; Brosa, M; Carles, M; Garcia-Alamino, JM; Guyatt, G; Souto, JC | 1 |
| Lane, DA; Lee, SI; Lip, GY; Sayers, M | 1 |
| Bartels, DB; Diener, HC; Dubner, SJ; Elsaesser, A; Halperin, JL; Huisman, MV; Lip, GY; Ma, C; Paquette, M; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Connolly, SJ; Ezekowitz, MD; Fukaya, T; Hori, M; Kleine, E; Reilly, PA | 1 |
| Birschmann, I; Blumenstock, G; Ebner, M; Härtig, F; Kuhn, J; Peter, A; Poli, S; Russo, F; Spencer, C; Winter, N; Wolf, M; Ziemann, U; Zuern, CS | 1 |
| Brueckmann, M; Clemens, A; Connolly, SJ; Ezekowitz, MD; Nagarakanti, R; Noack, H; Reilly, P; Wallentin, L; Yusuf, S | 1 |
| Ho, P; La Brooy, B; Lim, K | 1 |
| Holzgreve, H | 1 |
| Buck, B; Butcher, K; Gioia, L; Jeerakathil, T; Kate, M; Shuaib, A; Sivakumar, L | 1 |
| Gagg, J; Thachil, J | 1 |
| Kusano, K; Miyamoto, K; Nakasuka, K | 1 |
| Buitrago, F; Capilla Lozano, F; Gallego Fuentes, R; Rodríguez Pérez, L | 1 |
| Avgil-Tsadok, M; Behlouli, H; Eisenberg, MJ; Essebag, V; Jackevicius, CA; Pilote, L; Rahme, E | 1 |
| Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Konstantara, F; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tziomalos, K | 1 |
| Ang, ES; De Silva, DA; Fabiaña, N; Ramaswami, AP | 1 |
| Athanasakis, K; Bilitou, A; Karampli, E; Kyriopoulos, J; Tsounis, D | 1 |
| Chan, EW; Chan, PH; Chiang, CE; Hai, JJ; Huang, D; Lau, CP; Li, WH; Siu, CW; Tse, HF; Wong, IC; Yin, LX; Zhu, J | 1 |
| Capuana, ML; Falcou, A; Pieroni, A; Toni, D | 1 |
| Brueckmann, M; Cotton, D; Cronin, L; Diener, HC; Duffy, C; Easton, JD; Granger, CB; Sacco, RL | 1 |
| Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Mizuno, S; Nagamine, Y; Sano, H; Tanahashi, N | 1 |
| Collins, J; Fraeman, K; Reynolds, MW; Schnee, J; Schwartzman, E; Siu, K; Villines, TC | 1 |
| Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD; Zint, K | 1 |
| Heeger, CH; Kuck, KH; Lemes, C; Lin, T; Mathew, S; Metzner, A; Ouyang, F; Plesman, J; Rillig, A; Tilz, RR; Wissner, E; Wohlmuth, P | 1 |
| Eikelboom, J; Weitz, JI | 1 |
| Brueckmann, M; Clemens, A; Kreuzer, J; Liesenfeld, KH; Schulze, F | 1 |
| Afshari, F; Bösche, LI; Ewers, A; Gotzmann, M; Mügge, A; Schöne, D | 1 |
| Cairns, JA; Ciaccia, A; Fisher, WD; Kong, C; Semchuk, W; Turpie, AG; Weitz, JI | 1 |
| McCarthy, M | 1 |
| Azimi, N; Forest, CP; Holden, A | 1 |
| Avgil Tsadok, M; Humphries, KH; Jackevicius, CA; Pilote, L; Rahme, E | 1 |
| Bianchi, V; Calabrò, P; Cavallaro, C; D'Onofrio, A; De Vivo, S; Nigro, G; Russo, V; Santangelo, L; Sarubbi, B; Vecchione, F | 1 |
| Bouget, J; Oger, E | 1 |
| Potpara, TS | 1 |
| Yasaka, M | 1 |
| Kanorsky, SG; Shevelev, VI | 2 |
| Andreu-Cayuelas, JM; Flores-Blanco, PJ; García-Alberola, A; Lip, GY; Manzano-Fernández, S; Mateo-Martínez, A; Pastor-Pérez, FJ; Puche, CM; Roldán, V; Valdés, M | 1 |
| Borges, M; Caldeira, D; Costa, J; Fiorentino, F; Gouveia, M; Inês, M; Lopes Pereira, C; Pinheiro, L; Vaz-Carneiro, A | 1 |
| Roca, B; Roca, M | 1 |
| Barake, W; Baranchuk, A; Chu, K; Lamb, T; Lamba, J; Marr, JN; McIntyre, WF; Mohajer, K; Oqab, Z; Quadros, K; Quinn, KL; van Oosten, E; Yazdan-Ashoori, P | 1 |
| Bruno, A; Deitelzweig, S; Gupta, K; Lin, J; Lingohr-Smith, M; Tate, N; Trocio, J | 1 |
| McBane, RD; Schaefer, JK; Wysokinski, WE | 1 |
| Andersson, U; Aulin, J; Connolly, SJ; Ezekowitz, MD; Hijazi, Z; Huber, K; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L | 1 |
| Bertrand, M; Blotière, PO; Bouillon, K; Maura, G; Ricordeau, P; Zureik, M | 1 |
| Hussein, A; Saliba, W; Wazni, OM | 1 |
| How, CH | 1 |
| Cheung, BM; Kumana, CR; Lauder, IJ; Siu, DC; Tse, HF | 1 |
| Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH; Yen, KC | 1 |
| Al-Khalili, F; Benson, L; Lindström, C | 1 |
| Andrade, JG; Ciaccia, A; Connors, S; Krahn, AD; Purdham, D; Skanes, AC | 1 |
| Shao, XH; Wan, HB; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Breuer, L; Kallmünzer, B; Köhrmann, M; Kurka, N; Ringwald, J; Schwab, S; Volbers, B | 1 |
| Dolginsky, M; Kym, E; Nolting, L; Orrico, KB; Romanelli, RJ | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 1 |
| Beyer-Westendorf, J; Ehlken, B; Evers, T | 1 |
| Bartels, GL; Geluk, CA; Korenstra, J; Piersma-Wichers, M; Posma, JL; Rienstra, M; Tieleman, RG; Van Gelder, IC; Veeger, NJ; Wijtvliet, EP | 1 |
| Dagres, N; Hindricks, G; Jokic, V; Lane, DA; Larsen, TB; Lip, GY; Potpara, TS | 1 |
| Alamneh, EA; Bereznicki, LR; Chalmers, L | 1 |
| Caughey, GE; Pratt, NL; Ramsay, EN; Roughead, EE; Shakib, S | 1 |
| Alcocer, L | 1 |
| Ferreira, J; Silva Miguel, L | 1 |
| Åsberg, S; Hijazi, Z; Norrving, B; Oldgren, J; Terent, A | 1 |
| Brueckmann, M; Clemens, A; Connolly, SJ; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kent, AP; Noack, H; Oldgren, J; Pogue, J; Reilly, PA; Spahr, J; Wallentin, L; Yusuf, S | 1 |
| Finsterer, J; Heger, M; Stöllberger, C | 1 |
| Acin, F; Bleda, S; Cañibano, C; De Haro, J; Varela, C | 1 |
| Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H | 1 |
| Baik, SH; Hernandez, I; Zhang, Y | 1 |
| Coleman, CI; Evers, T; Tangirala, M | 2 |
| Baker, D; Narasimhan, S; Wilsmore, B | 1 |
| Füessl, HS; Stiefelhagen, P | 1 |
| Aksoy, H; Ata, N; Ayturk, M; Dal, K; Ozkan, S; Ozturk, M; Şabanoglu, C; Tanalp, AC; Topaloglu, C; Yavuz, B; Yavuz, BB | 1 |
| Hayes, CJ; Martin, BC; Shah, A; Shewale, A | 1 |
| Pickl, S | 1 |
| Alioğlu, E; Altın, C; Bilgin, N; Çetin, N; Dalgıç, O; Özdemirkıran, T; Özpelit, E; Özpelit, ME; Pekel, N; Tengiz, İ; Topaloğlu, C; Tülüce, K; Tunçer, E; Türk, UÖ; Türkoğlu, Eİ | 1 |
| Fonarow, GC; Gersh, BJ; Kim, S; Kowey, PR; Mahaffey, KW; O'Brien, EC; Peterson, ED; Piccini, JP; Thomas, L | 1 |
| Aronow, WS; Chatterjee, S; Kundu, A; Owan, T; Ryan, JJ; Sardar, P | 1 |
| Dittmeier, M; Fluri, F; Kleinschnitz, C; Kraft, P; Schuhmann, MK; Wassmuth, K | 1 |
| Bereczki, D; Mirolovics, Á; Papp, C; Zsuga, J | 1 |
| Coscioni, E; Izzo, R; Losi, MA; Rozza, F; Stabile, E; Trimarco, B | 1 |
| Cigarroa, J; Henrikson, CA; Steinberg, JS; Tereshchenko, LG | 1 |
| Bjerregaard Larsen, T; Gorst-Rasmussen, A; Lip, GY | 1 |
| Bair, TL; Bunch, TJ; Crandall, BG; Cutler, MJ; Day, JD; Jacobs, V; Mallender, C; May, HT; Osborn, JS; Stevens, SM; Weiss, JP; Woller, SC | 1 |
| Müller, A; Schäfer, N; Wüllner, U | 1 |
| Cappato, R; De Caterina, R; Ezekowitz, MD; Giugliano, RP; Patel, MR; Piccini, JP; Renda, G; Ricci, F; Zimarino, M | 1 |
| Brouns, R; Cornu, P; Desmaele, S; Dupont, AG; Steurbaut, S | 1 |
| Dickfeld, T; Goldner, R; Schleichert, R | 1 |
| Abe, H; Aizawa, Y; Fujii, Y; Jimbo, Y; Sato, M; Takahashi, H; Takano, H | 1 |
| Battat, E; Bitterman, H; Dotan, SG; Eikelboom, JW; Ellis, MH; Ginsberg, JS; Hammerman, A; Hirsh, J; Neuman, T | 1 |
| Godier, A; Martin, AC; Rosencher, N; Susen, S | 1 |
| Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI | 1 |
| Al-Ahmad, A; Barnes, GD; Freeman, JV; Garber, AM; Go, AS; Heidenreich, PA; Hlatky, MA; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP | 1 |
| Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S | 1 |
| Kjældgaard, JN; Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F | 1 |
| Mizoguchi, T; Yasaka, M | 1 |
| Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW | 1 |
| Kaboli, PJ; Kalil, RS; Liu, X; Vaughan-Sarrazin, M | 1 |
| Abraham, NS; Asirvatham, SJ; Bellolio, MF; Del-Carpio Munoz, F; Gersh, BJ; McBane, RD; Noseworthy, PA; Rabinstein, AA; Shah, ND; Yao, X | 1 |
| Ako, J; Fujiishi, T; Fukaya, H; Horiguchi, A; Igarashi, T; Ishizue, N; Kishihara, J; Murakami, M; Nakamura, H; Nishinarita, R; Niwano, S; Oikawa, J; Satoh, A; Yoshizawa, T | 1 |
| Ageno, W; Eikelboom, J; Lip, GY | 1 |
| Chai, F; Ding, Y; Liu, X; Sun, L; Webster, TJ; Zhang, Y; Zheng, C | 1 |
| Fukuoka, H; Hoshida, S; Ikeoka, K; Inui, H; Kanda, T; Shinoda, Y; Sunaga, A; Uematsu, M; Watanabe, T | 1 |
| Abraham, NS; Bellolio, MF; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Chien, KL; Hu, MM; Lin, SY; Lin, ZF; Su, CL; Wang, J; Wu, FL | 1 |
| Beshir, SA; Chee, KH; Lo, YL | 1 |
| Carmo, J; Ferreira, J; Mendes, M; Moscoso Costa, F | 1 |
| Hamilton, M; Horblyuk, R; Kamble, S; Keshishian, A; Lip, GY; Mardekian, J; Pan, X | 1 |
| Imazu, T; Kimura, R; Maeda, Y; Matsuda, S; Matsumoto, A; Murakami, T; Nakamura, M | 1 |
| Gislason, GH; Lee, CJ; Lindhardt, TB; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| Bhatt, DL; Blatchford, J; Brueckmann, M; Cannon, CP; Ellis, SG; Ferreiros Ripoll, E; Gropper, S; Hohnloser, SH; Kimura, T; Kreuzer, J; Lip, GY; Manassie, J; Massaro, JM; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Milling, TJ; Spyropoulos, AC | 1 |
| Peacock, WF; Villines, TC | 1 |
| Eikelboom, J; Merli, G | 1 |
| Granger, CB; Hawkins, NM; Jhund, PS; McMurray, JJ; O'Meara, E; Petrie, MC; Pfeffer, MA; Pozzi, A; Solomon, SD; Swedberg, K; Virani, S; Yusuf, S | 1 |
| Buck, J; Cram, P; Gage, BF; Kaboli, P; Vaughan Sarrazin, MS | 1 |
| Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
| Hernandez, I; Zhang, Y | 1 |
| Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH | 1 |
| Henry, BL; Kumar, R; Rahman, AM | 1 |
| Bernstein, R; Butcher, K; Campbell, B; Cloud, G; Davalos, A; Davis, S; Diener, HC; Ferro, JM; Grond, M; Krieger, D; Ntaios, G; Slowik, A; Touzé, E | 1 |
| Chillarige, Y; Goulding, MR; Graham, DJ; Hsueh, YH; Izem, R; Kelman, JA; Liao, J; MaCurdy, TE; Mott, K; Reichman, ME; Southworth, MR; Wei, Y; Wernecke, M; Worrall, C | 1 |
| Torjesen, I | 1 |
| Bajorek, BV; Pandya, E | 1 |
| Barrios, V; Masjuan, J | 1 |
| Bhave, A; Dalal, JJ; Dhall, A | 1 |
| Aisenberg, J; Brueckmann, M; Chatterjee, P; Connolly, S; Desai, J; Ezekowitz, M; Flack, KF; Ilgenfritz, J; Kolb, JM; Reilly, P; Wallentin, LC; Yusuf, S | 1 |
| Hernandez, I; Smith, KJ; Zhang, Y | 1 |
| Kreps, B; Schulz, JG | 1 |
| Butala, NM; Kartoun, U; Kennedy, KF; Mahmood, S; Secemsky, EA; Shaw, SY; Wasfy, JH; Yeh, RW | 1 |
| Assar, MD; Ball, T; Cox, KM; McCullough, PA | 1 |
| Keskar, V; Sood, MM | 1 |
| Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Nishizaki, K; Okumura, K; Sasaki, K; Sasaki, S; Shoji, Y; Tomita, H; Tsushima, Y | 1 |
| Doukky, R; Jaffer, AK; Moseley, A; Volgman, AS; Williams, KA | 1 |
| Bartels, DB; Bykov, K; Huybrechts, K; Schneeweiss, S; Seeger, JD | 1 |
| Dai, Y; Gao, X; Tan, HQ; Yang, YM; Zhu, J | 1 |
| Barcellona, D; Cianchetti, ME; Mameli, A; Marongiu, F; Musu, M; Porru, M; Ruberto, MF; Schirru, P | 1 |
| Bhatt, DL; Fonarow, GC; Harding, T; Hernandez, AF; Khan, Y; Peterson, ED; Schwamm, LH; Suter, RE; Xian, Y | 1 |
| Abraham, NS; McBane, RD; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Chen, HC; Liu, CY | 1 |
| Guo, L; Hong, Y; Li, S; Wang, P; Zhong, X | 1 |
| Etminan, M; Guo, M; Talany, G | 1 |
| Abraham, NS; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Bhurtu, A; Bundhun, PK; Huang, WQ; Pursun, M; Soogund, MZ; Teeluck, AR | 1 |
| Biagi, C; Conti, V; Donati, M; Melis, M; Monaco, L; Motola, D; Vaccheri, A; Venegoni, M | 1 |
| Weißbach, L; Zotz, RB | 1 |
| Bhatt, DL; Vaduganathan, M | 1 |
| Ayyagari, P; Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Bhatt, DL; Federspiel, JJ; Fonarow, GC; Hernandez, AF; Laskowitz, DT; Peterson, ED; Schwamm, LH; Smith, EE; Xian, Y | 1 |
| Bluecher, A; Ferreirós, N; Harder, S; Labocha, S; Meyer Dos Santos, IM; Meyer Dos Santos, S; Picard-Willems, B; Singer, OC | 1 |
| Bowrin, K; Briere, JB; Roberts, J; Tatarsky, B; Wood, R | 1 |
| Bice, J; Crompton, DE; Lee-Archer, M; Ng, FC; Rodda, A | 1 |
| Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F | 1 |
| Weitz, JI | 2 |
| Bartels, DB; Diener, HC; Dubner, SJ; Elsaesser, A; Halperin, JL; Huisman, MV; Lip, GY; Ma, CS; Paquette, M; Rothman, KJ; Teutsch, C; Zint, K | 1 |
| Kawada, T | 1 |
| Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AJ; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S | 1 |
| Connolly, SJ; Coppens, M; Eikelboom, JW; Ezekowitz, M; Lauw, MN; Nakamya, J; Oldgren, J; Wallentin, L; Wang, J; Yusuf, S | 1 |
| Bai, Y; Deng, H; Lip, GY; Shantsila, A | 1 |
| Bovi, P; Cappellari, M; Facchinetti, R; Forlivesi, S; Squintani, GM | 1 |
| Dowlatshahi, D; Frymire, E; Giulivi, A; Gomes, T; Holbrook, AM; Johnson, AP; Khuu, W; Mamdani, M; Schulman, S; Shepherd, LE; Simpson, CS; Wells, PS; Xu, Y | 1 |
| EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I | 1 |
| Franca, LR; Haertter, S; Huang, F | 1 |
| Antoniou, T; Juurlink, D; Mamdani, M | 1 |
| Antoniou, T; Gomes, T; Hollands, S; Juurlink, DN; Macdonald, EM; Mamdani, MM; Tadrous, M; Yao, Z | 1 |
| Brand, S; Crespo, C; Kansal, A; Monreal-Bosch, M; Soulard, S | 1 |
| Atzema, C; Behlouli, H; Eisenberg, MJ; Essebag, V; Ho, PM; Humphries, KH; Jackevicius, CA; Lu, L; Pilote, L; Rahme, E; Tsadok, MA; Tu, JV; Turakhia, M; Zhou, L | 1 |
| Gaudio, C; Greco, C; Pelliccia, F; Schiariti, M; Tanzilli, G; Viceconte, N | 1 |
| Kolegova, II; Koziolova, NA; Polyanskaya, EA | 1 |
| Bundhun, PK; Chaudhary, N; Yuan, J | 1 |
| Breithardt, G | 1 |
| Spyropoulos, AC | 1 |
| Bode, Ch; Schwarz, M | 1 |
| Connolly, S; Ezekowitz, MD; Oldgren, J; Parekh, A; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Yusuf, S | 1 |
| Gage, BF | 1 |
| Alings, M; Connolly, SJ; Darius, H; Diaz, R; Diener, HC; Eikelboom, J; Ezekowitz, MD; Joyner, CD; Lewis, BS; Oldgren, J; Parekh, A; Pogue, J; Reilly, PA; Themeles, E; Varrone, J; Wallentin, L; Wang, S; Xavier, D; Yusuf, S; Zhu, J | 1 |
| Thorsten, L | 1 |
| Liakishev, AA | 1 |
| Donnan, GA | 1 |
| Hankey, GJ | 1 |
| Spinler, SA | 1 |
| Ibrahim, S; Jespersen, J; Poller, L | 1 |
| Khoo, CW; Lip, GY | 1 |
| Laufs, U; Röther, J | 1 |
| Albers, GW; Schwartz, NE | 1 |
| Qureshi, AI; Siddiqui, FM | 1 |
| Dempfle, CE; Hennerici, MG | 2 |
| Lane, DA; Lip, GY | 3 |
| Crijns, H; Röther, J | 1 |
| Hankey, GJ; Raju, NC | 1 |
| Alings, M; Connolly, SJ; Dans, A; Eikelboom, J; Ezekowitz, MD; Flather, M; Franzosi, MG; Oldgren, J; Pais, P; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Alban, S; Völler, H; Westermann, D | 1 |
| Chan, L | 1 |
| Jamil-Copley, S; Kanagaratnam, P | 1 |
| Brouns, R; De Keyser, J; De Raedt, S; De Smedt, A; Nieboer, K | 1 |
| Lam, YY; Ma, TK; Yan, BP | 1 |
| Broukhim, M; Halperin, JL | 1 |
| Clemens, A; Lip, GY; Noack, H; Plumb, JM; Roskell, NS | 1 |
| Edwards, D | 1 |
| Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP | 1 |
| Connolly, SJ; Di Pasquale, G; Diener, HC; Ezekowitz, MD; Reilly, PA; Wallentin, L; Xavier, D; Yang, S; Yusuf, S | 1 |
| Baumhäkel, M; Böhm, M; Schirmer, SH | 1 |
| Thompson, CA | 1 |
| Heidbuchel, H; Verhamme, P | 1 |
| Neilson, RF | 1 |
| Aikens, TH; Chernick, MR; Connolly, SJ; Ezekowitz, MD; Lip, GY; Parekh, A; Pogue, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S | 1 |
| Ahrens, I; Lip, GY; Peter, K | 1 |
| Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
| Garnock-Jones, KP | 1 |
| Connolly, SJ | 1 |
| You, JH | 1 |
| Calvo Romero, JM | 1 |
| Braunwald, E; Steffel, J | 1 |
| Kirsch, B | 1 |
| Douketis, JD | 1 |
| Bradley-Kennedy, C; Connolly, S; Kansal, AR; Linnehan, J; Peng, S; Plumb, JM; Sorensen, SV | 1 |
| Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Eikelboom, JW; Haroun, MJ; Paikin, JS | 1 |
| Uchiyama, S | 2 |
| Guay, DR | 1 |
| Gums, JG | 1 |
| Beasley, BN; Temple, R; Unger, EF | 1 |
| Edwards, DB; Silverberg, J | 1 |
| Berg, AM | 1 |
| Alonso de Leciñana, M; Aparicio, M; Buisan, J; García-Caldentey, J; Guillán, M; Masjuan, J; Matute, MC | 1 |
| Yamashita, T | 1 |
| Cannon, CP; Stecker, EC | 1 |
| Dobrev, D | 1 |
| Gage, BF; Shah, SV | 1 |
| Ajzenberg, N; Dumont, B; Faille, D | 1 |
| Arnaout, S; Musallam, KM; Rabah, A; Sawaya, FJ; Sawaya, J | 1 |
| Batjer, HH; Bendok, BR; Bernstein, R; Rahme, RJ | 1 |
| Aizawa, Y; Atarashi, H; Inoue, H; Kamakura, S; Koretsune, Y; Kumagai, K; Mitamura, H; Ogawa, S; Okumura, K; Sugi, K; Yamashita, T; Yasaka, M | 1 |
| Fuster, V; Halperin, JL; Viles-Gonzalez, JF | 1 |
| Aikens, TH; Ezekowitz, MD; Nagarakanti, R; Shapiro, T | 1 |
| Qureshi, AI; Siddiqui, FM; Watanabe, M | 1 |
| Aribaud, A; Drouet, L; Eftekhari, P; Ginisty, S; Huy, PT; Legrand, M; Mateo, J; Payen, D | 1 |
| Jacobs, JM; Stessman, J | 1 |
| Eckardt, L; Shin, DI | 1 |
| Kreuzer, J | 1 |
| Blommel, AL; Blommel, ML | 1 |
| Encinas, J; Ikegami, K; Ohmura, T; Takahashi, I | 1 |
| Ganjehei, L; Massumi, A; Rasekh, A; Razavi, M | 1 |
| Belavic, JM | 1 |
| Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J | 1 |
| Mega, JL | 1 |
| Mousa, SA | 1 |
| Hunchuck, JE; Lake, JD | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C | 1 |
| Bartholomew, JR; Wartak, SA | 1 |
| Bode, C; Diener, HC; Kaeufer, T | 1 |
| Henry, DM | 1 |
| Brueckmann, M; Clemens, A; Eikelboom, J; Healey, JS; Oldgren, J; Sinnaeve, PR | 1 |
| Banerjee, A; Lip, GY; Marín, F | 1 |
| Nagatani, K; Nawashiro, H; Osada, H; Otani, N; Takeuchi, S; Wada, K | 1 |
| Yates, SW | 1 |
| Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L | 1 |
| Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Beyth, RJ; Landefeld, CS | 1 |
| Golembiewski, JA | 1 |
| Al-Khatib, SM; Alexander, JH; Granger, CB; Lopes, RD; Mahaffey, KW; Patel, MR | 1 |
| Panchenko, EP | 1 |
| Garwood, CL; Hwang, JM; Moser, LR | 1 |
| Calle Escobar, ML; Casado Naranjo, I; Jiménez Caballero, PE; Portilla-Cuenca, JC; Romero Sevilla, RM | 1 |
| Diener, HC; Hohnloser, SH; Lip, GY; Weber, R | 1 |
| Alberts, MJ; Bernstein, RA; Garcia, DA; Naccarelli, GV | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Kamal, AK; Khan, M; Raza, E | 1 |
| Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Diener, HC; Eikelboom, J; Granger, CB; Hacke, W | 1 |
| Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ | 1 |
| Mullard, A | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Easton, JD; Johnston, SC; Kamel, H; Kim, AS | 1 |
| Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ | 1 |
| Brueckmann, M; Clemens, A; Diener, HC; Huisman, MV; Lip, GY; van Ryn, J | 1 |
| Alpert, JS | 1 |
| Connolly, SJ; Eikelboom, JW; Hart, RG; Quinlan, DJ; Yusuf, S | 1 |
| Brueckmann, M; Connolly, S; Ezekowitz, M; Flaker, G; Hohnloser, SH; Noack, H; Reilly, P; Wallentin, L; Yusuf, S | 1 |
| Calleja-Puerta, S | 1 |
| Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM | 1 |
| Abdelhafiz, AH; Ali, A; Bailey, C | 1 |
| Iyer, V; Reiffel, JA; Singh, HS | 1 |
| Bergholdt Asmussen, M; Langkilde, LK; Overgaard, M | 1 |
| Cowie, MR; Gani, R; Kansal, AR; Pan, F; Plumb, JM; Robinson, P; Sorensen, SV | 1 |
| Wise, J | 1 |
| Avecilla, ST; Chandler, WL; Ferrell, C; Reyes, M | 1 |
| DiNicolantonio, JJ | 1 |
| Ibayashi, S; Matsumoto, M; Nagao, T; Nagata, K; Nakagawara, J; Tanahashi, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yasaka, M | 1 |
| Palareti, G; Tripodi, A | 1 |
| Bryer, A | 1 |
| Baumgarten, P; Bohmann, F; Foerch, C; Lindhoff-Last, E; Mittelbronn, M; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Katsnelson, M; Moscucci, M; Sacco, RL | 1 |
| Nair, G; Teddy, P | 1 |
| Ahmed, S; Levin, V; Malacoff, R; Martinez, MW | 1 |
| Baker, RI; Harper, P; McLintock, C | 1 |
| Coory, MD; Martin, JH | 1 |
| Chryssidis, S; Jannes, J; Koblar, SA; Moey, AW; Robinson, M | 1 |
| Brouns, R; De Keyser, J; De Raedt, S; De Smedt, A; Jochmans, K; Luijckx, GJ; Moens, M; Uyttenboogaart, M; Van Hooff, RJ | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Haas, S; Schellong, SM; Spannagl, M | 1 |
| Lip, GY; Marín, F; Roldán, V | 1 |
| Bommer, WJ | 1 |
| Kowey, PR; Naccarelli, GV | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Lewalter, T | 1 |
| Das, P; Jha, SK; Kabra, R; Koshy, SK; Shaheen, MH | 1 |
| Ismael, AG; Ribowsky, JH | 1 |
| Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
| Gállego, J; Gil Alzueta, MC | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Freeman, MK; Hughes, PJ | 1 |
| Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J | 1 |
| McKeage, K | 1 |
| Diener, HC; Hohnloser, SH | 1 |
| Ansell, J; Mantha, S | 1 |
| Cheng, G; Tsui, KK; Wong, RS; You, JH | 1 |
| Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC | 1 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Pollack, CV | 1 |
| Fareed, J; Kalodiki, E; Lewis, B | 1 |
| Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C | 1 |
| Barry, M; McCullagh, L | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Berthold, HK | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Zhang, S | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K | 1 |
| Griffiths, M; Scully, C | 1 |
| Taylor, J | 2 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Cannon, CP; Kohli, P | 1 |
| Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
| Crijns, HJ; Pisters, R; Ten Cate, H | 1 |
| Bohmann, F; Foerch, C; Lindhoff-Last, E; Mirceska, A; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Alonso-Coello, P; Guyatt, G; Zhou, Q | 1 |
| Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Kopecky, S | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Galle, PR; Hoffman, A | 1 |
| Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC | 1 |
| Brouwers, PJ; Kappelle, LJ; Koudstaal, PJ; Roos, YB; van Dijk, EJ | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| Marrone, AC; Marrone, LC | 1 |
| Esmon, CT | 1 |
| Le Heuzey, JY | 1 |
| Ellis, CR; Nagarakanti, R | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Graf, L; Tsakiris, DA | 1 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| Aalbers, J; Hardy, G | 1 |
| Aspoeck, G; Goebel, G; Griesmacher, A; Halbmayer, WM; Haushofer, AC; Loacker, L; Quehenberger, P; Schnapka-Koepf, M; Tomasits, J; Weigel, G | 1 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| García Alegría, J | 1 |
| Ruiz-Giménez Arrieta, N | 1 |
| Suárez Ortega, S | 1 |
| Gliem, M; Hartung, HP; Hermsen, D; Jander, S; van Rooijen, N | 1 |
| Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Eikelboom, JW; Quinlan, DJ; Weitz, JI | 1 |
| Lazo-Langner, A; Sun, D | 1 |
| Barrios, V; Escobar, C | 1 |
| Dabitz, R; Ochs, G | 1 |
| Crijns, HJ; Lane, DA; Lip, GY; Nieuwlaat, R; Pisters, R | 1 |
| Boehlen, F; de Moerloose, P | 1 |
| Aalbers, J | 2 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Coccheri, S; Orlando, D | 1 |
| Sinnaeve, PR; Van de Werf, F | 1 |
| Brueckmann, M; Connolly, SJ; Dans, AL; Eikelboom, JW; Ezekowitz, M; Nakamya, J; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Deitelzweig, SB | 1 |
| Eichler, K; Plessow, R; Pletscher, M; Wieser, S | 1 |
| Eraso, LH; Merli, GJ; Perez, A | 1 |
| Cucchiara, B; Kasner, SE; Messe, S; Mullen, MT; Rybinnik, I | 1 |
| Annemans, L; Thijs, V; Wouters, H | 1 |
| Brill, D | 1 |
| Greenspon, AJ | 1 |
| Grove, EL; Husted, SE; Kraglund, KL; Modrau, B | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Re, G; Toni, D | 1 |
| Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW | 1 |
| Finsterer, J; Höllerl, F; Stöllberger, C | 1 |
| Abrahám, P; Andréka, P; Csillik, A; Földesi, C; Fontos, G; Kardos, A; Kis, Z; Pál, M; Som, Z; Szatmári, A; Temesvári, A | 1 |
| Sarah, S | 1 |
| Gustafsson, D | 1 |
| Ieko, M | 1 |
| Nendaz, M; Perrier, A | 1 |
| Chevalier, A; Nutescu, EA; Shapiro, NL | 1 |
340 review(s) available for dabigatran and Stroke
| Article | Year |
|---|---|
Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Obesity, Morbid; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Humans; Stroke; Vitamin K | 2022 |
Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2021 |
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Rivaroxaban; Spain; Stroke; Vitamin K | 2022 |
Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2022 |
The use of non-vitamin K oral anticoagulants in dialysis patients-A systematic review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Rivaroxaban; Stroke; Vitamin K | 2022 |
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Venous Thromboembolism | 2022 |
Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Intracranial Hemorrhages; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2022 |
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2022 |
Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulant Among Patients With Nonvalvular Atrial Fibrillation and Cancer: A Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Ischemic Stroke; Neoplasms; Network Meta-Analysis; Stroke; Treatment Outcome; Warfarin | 2022 |
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Body Mass Index; Body Weight; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2022 |
The association of non-vitamin K antagonist oral anticoagulants
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Osteoporotic Fractures; Rivaroxaban; Stroke; Warfarin | 2023 |
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States | 2022 |
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Dialysis; Rivaroxaban; Stroke; Warfarin | 2022 |
Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Stroke; Venous Thromboembolism | 2023 |
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2022 |
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2023 |
Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pharmacology, Clinical; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2023 |
Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke.
Topics: Antithrombins; Dabigatran; Hemorrhagic Stroke; Humans; Intracranial Hemorrhages; Ischemic Stroke; Stroke | 2023 |
Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Incidence; Japan; Product Surveillance, Postmarketing; Pyridones; Rivaroxaban; Stroke | 2023 |
Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Brain Ischemia; Dabigatran; Humans; Intracranial Hemorrhages; Ischemic Stroke; Multicenter Studies as Topic; Observational Studies as Topic; Stroke; Thrombolytic Therapy | 2023 |
[Neurological perspective in the choice of direct oral anticoagulants for prevention of stroke in atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Stroke | 2023 |
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2023 |
Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Pyridones; Rheumatic Heart Disease; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2023 |
Altered plasma levels of apixaban in major gastrointestinal tract surgery: A case report and review of the literature.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Tract; Hemorrhage; Humans; Rivaroxaban; Stroke | 2023 |
Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2023 |
Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20 Years: A Bibliometric Analysis Via CiteSpace and VOSviewer.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Venous Thromboembolism; Warfarin | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke | 2023 |
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease.
Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Heart Defects, Congenital; Heart Valve Diseases; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke; Survival Analysis; Thiazoles; Vitamin K | 2019 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2020 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2020 |
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Care Bundles; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2020 |
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism | 2020 |
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2020 |
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Humans; Japan; Rivaroxaban; Stroke; Warfarin | 2020 |
Periprocedural Management of Oral Anticoagulation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Surgical Procedures, Operative; Warfarin | 2020 |
[Personalized approach for direct oral anticoagulant prescription: from theory to practice].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Precision Medicine; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2019 |
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin | 2020 |
A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Technology Assessment, Biomedical | 2020 |
Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Failure; Humans; Network Meta-Analysis; Pyridones; Rivaroxaban; Stroke; Warfarin | 2020 |
Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Liver Diseases; Pyrazoles; Pyridones; Stroke | 2021 |
A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Stroke; Venous Thromboembolism | 2021 |
Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2021 |
Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2021 |
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Switching between direct oral anticoagulants: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? - A systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Network Meta-Analysis; Rivaroxaban; Stroke; Warfarin | 2021 |
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Italy; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2021 |
Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Intracranial Hemorrhages; Randomized Controlled Trials as Topic; Stroke | 2022 |
Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Observational Studies as Topic; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2021 |
Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Network Meta-Analysis; Pyridones; Rivaroxaban; Stroke | 2021 |
Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Stroke | 2021 |
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Stroke; Venous Thromboembolism; Warfarin | 2021 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2021 |
Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Rivaroxaban; Stroke; Warfarin | 2021 |
Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Rivaroxaban; Stroke; Vitamin K | 2023 |
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Thiazoles; Thrombin Time; Warfarin | 2017 |
Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis.
Topics: Anticoagulants; Dabigatran; Gastrointestinal Hemorrhage; Humans; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism | 2017 |
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2017 |
Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016).
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Consensus; Dabigatran; Delphi Technique; Europe; Evidence-Based Practice; Female; Humans; Long-Term Care; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Stroke; Thiazoles; Warfarin | 2017 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2017 |
What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
[State of the art: Direct oral anticoagulants and transfusion].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia | 2017 |
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Myocardial Infarction; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Factor Xa; Hemorrhage; Humans; Recombinant Proteins; Stroke; Thrombolytic Therapy; Vitamin K | 2017 |
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Male; Practice Guidelines as Topic; Stroke; Tissue Plasminogen Activator | 2017 |
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
[Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]
Topics: Activities of Daily Living; Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Stroke | 2018 |
[Clinico-Pharmacological and Clinical Basis of Multiplicity of Intake of Novel Oral Anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke | 2017 |
Direct oral anticoagulants: An update.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment | 2018 |
Advances in anticoagulation therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thrombosis | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2019 |
Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Intracranial Embolism; Male; Middle Aged; Stroke; Thrombolytic Therapy | 2018 |
Novel oral anticoagulants in chronic kidney disease: ready for prime time?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Venous Thromboembolism | 2018 |
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Case-Control Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2019 |
Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2018 |
THE GAP BETWEEN ECONOMIC EVALUATIONS AND CLINICAL PRACTICE: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS ON DABIGATRAN FOR ATRIAL FIBRILLATION.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Cost-Benefit Analysis; Dabigatran; Decision Making; Female; Humans; Male; Models, Economic; Quality-Adjusted Life Years; Stroke; Surveys and Questionnaires; United States; Vitamin K | 2018 |
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2019 |
Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Stroke; Thrombolytic Therapy | 2019 |
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Topics: Administration, Intravenous; Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Odds Ratio; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Tissue Plasminogen Activator | 2018 |
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Sweden; Thiazoles; Warfarin | 2018 |
Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; Warfarin | 2019 |
Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2019 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
Atrial Fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2019 |
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2019 |
Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Patient Selection; Preventive Health Services; Pyridines; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2013 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[The role of internal medicine in preventing stroke in atrial fibrillation].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Advances in the secondary prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes | 2012 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Interactions; Dyspepsia; Electric Countershock; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Pyridines; Randomized Controlled Trials as Topic; Stents; Stroke; Treatment Outcome | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolism; Humans; Quality-Adjusted Life Years; Stroke; Technology Assessment, Biomedical | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in gastroenterology practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Monitoring, Physiologic; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Stroke; Treatment Outcome | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
Stroke thrombolysis in patients taking dabigatran.
Topics: Aged; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Stroke; Thrombin Time; Thrombolytic Therapy | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Hemorrhage; Humans; International Normalized Ratio; Patient Selection; Pyridines; Risk Factors; Stroke; Treatment Outcome | 2013 |
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
[Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Intracranial Hemorrhages; Pyridines; Risk Assessment; Risk Factors; Stroke; Vitamin K | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Perioperative Care; Stroke; Warfarin | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
Topics: Amidines; Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Myocardial Infarction; Odds Ratio; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants: a focused review for stroke physicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Child; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessment; Stroke; Venous Thromboembolism; Warfarin | 2013 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Venous Thromboembolism | 2014 |
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Global Health; Humans; Incidence; Ischemic Attack, Transient; Stroke; Thromboembolism | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Hemorrhage; Humans; Risk Factors; Stroke | 2014 |
Risk of major bleeding and the standard doses of dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Stroke; Venous Thromboembolism | 2014 |
A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Topics: Anticoagulants; Antidotes; Antithrombins; Charcoal; Dabigatran; Female; Gastrointestinal Hemorrhage; Hospitals, University; Humans; Intracranial Hemorrhages; Male; Multiple Organ Failure; Partial Thromboplastin Time; Renal Dialysis; Retrospective Studies; Severity of Illness Index; Stroke; Treatment Outcome | 2015 |
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Drug Administration Schedule; Embolism; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Stroke; Vitamin K; Warfarin | 2014 |
Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessment; Risk Factors; Stroke | 2014 |
[Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diffusion Magnetic Resonance Imaging; Humans; Infusions, Intravenous; Male; Partial Thromboplastin Time; Recombinant Proteins; Stroke; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2014 |
[Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Practice Patterns, Physicians'; Stroke; Treatment Outcome | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome | 2014 |
[Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2014 |
[Oral anticoagulation in chronic kidney disease with atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke | 2015 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Dabigatran etexilate in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Humans; Pyridines; Stroke | 2013 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants: integration into clinical practice.
Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome | 2014 |
Does dabigatran interfere with intraablation heparinization?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Dabigatran; Heparin; Humans; Risk Factors; Stroke; Treatment Outcome; Warfarin; Whole Blood Coagulation Time | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism; Vitamin K; Warfarin | 2014 |
Atrial fibrillation - new frontiers in anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
[Progress of anticoagulation therapy in atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Stroke; Treatment Outcome; Warfarin | 2015 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Dabigatran (Pradaxa(®)): surgeon's friend or foe?
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Dental Care; Humans; Risk Factors; Stroke | 2014 |
Target-specific oral anticoagulants and the hospitalist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Hospitalists; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2015 |
[The use of dabigatran for prevention of ischemic stroke in patiets with atrial fibrillation: special features of treatment in different clinical situations].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Secondary Prevention; Stroke; Treatment Outcome | 2014 |
Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cerebral Hemorrhage; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Endovascular Procedures; Factor Xa Inhibitors; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thrombectomy; Thrombolytic Therapy; Tissue Plasminogen Activator | 2015 |
Dabigatran for the prevention and treatment of thromboembolic disorders.
Topics: Animals; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Intracranial Hemorrhages; Stroke; Thromboembolism | 2015 |
Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Comorbidity; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Risk Factors; Sex Factors; Stroke; Vitamin K | 2015 |
Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis.
Topics: Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Humans; Intracranial Hemorrhages; Pharmacovigilance; Randomized Controlled Trials as Topic; Stroke | 2015 |
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Odds Ratio; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2015 |
Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician.
Topics: Anticoagulants; Dabigatran; Emergency Medicine; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United Kingdom | 2015 |
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2015 |
New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage.
Topics: Animals; Anticoagulants; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Humans; Stroke | 2015 |
The new oral anticoagulants: Reasonable alternatives to warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis | 2015 |
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin | 2016 |
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; Hemorrhage; Humans; Ligation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Prothrombin; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2016 |
Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2016 |
Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Renal Insufficiency, Chronic; Stroke; Warfarin | 2016 |
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Medication Errors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drugs, Investigational; Evidence-Based Medicine; Humans; Mexico; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2016 |
Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Humans; Ischemia; Leg; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Direct oral anticoagulants: a guide for daily practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2016 |
Minimizing the Risk of Bleeding with NOACs in the Elderly.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Precision Medicine; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
[THE IMPORTANCE OF ANTICOAGULANT THERAPY IN PATIENTS WITH ARTIAL FIBRILLATION IN STROKE PREVENTION--SUMMARY OF INTERNATIONAL DATA AND NOVEL THERAPEUTIC MODALITIES].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Prevalence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles | 2016 |
Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2016 |
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
[Direct oral anticoagulant associated bleeding].
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Charcoal; Dabigatran; Hemorrhage; Humans; Prothrombin; Renal Dialysis; Stroke; Venous Thromboembolism | 2016 |
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism | 2016 |
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
[Anticoagulation for patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thrombolytic Therapy; Warfarin | 2016 |
Dabigatran in clinical practice: Contemporary overview of the evidence.
Topics: Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Stroke; Venous Thromboembolism; Warfarin | 2016 |
Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Observational Studies as Topic; Stroke; Vitamin K | 2016 |
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
A Review of the Clinical Subgroup Analyses From the RE-LY Trial.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2016 |
Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles | 2017 |
Current Perspective on Use of NOAC in Clinical Practice in India.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; India; Pyrazoles; Stroke; Warfarin | 2016 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2016 |
Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Mortality; Myocardial Infarction; Network Meta-Analysis; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Global Health; Hemorrhage; Humans; Incidence; Rivaroxaban; Secondary Prevention; Stroke | 2017 |
[NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2017 |
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2017 |
Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Intracranial Embolism; Intracranial Thrombosis; Rivaroxaban; Stroke; Warfarin | 2017 |
Anticoagulation Therapy and NOACs in Heart Failure.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2017 |
Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Global Health; Hemorrhage; Humans; Incidence; Stroke; Survival Rate | 2017 |
Brave new world: the current and future use of novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2008 |
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Cost-Benefit Analysis; Dabigatran; Humans; Platelet Aggregation Inhibitors; Pyridines; Stroke; Ticlopidine; Warfarin | 2010 |
[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Drug Therapy, Combination; Humans; Pyridines; Risk Factors; Stroke; Survival Rate; Thrombin; Vitamin K | 2010 |
Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Male; Middle Aged; Pyridines; Stroke; Warfarin | 2010 |
Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Health Care Costs; Humans; Prodrugs; Pyridines; Stroke; Thrombin; Treatment Outcome | 2010 |
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Biphenyl Compounds; Dabigatran; Humans; Irbesartan; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Warfarin | 2010 |
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Fibrinolytic Agents; Humans; Pyridines; Risk Factors; Stroke | 2010 |
[New oral anticoagulants: better than vitamin K antagonists?].
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K | 2010 |
Stroke in atrial fibrillation--hope on the horizon?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Heart Atria; Humans; Prostheses and Implants; Stroke; Warfarin | 2010 |
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Pyridines; Stroke; Thrombin; Venous Thromboembolism; Warfarin | 2011 |
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Health Status Indicators; Humans; Risk Assessment; Stroke; Vitamin K; Warfarin | 2011 |
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2010 |
[Novel anticoagulants for stroke prevention in atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2010 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Atrial fibrillation in 2010: advances in treatment and management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2011 |
Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Venous Thromboembolism | 2011 |
[Dabigatran, a new oral anticoagulant].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Interactions; Heparinoids; Humans; Pulmonary Embolism; Pyridines; Stroke; Venous Thromboembolism; Vitamin K | 2011 |
Frontiers of anticoagulation therapy for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2011 |
New options for stroke prevention in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2010 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Stroke; Warfarin | 2011 |
Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Risk Factors; Stroke; Thrombin | 2011 |
New anticoagulants for prevention of stroke in patients with atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Pyrazoles; Pyridones; Stroke | 2011 |
Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.
Topics: Benzimidazoles; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Humans; Incidence; Pyridines; Stroke; Thrombin | 2012 |
[New concepts in the therapy of atrial fibrillation].
Topics: Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Electric Countershock; Humans; Pacemaker, Artificial; Pyrrolidines; Stroke; Thromboembolism | 2011 |
Update on anti-coagulation in atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Humans; Male; Pyridines; Stroke | 2011 |
Dabigatran etexilate: A novel oral direct thrombin inhibitor.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Monitoring; Humans; Prodrugs; Pyridines; Stroke; Thrombin; United States; Venous Thromboembolism | 2011 |
[Pharmacological and clinical profiles of the direct thrombin inhibitor dabigatran etexilate methane sulfate (Prazaxa(®)) ].
Topics: Animals; Antithrombins; Benzimidazoles; Dabigatran; Haplorhini; Humans; Pyridines; Rats; Stroke; Thrombosis; Warfarin | 2011 |
Stroke prevention in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Catheterization; Cardiac Surgical Procedures; Dabigatran; Humans; Preventive Health Services; Stroke; Treatment Outcome; Warfarin | 2011 |
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Evidence-Based Medicine; Hemorrhage; Humans; Italy; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2011 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Stroke; Warfarin | 2012 |
[Atrial fibrillation: what the GP needs to know].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2011 |
Should dabigatran replace warfarin for stroke prevention in AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Pyridines; Stroke; Warfarin | 2011 |
Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Intracranial Hemorrhages; Pyridines; Risk Factors; Stroke | 2012 |
A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.
Topics: Animals; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Stroke | 2011 |
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Humans; Pyrazoles; Pyridones; Risk Factors; Stroke; Warfarin | 2011 |
Promise of factor Xa inhibition in atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Randomized Controlled Trials as Topic; Risk Factors; Stroke; United States; Warfarin | 2012 |
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemodynamics; Hemorrhage; Humans; Risk Factors; Stroke; Therapeutic Equivalency; Treatment Outcome; Ventricular Dysfunction, Left; Warfarin | 2011 |
Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Perioperative Care; Stroke; Thromboembolism; Vitamin K | 2011 |
Stroke prevention in atrial fibrillation: do we still need warfarin?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Decision Making; Factor Xa Inhibitors; Humans; Risk Factors; Stroke; Thrombin; Vitamin K; Warfarin | 2012 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Practice Guidelines as Topic; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Male; Stroke; Warfarin | 2012 |
Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke; Thrombosis; Warfarin | 2012 |
Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Stroke; Warfarin | 2012 |
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Stroke | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke | 2012 |
Dabigatran: a new chapter in anticoagulation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Food-Drug Interactions; Humans; Molecular Structure; Stroke; Thromboembolism; Treatment Outcome | 2012 |
Acute stroke management in patients taking dabigatran.
Topics: Anticoagulants; Benzimidazoles; Blood Coagulation Disorders; Case Management; Cerebral Hemorrhage; Cerebral Infarction; Dabigatran; Guidelines as Topic; Hemostasis; Hemostatics; Humans; Off-Label Use; Pyridines; Renal Dialysis; Reperfusion; Stroke; Vitamin K | 2012 |
[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Monitoring, Physiologic; Platelet Aggregation; Stroke; Thromboembolism; Warfarin | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants--key messages for the angiologist.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
[Dabigatran: a new therapeutic alternative in the prevention of stroke].
Topics: Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Double-Blind Method; Drug Interactions; Dyspepsia; Follow-Up Studies; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Risk; Stroke; Tissue Plasminogen Activator | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Economics, Pharmaceutical; Embolism; Humans; Pyridines; Quality-Adjusted Life Years; Stroke; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New oral anticoagulants in the ED setting: a review.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Female; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Challenges in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; International Normalized Ratio; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Monitoring, Ambulatory; Self Care; Stroke; Thromboembolism; Vitamin K; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Gastrointestinal disorders and dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dyspepsia; Humans; Pyridines; Stroke | 2013 |
[New oral anticoagulants for atrial fibrillation: a neurologist's view].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Dabigatran in clinical practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Humans; International Normalized Ratio; Pyridines; Stroke; Thromboembolism; Warfarin | 2012 |
Anticoagulant treatment: the end of the old agents?
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2012 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Evidence-Based Medicine; Hemorrhage; Humans; Risk Factors; Stroke | 2012 |
[Stroke risk--atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2013 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2013 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
The pharmacology and therapeutic use of dabigatran etexilate.
Topics: Antithrombins; Benzimidazoles; Dabigatran; Drug Interactions; Drug Monitoring; Embolism; Humans; Prodrugs; Pyridines; Stroke | 2013 |
Oral direct thrombin inhibitors in clinical development.
Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; Prodrugs; Pyridines; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.
Topics: Animals; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Humans; Molecular Structure; Patents as Topic; Prodrugs; Pyridines; Stroke; Structure-Activity Relationship; Thrombin; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2007 |
New anticoagulant agents: direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Atrial Fibrillation; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Half-Life; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Pyridines; Recombinant Proteins; Stroke; Sulfonamides; Thrombin | 2008 |
Preparing for the post-warfarin generation of antithrombotics.
Topics: Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clopidogrel; Fibrinolytic Agents; Fondaparinux; Humans; Oligosaccharides; Platelet Aggregation Inhibitors; Polysaccharides; Prodrugs; Pyridines; Stroke; Ticlopidine | 2004 |
72 trial(s) available for dabigatran and Stroke
| Article | Year |
|---|---|
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke | 2022 |
Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Heart Valve Diseases; Humans; Stroke; Treatment Outcome; Warfarin | 2022 |
Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial.
Topics: Aspirin; Cerebral Infarction; Dabigatran; Embolic Stroke; Humans; Intracranial Embolism; Male; Risk Factors; Stroke; Tomography, Emission-Computed, Single-Photon | 2022 |
Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brazil; Cognition; Dabigatran; Humans; Stroke; Warfarin | 2022 |
Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Hemorrhage; Humans; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Renal Insufficiency, Chronic; Rivaroxaban; Stroke | 2023 |
Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY.
Topics: Accidental Falls; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Retrospective Studies; Stroke; Warfarin | 2023 |
Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Stroke; Treatment Outcome; United States; Warfarin | 2023 |
Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Prognosis; Prospective Studies; Registries; Risk Factors; Stroke; Survival Rate; Withholding Treatment | 2020 |
MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists.
Topics: Aged; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Reperfusion; Rivaroxaban; Stroke; Thrombectomy; Treatment Outcome; Vitamin K | 2020 |
Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke.
Topics: Aged; Antithrombins; Brain Ischemia; Dabigatran; Female; Humans; Male; Middle Aged; Prospective Studies; Single-Blind Method; Stroke; Treatment Outcome | 2020 |
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Topics: Aged; Aged, 80 and over; Aspirin; Dabigatran; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Intracranial Embolism; Kidney Diseases; Male; Middle Aged; Recurrence; Stroke | 2020 |
Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Hong Kong; Humans; Mitral Valve Stenosis; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2020 |
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Topics: Aged; Angiotensin-Converting Enzyme 2; Antithrombins; Atrial Fibrillation; Betacoronavirus; Biomarkers; Cohort Studies; Coronavirus Infections; COVID-19; Dabigatran; Female; Humans; Male; Middle Aged; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazoles; Pyridones; Risk Factors; SARS-CoV-2; Stroke; Warfarin | 2020 |
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Atrial Fibrillation; Dabigatran; Humans; Italy; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2020 |
Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis.
Topics: Anticoagulants; Cerebral Veins; Dabigatran; Humans; Prospective Studies; Sinus Thrombosis, Intracranial; Stroke; Treatment Outcome; Venous Thrombosis; Warfarin | 2022 |
Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; China; Dabigatran; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Female; Heparin; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Time Factors; Treatment Outcome; Warfarin; Whole Blood Coagulation Time | 2021 |
An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medicare; Rivaroxaban; Stroke; Treatment Outcome; United States | 2021 |
Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Canada; Dabigatran; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Time Factors; Warfarin | 2021 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Postoperative Complications; Stroke; Warfarin | 2017 |
Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Risk Factors; Stroke; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling; Warfarin | 2018 |
Dabigatran following acute transient ischemic attack and minor stroke II (DATAS II).
Topics: Administration, Oral; Antithrombins; Cerebral Hemorrhage; Dabigatran; Female; Humans; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Recurrence; Sample Size; Stroke; Treatment Outcome | 2017 |
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2017 |
Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Hemorrhage; Humans; Incidence; Prospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2017 |
Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Hemorrhage; Humans; Incidence; Male; Risk Assessment; Stroke; Time Factors; Warfarin | 2018 |
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Internationality; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Proportional Hazards Models; Risk Assessment; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Warfarin | 2018 |
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Omeprazole; Perioperative Period; Peripheral Arterial Disease; Placebo Effect; Proton Pump Inhibitors; Stroke; Thrombosis; Treatment Outcome; Troponin; Venous Thromboembolism | 2018 |
When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Incidence; Intraoperative Care; Male; Middle Aged; Preoperative Care; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Whole Blood Coagulation Time | 2019 |
Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Regression Analysis; Rivaroxaban; Severity of Illness Index; Stroke | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Assessment; Stroke; Thromboembolism; Ticagrelor; Warfarin | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Intracranial Embolism; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Stroke | 2019 |
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Benzimidazoles; Brain Ischemia; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyridines; Stroke; Warfarin | 2013 |
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2013 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Stroke; Treatment Outcome | 2013 |
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Stroke; Thromboembolism; Warfarin | 2013 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes Mellitus; Embolism; Female; Hemorrhage; Humans; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Stroke | 2014 |
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Glomerular Filtration Rate; Humans; Internationality; Kidney; Male; Middle Aged; Models, Biological; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2014 |
Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Humans; Male; Middle Aged; Stroke; Turkey; Warfarin | 2016 |
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Diabetes Mellitus; Drug Evaluation; Female; Humans; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2015 |
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.
Topics: Aged; Asian People; Creatinine; Dabigatran; Embolism; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Stroke; Warfarin | 2015 |
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial).
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Stroke; Treatment Outcome; Warfarin | 2015 |
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT E
Topics: Administration, Oral; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Fibrinolytic Agents; Humans; Intracranial Embolism; Prospective Studies; Research Design; Secondary Prevention; Stroke | 2015 |
[COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Monitoring; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Dabigatran; Female; Hemorrhage; Humans; Interleukin-6; Male; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Stroke; Thromboembolism; Warfarin | 2015 |
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor VIIa; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Prognosis; Risk Factors; Stroke; Warfarin | 2016 |
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Stroke; Treatment Outcome; Warfarin; Young Adult | 2016 |
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrilla
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Protocols; Coronary Artery Disease; Coronary Thrombosis; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Stents; Stroke; Time Factors; Treatment Outcome; Warfarin | 2016 |
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chemoprevention; Dabigatran; Embolism; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Male; Prevalence; Prospective Studies; Stroke; Warfarin | 2017 |
[Dabigatran versus warfarin for the prevention of stroke in Chinese patients with nonvalvular atrial fibrillation: Chinese subpopulation analysis of RE-LY].
Topics: Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Prospective Studies; Stroke; Warfarin | 2016 |
Effects of dabigatran according to age in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Netherlands; Ontario; Risk Assessment; Risk Factors; Stroke; Survival Rate; Sweden; Time Factors; United States | 2017 |
[The Choice of Anticoagulant Therapy in Patients With Non-Valvular Atrial Fibrillation and Chronic Kidney Disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Warfarin | 2017 |
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Transesophageal; Electric Countershock; Follow-Up Studies; Humans; Intracranial Thrombosis; Prospective Studies; Pyridines; Research Design; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Dyspepsia; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Liver; Male; Middle Aged; Myocardial Infarction; Prodrugs; Proportional Hazards Models; Pyridines; Stroke; Warfarin | 2009 |
[Dabigatran versus Warfarin in patients with atrial fibrillation. Results of the RE-LY study].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Prodrugs; Pyridines; Single-Blind Method; Stroke; Time Factors; Treatment Outcome; Warfarin | 2009 |
Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke; Treatment Outcome; Warfarin | 2010 |
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2010 |
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; International Cooperation; Ischemic Attack, Transient; Longitudinal Studies; Male; Pyridines; Stroke; Treatment Outcome; Warfarin | 2010 |
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyridines; Risk Factors; Stroke; Treatment Outcome; Vitamin K; Warfarin | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Transesophageal; Electric Countershock; Electric Stimulation Therapy; Hemorrhage; Humans; Incidence; Retrospective Studies; Stroke; Warfarin | 2011 |
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Stroke; Warfarin | 2011 |
Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Follow-Up Studies; Humans; Prospective Studies; Pyridines; Risk Factors; Stroke; Vitamin K; Warfarin | 2011 |
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Warfarin | 2011 |
[Expectation to and problems of thrombin inhibitor].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2011 |
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.
Topics: Aged, 80 and over; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Costs; Embolism; Female; Follow-Up Studies; Humans; Male; Models, Economic; Pyridines; Stroke; United Kingdom | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain Ischemia; Cardiac Pacing, Artificial; Cataract Extraction; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Risk Factors; Stroke; Thromboembolism; Warfarin | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Life Expectancy; Quality-Adjusted Life Years; Stroke; Sweden; Warfarin | 2013 |
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
817 other study(ies) available for dabigatran and Stroke
| Article | Year |
|---|---|
Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Gastrointestinal Hemorrhage; Humans; Obesity, Morbid; Retrospective Studies; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2022 |
Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Dabigatran; Hemorrhage; Humans; Hypertension; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Stroke | 2022 |
Adherence and persistence to rivaroxaban in non-valvular atrial fibrillation patients receiving 30- or 90-day supply prescription fills.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medicare; Medication Adherence; Prescriptions; Retrospective Studies; Rivaroxaban; Stroke; United States | 2022 |
"I just didn't want to trust it at all": Atrial fibrillation patient's treatment experience of rivaroxaban and warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; Humans; Rivaroxaban; Stroke; Trust; Warfarin | 2022 |
Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Defining the duration of the dispensation of oral anticoagulants in administrative healthcare databases.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Delivery of Health Care; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Humans; Kidney; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device.
Topics: Administration, Oral; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke; Thrombosis; Treatment Outcome; Warfarin | 2022 |
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2022 |
Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
[ANMCO Position paper: Prescription appropriateness of direct oral anticoagulants for stroke and systemic thromboembolis with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Prescriptions; Pyridones; Rivaroxaban; Stroke | 2021 |
Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amyloidosis; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiomyopathies; Dabigatran; Factor Xa Inhibitors; Female; Heart Failure; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2022 |
Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia, Southeastern; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Humans; Male; Patient Satisfaction; Perception; Prevalence; Republic of Korea; Retrospective Studies; Risk Management; Stroke; Time Factors; Vitamin K | 2021 |
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran; Fluconazole; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Cause of Death; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Sex Factors; Stroke; Thromboembolism; Turkey | 2021 |
Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Machine Learning; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Semantic Web; Stroke; Wales | 2022 |
Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Embolism; Hemorrhage; Humans; Risk Factors; Stroke; Warfarin | 2022 |
Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Indicators and Reagents; Prothrombin Time; Pyridones; Rivaroxaban; Stroke | 2022 |
Serum or Plasma for Quantification of Direct Oral Anticoagulants?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Citrates; Dabigatran; Edetic Acid; Factor X; Humans; Pyridones; Rivaroxaban; Stroke | 2022 |
Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolic Stroke; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2022 |
Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Female; Humans; Male; Propensity Score; Scotland; Stroke; Warfarin | 2022 |
Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; HIV Infections; Humans; Male; Pyridones; Ritonavir; Rivaroxaban; Stroke; Warfarin | 2023 |
Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes.
Topics: Anticoagulants; Dabigatran; Delivery of Health Care; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Ischemic Stroke; Male; Pyridones; Rivaroxaban; Stroke | 2022 |
Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Cohort Studies; Dabigatran; General Practice; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Prospective Studies; Registries; Stroke; Vitamin K | 2022 |
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Prospective Studies; Pyridones; Registries; Rivaroxaban; Stroke | 2022 |
Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Mitral Valve Stenosis; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Obesity Paradox in Atrial Fibrillation and its Relation with the New Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Thrombin | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemia; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2022 |
Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Epistaxis; Humans; Propensity Score; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.
Topics: Anticoagulants; Asian People; Atorvastatin; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Rivaroxaban; Simvastatin; Singapore; Stroke | 2023 |
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Dabigatran; England; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Interrupted Time Series Analysis; Pandemics; Prescriptions; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2022 |
Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Stroke; Warfarin | 2022 |
Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; France; Humans; Rivaroxaban; Stroke; United States | 2022 |
Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Japan; Stroke | 2022 |
The changing use of anticoagulants in New Zealand.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; New Zealand; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
[First case of thrombolysis with non-immunogenic staphylokinase in a patient with ischemic stroke receiving dabigatran etexilate followed by thrombectomy].
Topics: Anticoagulants; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Humans; Ischemic Stroke; Metalloendopeptidases; Stroke; Thrombectomy; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2022 |
A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Overweight; Prospective Studies; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vasculitis; Warfarin | 2022 |
Warfarin Is Associated With Higher Rates of Upper But Not Lower Gastrointestinal Bleeding Compared with Direct Oral Anticoagulants: A Population-Based Propensity-Weighted Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Stroke; Warfarin | 2023 |
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Ischemic Stroke; Medicare; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2022 |
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; France; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of mayor bleeding using BIFAP database in Spain.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Spain; Stroke; Tramadol | 2023 |
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Registries; Stroke; Vitamin K | 2022 |
Bleeding risk of oral anticoagulants in liver cirrhosis.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Liver Cirrhosis; New Zealand; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Comparison of Dabigatran Versus Warfarin Treatment for the Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2022 |
Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Hypertension; Male; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2022 |
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2022 |
Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy.
Topics: Aged; Aged, 80 and over; Antidotes; Antithrombins; Dabigatran; Female; Humans; Ischemic Stroke; Male; Retrospective Studies; Stroke; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2022 |
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial.
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Gastrointestinal Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019).
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Male; Primary Health Care; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; COVID-19; Cross-Sectional Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Thrombin | 2023 |
Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Male; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Prospective Studies; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin | 2023 |
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Medicare; Multimorbidity; Pyridones; Risk Assessment; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score-weighted study.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Propensity Score; Rivaroxaban; Stroke | 2023 |
Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: Insight from the AFTER-2 trial.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparison of medication adherence to different oral anticoagulants: population-based cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Medication Adherence; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Topics: Administration, Oral; Adolescent; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5-Year Retrospective Cohort Study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-treated Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Dizziness; Hemorrhage; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Syncope | 2023 |
Retrospective analysis of gastrointestinal bleedings with direct oral anticoagulants reported to EudraVigilance.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Stroke thrombolysis in a patient on dabigatran in the extended time window.
Topics: Antithrombins; Brain Ischemia; Dabigatran; Humans; New Zealand; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator | 2022 |
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Female; Humans; Male; Patient Acceptance of Health Care; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Direct oral anticoagulants and warfarin safety in rural patients with obesity.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Retrospective Studies; Rural Population; Stroke; Warfarin | 2023 |
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Developing Countries; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Liver Diseases; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2023 |
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Ischemic Stroke; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke; Vitamin K; Young Adult | 2023 |
Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Belgium; Cohort Studies; Dabigatran; Dementia; Humans; Rivaroxaban; Stroke | 2023 |
Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2023 |
Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World Patients.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Kidney; Rivaroxaban; Stroke; Warfarin | 2023 |
Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Hypertension; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2023 |
Direct oral anticoagulants: patient reported adherence and minor bleedings.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Patient Reported Outcome Measures; Pyridones; Rivaroxaban; Stroke | 2023 |
Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2023 |
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thromboembolism; Vitamin K; Warfarin | 2023 |
DOAC Dosing Discordance Using Different Estimates of Kidney Function and Outcomes.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2023 |
Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Delivery of Health Care; Hemorrhage; Humans; Male; Prevalence; Pyridones; Rivaroxaban; Stroke | 2023 |
Safety and mortality outcomes for direct oral anticoagulants in renal transplant recipients.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Kidney Transplantation; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2023 |
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Flecainide; Hemorrhage; Hospitalization; Humans; Ischemic Stroke; Male; Medicare; Retrospective Studies; Rivaroxaban; Sotalol; Stroke; United States | 2023 |
The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Levetiracetam; Male; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism | 2023 |
A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medication Adherence; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2023 |
Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Prospective Studies; Stroke; Vitamins | 2023 |
Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Stroke | 2023 |
Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Embolism; Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke; Treatment Outcome | 2023 |
ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus; Hemorrhage; Humans; Rivaroxaban; Stroke | 2023 |
Pearls in Anticoagulation Management for Patients With Left Ventricular Assist Devices.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Heart-Assist Devices; Humans; Pyridones; Stroke; Warfarin | 2023 |
Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
[A case of recurrent stroke with carotid-web despite dabigatran treatment successfully treated by carotid endarterectomy].
Topics: Adult; Carotid Arteries; Cerebral Infarction; Dabigatran; Endarterectomy, Carotid; Female; Humans; Ischemic Stroke; Stroke | 2023 |
Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2023 |
Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2023 |
Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Failure, Chronic; Registries; Retrospective Studies; Rivaroxaban; Stroke | 2023 |
Utilization of direct oral anticoagulants in a Saudi tertiary hospital: a retrospective cohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Retrospective Studies; Rivaroxaban; Saudi Arabia; Stroke; Tertiary Care Centers; Venous Thrombosis | 2023 |
Benefits and Harms of Standard Versus Reduced-Dose Direct Oral Anticoagulant Therapy for Older Adults With Multiple Morbidities and Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medicare; Morbidity; Retrospective Studies; Rivaroxaban; Stroke; United States | 2023 |
Gastrointestinal bleeding with direct oral anticoagulants in patients with atrial fibrillation and anaemia.
Topics: Administration, Oral; Anemia; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyridones; Rivaroxaban; Stroke | 2023 |
Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Ischemic Stroke; Retrospective Studies; Rivaroxaban; Stroke; Subarachnoid Hemorrhage; Vitamin K; Warfarin | 2023 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles | 2019 |
Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United Kingdom | 2019 |
[Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Costs and Cost Analysis; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Primary Health Care; Propensity Score; Stroke; Thromboembolism; Vitamin K | 2020 |
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Rivaroxaban; Stroke; Vitamin K | 2020 |
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; France; Hemorrhage; Humans; Myocardial Infarction; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2020 |
NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surveys and Questionnaires; Thiazoles | 2020 |
Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K | 2020 |
Idarucizumab for Intravenous Thrombolysis and Endovascular Thrombectomy in Acute Stroke: A Case Report.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Brain Ischemia; Dabigatran; Humans; Male; Stroke; Thrombectomy; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2020 |
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
Topics: Antithrombins; Atrial Fibrillation; Cause of Death; Cohort Studies; Dabigatran; Follow-Up Studies; Hemorrhage; Humans; Incidence; Myocardial Infarction; Prospective Studies; Registries; Stroke; Time Factors; Treatment Outcome | 2019 |
Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Taiwan; Warfarin | 2020 |
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2020 |
[How to maintain an adherence to oral anticoagulant in a patient with atrial fibrillation?]
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2019 |
Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin; Young Adult | 2020 |
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Dabigatran; Dysarthria; Female; Humans; Paresis; Stroke; Tissue Plasminogen Activator; Treatment Outcome | 2019 |
Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Prejudice; Rivaroxaban; Stroke; Vitamin K | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
Topics: Aged; Anticoagulants; Atrial Fibrillation; China; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Treatment Outcome | 2020 |
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Norway; Patient Safety; Pyrazoles; Pyridones; Registries; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2020 |
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Germany; Humans; Intracranial Hemorrhages; Ischemic Stroke; Retrospective Studies; Stroke; Thrombolytic Therapy | 2020 |
[Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cause of Death; Comorbidity; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Medication Adherence; Platelet Aggregation Inhibitors; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2020 |
Outcome of non-vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Appendage; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Stroke; Thrombosis; Time Factors; Treatment Outcome | 2020 |
Persistence, effectiveness and safety of dabigatran in "real-world" Chinese patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Brain Ischemia; China; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Stroke; Time Factors; Treatment Outcome | 2020 |
Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Retrospective Studies; Rivaroxaban; Stroke; Taiwan | 2020 |
Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medicare; Off-Label Use; Practice Patterns, Physicians'; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Time Factors; Treatment Outcome; United States | 2020 |
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Computer Simulation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Drug Costs; Drug Substitution; Drugs, Generic; Female; Humans; Male; Markov Chains; Models, Biological; Models, Economic; Quality-Adjusted Life Years; Stroke; Therapeutic Equivalency; Treatment Outcome; United States; Young Adult | 2020 |
Idarucizumab before reperfusion therapy in stroke patients on dabigatran: No more cold sweat.
Topics: Antibodies, Monoclonal, Humanized; Dabigatran; Humans; Stroke; Sweat | 2020 |
Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Drug Utilization; Female; Humans; Male; New Zealand; Registries; Reperfusion; Stroke; Time-to-Treatment | 2020 |
Early Anticoagulation for Minor Non-Cardioembolic Stroke and Transient Ischemic Attack: Too Early to Call.
Topics: Anticoagulants; Brain Ischemia; Dabigatran; Humans; Ischemic Attack, Transient; Stroke | 2020 |
Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Japan; Male; Middle Aged; Population Surveillance; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome | 2020 |
Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Platelet Aggregation; Stroke | 2020 |
Idarucizumab for dabigatran reversal in daily clinical practice: A case series.
Topics: Antibodies, Monoclonal, Humanized; Brain Ischemia; Dabigatran; Humans; Stroke | 2020 |
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Australia; Brain Ischemia; Dabigatran; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Middle Aged; New Zealand; Stroke; Tenecteplase; Thrombectomy; Thrombolytic Therapy | 2020 |
Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation.
Topics: Adenine; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Piperidines; Plasma; Stroke; Treatment Outcome | 2020 |
Trends in anticoagulant prescribing: a review of local policies in English primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; England; Female; Humans; Male; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; State Medicine; Stroke; Thiazoles; Warfarin | 2020 |
Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Substitution; Europe; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Israel; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Protective Factors; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vitamin K; Young Adult | 2020 |
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiologists; Clinical Trials, Phase III as Topic; Consensus; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2020 |
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |
Early Dabigatran Treatment After Transient Ischemic Attack and Minor Ischemic Stroke Does Not Result in Hemorrhagic Transformation.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Dabigatran; Humans; Ischemic Attack, Transient; Ischemic Stroke; Middle Aged; Prospective Studies; Stroke; Treatment Outcome; United States | 2020 |
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2020 |
Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Kidney Diseases; Male; Middle Aged; Prospective Studies; Rivaroxaban; Stroke | 2020 |
Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Blood Pressure; Dabigatran; Humans; Risk Factors; Stroke; Thrombin; Warfarin | 2020 |
[Stroke Prevention in Patients with Atrial Fibrillation in Real Clinical Practice, Emphasis on Efficacy and Safety of Anticoagulant Therapy].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2020 |
Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Prospective Studies; Rivaroxaban; Stroke; Vitamin K | 2020 |
Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hip Fractures; Hong Kong; Humans; Male; Osteoporotic Fractures; Pyrazoles; Pyridones; Rivaroxaban; Spinal Fractures; Stroke; Warfarin | 2020 |
Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Humans; Ischemic Stroke; Male; Registries; Retrospective Studies; Stroke | 2020 |
Remaining activity of temporary interrupted direct oral anticoagulants and its impact on intra-ablation heparinization in patients with atrial fibrillation: Comparisons across four drugs and two dose regimens.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pharmaceutical Preparations; Pyridones; Rivaroxaban; Stroke | 2020 |
Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Perception; Prospective Studies; Stroke; Vitamin K | 2020 |
Dabigatran and the Risk of Staphylococcus aureus Bacteremia: A Nationwide Cohort Study.
Topics: Administration, Oral; Bacteremia; Cohort Studies; Dabigatran; Humans; Staphylococcus aureus; Stroke; Warfarin | 2021 |
Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Humans; India; Netherlands; Retrospective Studies; Rivaroxaban; Spain; Stroke | 2021 |
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Warfarin | 2020 |
[Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Pharmacogenomic Testing; Stroke | 2019 |
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Frail Elderly; Hemorrhage; Humans; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Vitamin K; Warfarin | 2021 |
Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF.
Topics: Atrial Fibrillation; Dabigatran; Heart Failure; Humans; Prospective Studies; Stroke | 2020 |
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Male; Rivaroxaban; Spain; Stroke; Vitamin K | 2021 |
Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Hemorrhage; Health Services for the Aged; Humans; Male; Medicare; Risk Factors; Stroke; United States; Warfarin | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Electrophysiological effects of non-vitamin K antagonist oral anticoagulants on atrial repolarizing potassium channels.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Potassium Channels; Pyridones; Rivaroxaban; Stroke | 2020 |
Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Medicare; Mortality; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; United States; Warfarin | 2020 |
Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
Topics: Administration, Intravenous; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Hypertension; Male; Renal Insufficiency, Chronic; Stroke; Thrombolytic Therapy | 2020 |
Adherence to dabigatran and the influence of dabigatran-induced gastrointestinal discomfort in the real-world practice.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Male; Medication Adherence; Middle Aged; Republic of Korea; Stroke | 2021 |
Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Secondary Prevention; Stroke | 2020 |
Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Breast Neoplasms; Cohort Studies; Dabigatran; Female; Humans; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2021 |
[Predictive value of four score systems on the bleeding risk in atrial fibrillation patients treated with dabigatran].
Topics: Aged; Anticoagulants; Atrial Fibrillation; China; Dabigatran; Humans; Male; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Stroke | 2020 |
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study.
Topics: Aged; Atrial Fibrillation; Blood Loss, Surgical; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Perioperative Care; Pyrazoles; Pyridones; Risk Adjustment; Rivaroxaban; Stroke | 2020 |
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Interactions; Drug Monitoring; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Metabolic Clearance Rate; Observational Studies as Topic; Polypharmacy; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles | 2020 |
Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Female; Humans; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Stroke | 2020 |
Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests.
Topics: Acute Disease; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Partial Thromboplastin Time; Prognosis; Prothrombin Time; Retrospective Studies; Rivaroxaban; Severity of Illness Index; Stroke | 2020 |
Treatment of intracerebral hemorrhage: From specific interventions to bundles of care.
Topics: Administration, Oral; Anticoagulants; Cerebral Hemorrhage; Dabigatran; Hematoma; Humans; Stroke | 2020 |
Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Dementia; Female; Humans; Male; Pyridones; Rivaroxaban; Stroke | 2021 |
[Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Treatment Outcome | 2020 |
Patterns of anticoagulation therapy in atrial fibrillation: results from a large real-life single-center registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Warfarin; Young Adult | 2020 |
Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2021 |
Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Asia; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Stroke; Time Factors; Treatment Outcome; Vitamin K | 2020 |
Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Thrombosis; Warfarin | 2021 |
Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Dabigatran; Factor Xa Inhibitors; Female; General Practice; Geography; Humans; Logistic Models; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Warfarin | 2021 |
Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Czech Republic; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Retrospective Studies; Stroke; Warfarin | 2021 |
Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2021 |
Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines.
Topics: Aged; Aged, 80 and over; Antithrombins; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Native Hawaiian or Other Pacific Islander; New Zealand; Primary Health Care; Renal Insufficiency; Retrospective Studies; Socioeconomic Factors; Stroke | 2020 |
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Deductibles and Coinsurance; Drug Costs; Factor Xa Inhibitors; Female; Humans; Male; Medicare Part C; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sample Size; Stroke; Thiazoles; United States; Warfarin | 2021 |
A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Singapore; Stroke; Vitamin K; Warfarin; Young Adult | 2020 |
Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Mortality; Propensity Score; Pyrazoles; Pyridones; Stroke; Warfarin | 2021 |
[Direct oral anticoagulants and pregnancy].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Pregnancy; Stroke | 2021 |
Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China.
Topics: Anticoagulants; Atrial Fibrillation; China; Cost-Benefit Analysis; Dabigatran; Humans; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2021 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Valve Diseases; Humans; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome | 2021 |
Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Failure; Humans; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Current status of oral anticoagulant adherence in Japanese patients with atrial fibrillation: A claims database analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Japan; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Coronary Artery Disease; Dabigatran; Embolism; Female; Health Care Costs; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Peripheral Arterial Disease; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States; Warfarin | 2021 |
Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Prospective Studies; Pyridones; Rivaroxaban; Stroke | 2021 |
Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Proton Pump Inhibitors; Rivaroxaban; Stroke; Upper Gastrointestinal Tract; Warfarin | 2022 |
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Obesity; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Coronary Disease; Dabigatran; Diabetes Mellitus; Embolism; Female; Heart Failure; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Polypharmacy; Proportional Hazards Models; Stroke; Warfarin | 2021 |
Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Patient Satisfaction; Stroke; Surveys and Questionnaires; Taiwan; Warfarin | 2021 |
Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medication Adherence; Middle Aged; Netherlands; Pyridones; Rivaroxaban; Stroke | 2021 |
[Efficiency of the Decision-Making Module in the Personalized Choice of an Anticoagulant].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Middle Aged; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2021 |
Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Middle Aged; Prospective Studies; Stroke; Vitamin K | 2021 |
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2021 |
Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Multimorbidity; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Angiotensin II; Animals; Antithrombins; Atrial Fibrillation; Body Mass Index; Catheter Ablation; Cohort Studies; Dabigatran; Dogs; Embolism; Factor Xa Inhibitors; Female; Genotype; Hemorrhage; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Middle Aged; Norepinephrine; Obesity; Polymorphism, Single Nucleotide; Retrospective Studies; Rivaroxaban; Stroke; Sympathectomy | 2017 |
Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Canada; Cohort Studies; Dabigatran; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Uterine Hemorrhage; Warfarin | 2021 |
Laboratory assessment of the direct oral anticoagulants: who can benefit?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Laboratories; Pyridones; Rivaroxaban; Stroke | 2021 |
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Evaluation of Prescribing Practices and Outcomes Using Direct-acting Oral Anticoagulants After Cardiac Surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Cardiac Surgical Procedures; Dabigatran; Factor Xa Inhibitors; Humans; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2021 |
The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2021 |
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2021 |
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Confidence Intervals; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2021 |
Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Stroke; Treatment Outcome | 2021 |
Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2021 |
Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Mellitus, Type 2; Electronic Health Records; Eye Diseases; Humans; Kidney; Kidney Diseases; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Rivaroxaban; Stroke; Warfarin | 2022 |
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Dabigatran; Female; Heart Disease Risk Factors; Humans; Intracranial Hemorrhages; Ischemic Stroke; Male; Middle Aged; Risk Factors; Stroke; Treatment Outcome; Vitamin K | 2021 |
Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Cross-Sectional Studies; Dabigatran; Humans; Inpatients; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
[Atrial fibrillation in old age: risk management and features of the use of direct oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Risk Management; Rivaroxaban; Russia; Stroke | 2021 |
Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarin.
Topics: Administration, Oral; Anticoagulants; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2022 |
Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Body Weight; Cross-Sectional Studies; Dabigatran; Humans; Pharmacists; Physicians; Retrospective Studies; Rivaroxaban; Stroke | 2022 |
Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Obesity; Rivaroxaban; Stroke | 2021 |
Dabigatran-induced oesophagitis improved by switching medication to apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Esophagitis; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2021 |
Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation - a prospective cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Registries; Rivaroxaban; Stroke; Switzerland | 2017 |
Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.
Topics: Accidental Falls; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hip Fractures; Hong Kong; Humans; Male; Osteoporotic Fractures; Poisson Distribution; Propensity Score; Retrospective Studies; Risk; Spinal Fractures; Stroke; Warfarin | 2017 |
Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Vitamin K | 2017 |
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Chi-Square Distribution; Comparative Effectiveness Research; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medicare Part D; Multivariate Analysis; Patient Admission; Propensity Score; Proportional Hazards Models; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Treatment Outcome; United States; Warfarin | 2017 |
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Topics: Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Coagulants; Dabigatran; Diffusion Magnetic Resonance Imaging; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Male; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2017 |
Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Comorbidity; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Transfusion; Cause of Death; Comparative Effectiveness Research; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Logistic Models; Male; Mortality; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke | 2017 |
Response by Bai et al to Letter Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis".
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Letter by Machado-Alba et al Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis".
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.
Topics: Aged; Atrial Fibrillation; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Male; Perfusion Imaging; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Female; Germany; Humans; Intracranial Hemorrhages; Male; Retrospective Studies; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator | 2017 |
Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
Topics: Ablation Techniques; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Belgium; Cryosurgery; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Intraoperative Period; Italy; Male; Middle Aged; Postoperative Complications; Prognosis; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thiazoles; Time Factors; Vitamin K | 2017 |
Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; End Stage Liver Disease; Hemorrhage; Humans; Male; Patient Care Management; Risk Adjustment; Risk Assessment; Stroke; Treatment Outcome | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Vitamin K; Young Adult | 2017 |
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Risk; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Costs and Cost Analysis; Dabigatran; Female; Health Care Costs; Hospitalization; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Propensity Score; Proportional Hazards Models; Quality of Life; Retrospective Studies; Risk; Stroke; Warfarin | 2017 |
Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Female; Hemorrhage; Hospitalization; Humans; Male; Patient Acceptance of Health Care; Patient Readmission; Retrospective Studies; Stroke; United States; Warfarin | 2019 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2017 |
Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Substitution; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Vitamin K | 2018 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Choice of oral anticoagulants in older patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Stroke; Thiazoles; Warfarin | 2017 |
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
A comparison between vitamin K antagonists and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin | 2017 |
Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2017 |
Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Decision Making; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comorbidity; Dabigatran; Databases, Factual; Female; France; Health Care Surveys; Humans; Male; Medication Adherence; Middle Aged; Myocardial Ischemia; Rivaroxaban; Stroke; Vitamin K | 2017 |
New oral anticoagulant prescription rate and risk of bleeding in an Italian region.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Cross-Over Studies; Dabigatran; Drug Prescriptions; Female; Hemorrhage; Hospitalization; Humans; Italy; Male; Middle Aged; Prevalence; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Time Factors | 2017 |
Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiology; Dabigatran; Embolism; Female; Hemorrhage; Hospital Charges; Humans; Male; Middle Aged; Netherlands; Propensity Score; Retrospective Studies; Sex Factors; Stroke | 2017 |
Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Topics: Aged; Aged, 80 and over; Antithrombins; Blood Coagulation Disorders; Blood Coagulation Tests; Dabigatran; Emergencies; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Partial Thromboplastin Time; Point-of-Care Testing; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thrombin Time; Thrombolytic Therapy | 2017 |
All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Follow-Up Studies; Health Care Costs; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stroke; Warfarin | 2017 |
Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
Topics: Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Brain Ischemia; Dabigatran; Drug Interactions; Female; Humans; Hypertension; Stroke; Thrombolytic Therapy; Treatment Outcome | 2017 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Dalteparin; Disability Evaluation; Enoxaparin; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Recurrence; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Seoul; Stroke; Time Factors; Treatment Outcome | 2017 |
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2017 |
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2017 |
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke | 2018 |
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Humans; Medicare; Rivaroxaban; Stroke; United States | 2018 |
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pennsylvania; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2017 |
Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Drug Prescriptions; Factor Xa Inhibitors; Female; Humans; Linear Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health | 2017 |
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Coagulation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; Warfarin | 2017 |
Prevalence of Intracranial Hemorrhage after Blunt Head Trauma in Patients on Pre-injury Dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Head Injuries, Closed; Hospitals, University; Humans; Intracranial Hemorrhage, Traumatic; Male; Middle Aged; Prevalence; Pulmonary Embolism; Retrospective Studies; Stroke; Tomography, X-Ray Computed; Trauma Centers; Urban Population; Venous Thrombosis | 2017 |
Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Socioeconomic Factors; Stroke | 2017 |
Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, Three-Dimensional; Humans; Male; Septal Occluder Device; Stroke; Thrombosis; Treatment Outcome | 2017 |
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Turkey | 2018 |
Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2017 |
Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Germany; Hemorrhage; Humans; Hypertension; Ischemic Attack, Transient; Male; Primary Health Care; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; France; Hemorrhage; Hospitalization; Humans; International Normalized Ratio; Male; Medication Adherence; Middle Aged; Rivaroxaban; Stroke; Vitamin K | 2018 |
Off-Label Use of Direct Oral Anticoagulants in Intracerebral Hemorrhage Patients With Prosthetic Valves.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Humans; Male; Off-Label Use; Stroke; Warfarin | 2017 |
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Japan; Magnetic Resonance Imaging; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin | 2018 |
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Propensity Score; Retrospective Studies; Stroke; Warfarin | 2017 |
Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Utilization; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Stroke; Thiazoles | 2018 |
Assessment of Predicted Rate and Associated Factors of Dabigatran-induced Bleeding Events in Malaysian Patients with Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Malaysia; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke | 2017 |
Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Inappropriate Prescribing; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Registries; Retrospective Studies; Rivaroxaban; Stroke; Thromboembolism | 2018 |
Bleeding with oral anticoagulant dabigatran is highly associated with occult cancers in atrial fibrillation patients.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Japan; Male; Middle Aged; Neoplasms, Unknown Primary; Prevalence; Retrospective Studies; Risk Factors; Stroke; Survival Rate | 2018 |
Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2017 |
[Stroke after discontinuation of new anticoagulants prior to surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Male; Middle Aged; Preoperative Care; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Stroke; Surgical Procedures, Operative; Time Factors; Tomography, X-Ray Computed | 2017 |
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hospitalization; Humans; Inpatients; Male; Middle Aged; Outpatients; Patient Discharge; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Dabigatran; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Care Costs; Hemorrhage; Hospitalization; Humans; International Normalized Ratio; Male; Middle Aged; Myocardial Infarction; Patient Acceptance of Health Care; Retrospective Studies; Stroke; United States; Warfarin | 2018 |
Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Patient Safety; Proportional Hazards Models; Risk; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
A comparison of dabigatran and warfarin for stroke prevention in elderly Asian population with nonvalvular atrial fibrillation: An audit of current practice in Malaysia.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cohort Studies; Dabigatran; Female; Humans; Malaysia; Male; Medical Audit; Retrospective Studies; Stroke; Warfarin | 2017 |
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.
Topics: Administration, Intravenous; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Tests; Brain Ischemia; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Retrospective Studies; Rivaroxaban; Stroke; Thrombolytic Therapy | 2018 |
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke.
Topics: Aged; Anticoagulants; Brain Ischemia; Chagas Cardiomyopathy; Dabigatran; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Retrospective Studies; Stroke; Warfarin | 2018 |
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Hemorrhage; Humans; Middle Aged; Neoplasms; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin; Young Adult | 2018 |
Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Models, Biological; Primary Prevention; Recurrence; Secondary Prevention; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2018 |
Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study).
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Longitudinal Studies; Medication Adherence; Patient Education as Topic; Prospective Studies; Reminder Systems; Stroke | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Drug Prescriptions; Drug Substitution; Female; France; Humans; Male; Primary Health Care; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2018 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Stroke; Warfarin | 2018 |
Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Creatinine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Kidney Function Tests; Male; Multivariate Analysis; Odds Ratio; Practice Guidelines as Topic; Pyrazoles; Pyridones; Registries; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke | 2018 |
Intravenous stroke thrombolysis after reversal of dabigatran effect by idarucizumab: first reported case in Hong Kong.
Topics: Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Blood Coagulation Tests; Dabigatran; Female; Hong Kong; Humans; Stroke; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain Ischemia; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Models, Biological; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
Renal function monitoring in patients prescribed dabigatran in the Compass Health Primary Health Organisation: a quality improvement audit.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Kidney Function Tests; Male; Medical Audit; Middle Aged; Quality Improvement; Stroke; Young Adult | 2018 |
District versus academic hospitals: differences in the clinical characteristics of patients with atrial fibrillation without valvular heart disease treated with oral anticoagulants
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Heart Valve Diseases; Hospitals, District; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism | 2018 |
[Intravenous thrombolysis and thrombectomy in stroke after dabigatran reversal by idarucizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Combined Modality Therapy; Dabigatran; Humans; Injections, Intravenous; Male; Stroke; Thrombectomy; Thrombolytic Therapy | 2018 |
Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study.
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Costs and Cost Analysis; Dabigatran; Female; Health Care Costs; Humans; Male; Patient Acceptance of Health Care; Secondary Prevention; Stroke; Taiwan; Warfarin | 2018 |
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants.
Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; New Zealand; Retrospective Studies; Stroke | 2018 |
Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: Two cases with hemorrhagic transformation.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Fatal Outcome; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Stroke; Thrombolytic Therapy | 2018 |
Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.
Topics: Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Drug Interactions; Hematoma, Subdural; Humans; Stroke; Thrombolytic Therapy; Trephining | 2018 |
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Confidence Intervals; Dabigatran; Drug Administration Schedule; Female; Follow-Up Studies; Global Health; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Primary Prevention; Prospective Studies; Registries; Risk Assessment; Sex Factors; Stroke; Survival Analysis; Time Factors | 2018 |
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Frail Elderly; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Warfarin | 2018 |
Management of oral anticoagulation in patients with atrial fibrillation: newer agents, newer conundrums?
Topics: Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
Microbleeds in ischemic vs hemorrhagic strokes on novel oral anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Cerebral Small Vessel Diseases; Comorbidity; Dabigatran; Female; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombolytic Therapy | 2018 |
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Survival Rate; Treatment Outcome; United States; Warfarin | 2018 |
Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prognosis; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; United States; Warfarin; Withholding Treatment; Young Adult | 2018 |
Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Models, Statistical; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2018 |
Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk Adjustment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2018 |
[Tactics of Selection of Anticoagulant Therapy in Patients With Atrial Fibrillation and Ischemic Heart Disease].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Myocardial Ischemia; Pyridones; Rivaroxaban; Stroke; Warfarin | 2018 |
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Peripheral Arterial Disease; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2018 |
Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.
Topics: Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Recombinant Proteins; Retrospective Studies; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2018 |
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Costs and Cost Analysis; Dabigatran; Databases, Factual; Drug Costs; Female; Humans; Male; Medicare; Medication Adherence; Proportional Hazards Models; Retrospective Studies; Stroke; United States; Warfarin | 2018 |
Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke pre
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Inappropriate Prescribing; Male; Medical Audit; Middle Aged; Prescriptions; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke | 2019 |
NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Follow-Up Studies; Humans; Incidence; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thrombolytic Therapy; Treatment Outcome; Victoria; Warfarin | 2019 |
Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Quebec; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2018 |
[Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Humans; Stroke; Thrombolytic Therapy | 2017 |
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome | 2018 |
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.
Topics: Anticoagulants; Computer Simulation; Confounding Factors, Epidemiologic; Dabigatran; Data Interpretation, Statistical; Epidemiologic Research Design; Hemorrhage; Humans; Propensity Score; Risk Assessment; Stroke; Warfarin | 2018 |
Switching off the jitters: Dabigatran as a candidate approach to halt atrial fibrillation?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2018 |
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Prehospital idarucizumab prior to intravenous thrombolysis in a mobile stroke unit.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Ambulances; Antibodies, Monoclonal, Humanized; Australia; Brain Ischemia; Dabigatran; Emergency Medical Services; Feasibility Studies; Female; Humans; Male; Stroke; Thrombolytic Therapy | 2019 |
Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Germany; Humans; Male; Middle Aged; Phenprocoumon; Platelet Aggregation Inhibitors; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult | 2018 |
Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridones; Rivaroxaban; Spain; Stroke | 2018 |
Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Israel; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2018 |
Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Biological Availability; Canada; Dabigatran; Drug Approval; Drug Interactions; Drugs, Generic; Humans; Needs Assessment; Stroke; Therapeutic Equivalency | 2018 |
Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Databases, Factual; Female; Humans; Male; Norway; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Registries; Risk Factors; Rivaroxaban; Sex Factors; Stroke | 2018 |
Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Fibrinolytic Agents; Humans; Male; Stroke; Tissue Plasminogen Activator | 2018 |
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Databases, Factual; Drug Dosage Calculations; Female; Hemorrhage; Humans; Inappropriate Prescribing; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Prevalence; Pyrazoles; Pyridines; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome | 2018 |
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Stroke | 2018 |
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Obesity, Morbid; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2019 |
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2019 |
In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate.
Topics: Anticoagulants; Aptamers, Nucleotide; Atrial Fibrillation; Dabigatran; Embolism; Gene Library; Hemorrhage; Humans; Ligands; SELEX Aptamer Technique; Sensitivity and Specificity; Stroke | 2018 |
Increased risk of myocardial infarction with dabigatran etexilate: Fact or fiction? A critical meta-analysis from integrating randomized controlled trials and real-world studies: Wine or spritzer?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin; Wine | 2018 |
Dabigatran - Idarucizumab-facilitated intravenous thrombolysis - Hemorrhagic transformation.
Topics: Antibodies, Monoclonal, Humanized; Dabigatran; Humans; Stroke | 2018 |
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Care Costs; Hemorrhage; Humans; Male; Medicare; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Rivaroxaban; Stroke; United States; Warfarin | 2019 |
Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Stroke; Thromboembolism; Treatment Outcome | 2018 |
Idarucizumab-facilitated intravenous thrombolysis in acute ischemic stroke: A therapeutic strategy requiring further investigation.
Topics: Antibodies, Monoclonal, Humanized; Brain Ischemia; Clinical Trials as Topic; Dabigatran; Humans; Stroke; Thrombolytic Therapy | 2018 |
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Drug Antagonism; Humans; Male; Stroke; Thrombolytic Therapy | 2019 |
Dabigatran - the First Approved DTI for SPAF.
Topics: Adenosine Triphosphatases; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Europe; Humans; India; Pyridines; Stroke; Warfarin | 2018 |
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
[Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2018 |
Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Angiography; Dabigatran; Diffusion Magnetic Resonance Imaging; Female; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Logistic Models; Magnetic Resonance Angiography; Male; Multivariate Analysis; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2018 |
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Registries; Renal Insufficiency, Chronic; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2018 |
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hepatic Insufficiency; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin | 2018 |
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Inpatients; Male; Middle Aged; Outpatients; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2018 |
Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Medicare; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Secondary Prevention; Skilled Nursing Facilities; Stroke; Thromboembolism; United States | 2018 |
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Scotland; Stroke; Treatment Outcome | 2019 |
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Aged; Prospective Studies; Stroke; Treatment Outcome; Vitamin K | 2019 |
Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Female; Gastrointestinal Diseases; Humans; Incidence; Male; Middle Aged; Netherlands; Proportional Hazards Models; Proton Pump Inhibitors; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke | 2018 |
Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Disease Progression; Drug Dosage Calculations; Drug Therapy, Combination; Female; Humans; Korea; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Treatment Outcome; Warfarin | 2018 |
Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Embolism; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Japan; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2019 |
Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antidotes; Dabigatran; Fibrinolytic Agents; Humans; Male; Recovery of Function; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator | 2019 |
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Adherence and Compliance; United States; Warfarin | 2019 |
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Military Medicine; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; United States Department of Defense; Young Adult | 2019 |
The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Drug Substitution; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; International Normalized Ratio; Logistic Models; Male; Multivariate Analysis; Practice Guidelines as Topic; Rivaroxaban; Stroke; Time Factors; Warfarin | 2019 |
[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cardiovascular Diseases; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Sweden; Thiazoles | 2018 |
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Factor Xa Inhibitors; Humans; Safety-Based Drug Withdrawals; Stroke; Warfarin | 2018 |
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Blood Coagulation; Brain Ischemia; Dabigatran; Disability Evaluation; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Recovery of Function; Retrospective Studies; Severity of Illness Index; Slovenia; Stroke; Thrombolytic Therapy; Time Factors; Time-to-Treatment; Tissue Plasminogen Activator; Treatment Outcome | 2019 |
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2018 |
Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Health Care Costs; Humans; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2018 |
[Efficacy of Idarucizmab in Patients with Intracranial Hemorrhage Preconditioned with Dabigatran].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Dabigatran; Humans; Intracranial Hemorrhages; Stroke; Warfarin | 2018 |
Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Atrial Fibrillation; Blood Coagulation; Cerebral Hemorrhage; Dabigatran; Drug Administration Schedule; Feasibility Studies; Female; Fibrinolytic Agents; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Risk Factors; Stroke; Taiwan; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2019 |
Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Creatinine; Dabigatran; Drug Monitoring; Female; Humans; Linear Models; Male; Medication Adherence; Middle Aged; Risk Assessment; Risk Factors; Severity of Illness Index; Stroke; Taiwan | 2019 |
Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study.
Topics: Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Fibrinolytic Agents; Humans; Male; Stroke; Tissue Plasminogen Activator | 2019 |
Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Italy; Male; Propensity Score; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2019 |
Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Chronic Disease; Comorbidity; Dabigatran; Female; Humans; Male; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2018 |
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Spain; Stroke; Thiazoles; Treatment Outcome | 2019 |
Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Preference; Prospective Studies; Rivaroxaban; Stroke; Warfarin | 2019 |
Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles | 2019 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin | 2019 |
Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Monitoring; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Stroke; Thromboembolism; Time Factors; Treatment Outcome | 2019 |
Statins and the risk of bleeding in patients taking dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Polypharmacy; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke | 2019 |
Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States; Warfarin; Young Adult | 2019 |
Dabigatran and warfarin in nonvalvular atrial fibrillation or atrial flutter in outpatient clinic practice in Brazil.
Topics: Aged; Aged, 80 and over; Ambulatory Care Facilities; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Brazil; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Network meta-analysis: a new analysis tool of the experimental evidence.
Topics: Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Dabigatran; Dasatinib; Data Interpretation, Statistical; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Warfarin | 2019 |
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Taiwan; Thromboembolism; Time Factors; Treatment Outcome; Warfarin | 2019 |
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2019 |
Cerebral Ischemia in Patients on Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Humans; Male; Middle Aged; Registries; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin | 2019 |
New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report.
Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Antiphospholipid Syndrome; Antithrombins; Carotid Arteries; Computed Tomography Angiography; Dabigatran; Female; Follow-Up Studies; Humans; Product Surveillance, Postmarketing; Pulmonary Embolism; Stroke; Treatment Outcome; Venous Thrombosis; Warfarin | 2019 |
Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Administration Schedule; Drug Substitution; Factor Xa Inhibitors; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2019 |
Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Substitution; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Vitamin K; Withholding Treatment | 2019 |
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Reversal of dabigatran with idarucizumab in hyperacute stroke: a new paradigm?
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Carotid Stenosis; Dabigatran; Endarterectomy; Humans; Magnetic Resonance Angiography; Male; Stroke | 2019 |
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Female; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2019 |
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Middle Aged; Pharmaceutical Preparations; Prospective Studies; Republic of Korea; Stroke; Warfarin | 2020 |
Deprivation and inequalities lead to worse outcomes with dabigatran etexilate.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Native Hawaiian or Other Pacific Islander; New Zealand; Proportional Hazards Models; Retrospective Studies; Risk Factors; Socioeconomic Factors; Statistics, Nonparametric; Stroke; Thromboembolism; Treatment Outcome; White People | 2018 |
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Decision-Making; Dabigatran; Decision Making, Shared; Decision Support Techniques; Female; Hemorrhage; Humans; Male; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2019 |
Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Australia; Comparative Effectiveness Research; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Myocardial Infarction; Propensity Score; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Veterans; Warfarin | 2019 |
Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Brain Ischemia; Dabigatran; Humans; Male; Stroke; Thrombolytic Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Taiwan; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin | 2019 |
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Hemorrhage; Humans; Male; Medicare; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States; United States Department of Defense; Warfarin; Young Adult | 2019 |
[The Nephrological Aspects of the Use of Rivaroxaban and Other Direct Peroral Anticoagulants in Non-Valvular Atrial Fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyridones; Rivaroxaban; Stroke | 2019 |
Renal Function Estimates and Dosing of Direct Oral Anticoagulants in Stroke Patients with Atrial Fibrillation: An Observational Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Middle Aged; Rivaroxaban; Stroke | 2018 |
Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Prescriptions; Embolism; Female; Hemorrhage; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stroke; Warfarin; Young Adult | 2019 |
Shared parameter model for competing risks and different data summaries in meta-analysis: Implications for common and rare outcomes.
Topics: Administration, Oral; Algorithms; Anticoagulants; Asymptomatic Infections; Atrial Fibrillation; Computer Simulation; Dabigatran; Hemorrhage; Humans; Likelihood Functions; Meta-Analysis as Topic; Motivation; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2020 |
RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures.
Topics: Ablation Techniques; Administration, Oral; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Treatment Outcome | 2018 |
Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR).
Topics: Antibodies, Monoclonal, Humanized; Brain Ischemia; Dabigatran; Emergency Medical Services; Germany; Hemorrhage; Humans; Registries; Stroke | 2019 |
Dabigatran etexilate: management in acute ischemic stroke.
Topics: Anticoagulants; Benzimidazoles; Cerebral Angiography; Coagulants; Dabigatran; Drug Therapy, Combination; Factor VIIa; Humans; Intracranial Hemorrhages; Intracranial Thrombosis; Male; Middle Aged; Prothrombin; Pyridines; Recombinant Proteins; Severity of Illness Index; Stroke; Suction; Tomography, X-Ray Computed | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Drug Utilization Review; Female; Health Expenditures; Hong Kong; Hospital Costs; Hospitals, Teaching; Humans; Male; Middle Aged; Preventive Health Services; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2013 |
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Prospective Studies; Stroke; Warfarin | 2013 |
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Female; Humans; International Normalized Ratio; Male; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; South Africa; Stroke; Warfarin | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Denmark; Dose-Response Relationship, Drug; Drug Prescriptions; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hospitalization; Humans; Incidence; Intracranial Hemorrhages; Logistic Models; Male; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Prospective Studies; Pulmonary Embolism; Pyridines; Registries; Stroke; Warfarin | 2013 |
Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Catheter Ablation; Dabigatran; Dose-Response Relationship, Drug; Female; Heparin; Humans; Male; Middle Aged; Pyridines; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency; Research Design; Selection Bias; Stroke; Warfarin | 2013 |
Is there really misuse and abuse of dabigatran?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Research Design; Stroke; Warfarin | 2013 |
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Computer Simulation; Dabigatran; Decision Support Techniques; Decision Trees; Female; France; Health Services Research; Humans; Incidence; Male; Models, Statistical; Multivariate Analysis; Outcome and Process Assessment, Health Care; Prevalence; Registries; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood-Brain Barrier; Cerebral Arteries; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Humans; Ischemia; Mice; Mice, Inbred C57BL; Rats; Stroke; Thrombolytic Therapy; Warfarin | 2013 |
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Health Care Costs; Humans; Models, Economic; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Embolism; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Premedication; Retrospective Studies; Risk Assessment; Stroke; Tennessee; Treatment Outcome; Warfarin | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Topics: Academic Medical Centers; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Substitution; Female; Humans; Male; Referral and Consultation; Stroke; United States; Warfarin | 2013 |
Dabigatran in clinical practice--one-year experience at Skåne University Hospital.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Registries; Stroke; Sweden | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Topics: Age Factors; Aged; Antithrombins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Female; Hemorrhage; Humans; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Retrospective Studies; Risk Factors; Stroke | 2013 |
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Coronary Occlusion; Cost-Benefit Analysis; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Markov Chains; Models, Statistical; Ontario; Percutaneous Coronary Intervention; Quality-Adjusted Life Years; Risk Factors; Stroke; Warfarin | 2013 |
Placing a value on new technologies.
Topics: Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Occlusion; Dabigatran; Female; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Male; Percutaneous Coronary Intervention; Stroke; Transplantation; Warfarin | 2013 |
Dabigatran has the upper hand on warfarin.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Ischemia; Stroke; Thrombolytic Therapy | 2013 |
Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Brain Ischemia; Contraindications; Dabigatran; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Middle Aged; Partial Thromboplastin Time; Patient Selection; Predictive Value of Tests; Risk Assessment; Risk Factors; Stroke; Thrombin Time; Thrombolytic Therapy; Time Factors; Treatment Outcome | 2014 |
New oral anticoagulants in atrial fibrillation forever?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Stroke | 2013 |
Ischemic stroke in an obese patient receiving dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Middle Aged; Obesity; Proton Pump Inhibitors; Stroke | 2013 |
Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care.
Topics: Adult; Aged; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; California; Dabigatran; Female; Follow-Up Studies; Hospitals, Veterans; Humans; Male; Medication Adherence; Middle Aged; Pharmaceutical Services; Retrospective Studies; Stroke; Treatment Outcome | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Capsules; Chi-Square Distribution; Cross-Sectional Studies; Dabigatran; Dyspepsia; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Interviews as Topic; Male; Medication Adherence; Patient Education as Topic; Risk Factors; Stroke; Time Factors | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
[New oral anticoagulants in nonvalvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Pyrazoles; Pyridones; Stroke | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Endovascular thrombectomy for acute ischemic stroke patients anticoagulated with dabigatran.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Angiography; Dabigatran; Endovascular Procedures; Female; Heart Failure; Humans; Paresis; Stroke; Thrombectomy; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
[Differential therapy with the new anticoagulants, 5].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2013 |
New oral anticoagulants in heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Failure; Humans; Male; Stroke; Warfarin | 2013 |
Dabigatran - neurosurgical anathema?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assessment; Stroke; Thrombosis; Warfarin | 2013 |
Dabigatran and mechanical heart valves--not as easy as we hoped.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2013 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
[Ischemic stroke after cardioversion and atrial flutter ablation in a patient taking dabigatran].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Cerebral Arteries; Dabigatran; Echocardiography; Electric Countershock; Humans; Male; Stroke | 2013 |
Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Fatal Outcome; Hematoma; Humans; Male; Risk Factors; Stroke; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Female; Half-Life; Hemorrhage; Humans; Kidney Diseases; Male; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thromboembolism; Warfarin | 2013 |
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Stroke | 2014 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
Evaluation of dabigatran utilization and risk among hospitalized patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cross-Sectional Studies; Dabigatran; Drug Interactions; Female; Humans; Inpatients; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2014 |
Acute ischemic stroke following cardioversion in a patient receiving dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Humans; Male; Stroke | 2013 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, Animal; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Rats; Rats, Wistar; Stroke; Tissue Plasminogen Activator; Warfarin | 2014 |
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Comorbidity; Dabigatran; Drug Dosage Calculations; Drug Substitution; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Education as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Registries; Risk Factors; Socioeconomic Factors; Stroke; Time Factors; Treatment Outcome; United States | 2013 |
Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Stroke | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Stroke; Survival Analysis; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment | 2014 |
Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Brain Ischemia; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Partial Thromboplastin Time; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator | 2014 |
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
Impaired renal function and bleeding in elderly treated with dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Female; Hemorrhage; Humans; Kidney; Kidney Function Tests; Male; Renal Insufficiency; Stroke | 2014 |
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Substitution; Early Termination of Clinical Trials; Female; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Middle Aged; Mitral Valve; Myocardial Infarction; Off-Label Use; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Vitamin K | 2014 |
Recurrent ischemic stroke in a patient with the Trousseau syndrome treated with dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Male; Recurrence; Stroke | 2014 |
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cross-Sectional Studies; Dabigatran; Fibrinolytic Agents; Humans; Registries; Stroke; Treatment Outcome | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Markov Chains; Pyridines; Stroke; Taiwan; Warfarin | 2014 |
The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Budgets; Cardiac Catheterization; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Drug Costs; Germany; Humans; Models, Economic; Pyridines; Stroke; Time Factors; Treatment Outcome; Warfarin | 2014 |
Lessons from the RE-ALIGN trial.
Topics: Aged; Anticoagulants; Benzimidazoles; Bioprosthesis; Clinical Trials, Phase II as Topic; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial Infarction; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Risk; Stroke; Thromboembolism; Warfarin | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
A new class of powerful and informative simultaneous confidence intervals.
Topics: Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biostatistics; Confidence Intervals; Dabigatran; Data Interpretation, Statistical; Humans; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
Enterococcus faecalis bacteremia and mitral valve endocarditis under dabigatran for stroke prevention.
Topics: Aged; Bacteremia; Benzimidazoles; beta-Alanine; Dabigatran; Endocarditis; Enterococcus faecalis; Fatal Outcome; Female; Gram-Positive Bacterial Infections; Heart Valve Diseases; Humans; Mitral Valve; Stroke | 2014 |
[The mirages of the new oral anticoagulants].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Interactions; Humans; Male; Paresis; Pharmacy Service, Hospital; Pyridines; Stroke | 2014 |
[Chinese practical guide of dabigatran etexilate for stroke prevention in patients with non-valvular atrial fibrillation].
Topics: Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Practice Guidelines as Topic; Pyridines; Stroke | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Male; Middle Aged; Stroke; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Retrospective Studies; Risk Factors; Stroke; Treatment Outcome; United States; United States Department of Veterans Affairs | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Female; Humans; Insurance Claim Review; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Risk; Stroke; United States; Warfarin | 2014 |
Boehringer Ingelheim withheld safety analyses on new anticoagulant, The BMJ investigation finds.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Disclosure; Drug Administration Schedule; Drug Industry; Hemorrhage; Humans; Information Dissemination; Patient Safety; Pyridines; Stroke | 2014 |
Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2015 |
Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Hong Kong; Humans; Male; Middle Aged; Risk Factors; Stroke; Treatment Outcome | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Substitution; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; International Normalized Ratio; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Stroke; United States; United States Department of Veterans Affairs; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
Topics: Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Stroke | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Denmark; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Registries; Secondary Prevention; Stroke; Treatment Outcome; Warfarin | 2014 |
Cardioembolic stroke in a patient taking Dabigatran Etexilate: the first case report of clinical and pharmacologic resistance.
Topics: Aged; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Embolism; Pyridines; Stroke; Treatment Failure | 2014 |
Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Surgical Procedures; Comparative Effectiveness Research; Computer Simulation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Equipment Design; Female; Health Care Costs; Humans; Male; Markov Chains; Models, Economic; Models, Statistical; Probability; Quality-Adjusted Life Years; Stroke; Treatment Outcome; Uncertainty; Warfarin | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Male; Stroke; Tissue Plasminogen Activator | 2014 |
Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Additional events in the RE-LY trial.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clopidogrel; Comorbidity; Dabigatran; Electric Countershock; Humans; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Kidney Diseases; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; Socioeconomic Factors; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Safety of dabigatran in an elderly population: single center experience in Italy.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Fibrinolytic Agents; Heartburn; Hemorrhage; Humans; Italy; Male; Middle Aged; Patient Compliance; Prospective Studies; Registries; Risk Factors; Stroke; Thromboembolism | 2015 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Stroke; Warfarin | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; China; Cohort Studies; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Time Factors; Warfarin | 2015 |
Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Sex Factors; Stroke | 2015 |
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Models, Theoretical; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; United Kingdom; Warfarin | 2014 |
Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Databases, Factual; Decision Support Techniques; Female; Hemorrhage; Humans; Male; Managed Care Programs; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Stroke; United States | 2014 |
Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Dose-Response Relationship, Drug; Feeding Behavior; Female; Glomerular Filtration Rate; Humans; Male; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke | 2015 |
CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Topics: Adolescent; Adult; Aged; Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Risk Assessment; Risk Factors; Severity of Illness Index; Stroke; Young Adult | 2015 |
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Blood Loss, Surgical; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Perioperative Care; Postoperative Hemorrhage; Propensity Score; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Surgical Procedures, Operative; Time Factors; Treatment Outcome; Warfarin | 2015 |
[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Prothrombin; Reproducibility of Results; Risk Assessment; Russia; Stroke; Thromboembolism; Treatment Outcome | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2015 |
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin | 2015 |
Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Comorbidity; Dabigatran; Denmark; Drug Prescriptions; Female; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Registries; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Warfarin | 2014 |
Patterns of oral anticoagulants use in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Drug Substitution; Drug Utilization Review; Female; Hospitals, University; Humans; Male; Practice Patterns, Physicians'; Quebec; Retrospective Studies; Stroke; Time Factors; Treatment Outcome; Warfarin | 2015 |
Novel Oral Anticoagulants for DC Cardioversion Procedures: Utilization and Clinical Outcomes Compared with Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Defibrillators, Implantable; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Embolism; Female; Germany; Hemorrhage; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Registries; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2015 |
Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Myocardial Infarction; Propensity Score; Retrospective Studies; Stroke; United States; Warfarin | 2015 |
Ischemic stroke in patients on dabigatran: a role for rescue thrombectomy?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Thrombectomy; Thrombolytic Therapy | 2015 |
'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry.
Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Ischemic Attack, Transient; Male; Stroke | 2015 |
Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Decision Support Techniques; Embolism; Evidence-Based Medicine; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Stroke; Warfarin | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population.
Topics: Aged; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2016 |
[Prevention and emergency measures].
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2015 |
[Advantages of NOAKs validated in clinical routine].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; General Practice; Humans; Stroke | 2015 |
Time to reconsider dabigatran 110 mg in the USA.
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Humans; Stroke; United States; United States Food and Drug Administration | 2015 |
Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Health Status Disparities; Humans; Japan; Male; Middle Aged; Neoplasms; Outpatients; Severity of Illness Index; Stroke; Treatment Outcome; Ultrasonography; Venous Thrombosis | 2015 |
Matching on the disease risk score in comparative effectiveness research of new treatments.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Comparative Effectiveness Research; Computer Simulation; Dabigatran; Female; Humans; Male; Mortality; Pharmacoepidemiology; Propensity Score; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Patient Admission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2015 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Europe; Female; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Female; Humans; Male; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2015 |
Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Fibrinolytic Agents; Hemorrhage; Humans; Male; Markov Chains; Quality-Adjusted Life Years; Self Care; Stroke; Thrombosis; Vitamin K; Warfarin | 2015 |
Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Audit; Dabigatran; Drug Substitution; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2015 |
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Registries; Stroke; Treatment Outcome; Vitamin K | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Point-of-Care Testing; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2015 |
Reversible Cognitive Impairment Associated with the Use of Dabigatran.
Topics: Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Cognition; Cognitive Dysfunction; Dabigatran; Follow-Up Studies; Humans; Male; Recovery of Function; Stroke | 2015 |
[First NOAK antidote soon to be approved].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Atrial Fibrillation; Dabigatran; Drug Approval; Hemorrhage; Humans; Infusions, Intravenous; Stroke; Time Factors | 2015 |
Dabigatran Therapy in Acute Ischemic Stroke Patients Without Atrial Fibrillation.
Topics: Aged; Antithrombins; Brain Ischemia; Dabigatran; Feasibility Studies; Female; Humans; Male; Middle Aged; Stroke; Time Factors; Treatment Outcome | 2015 |
Effect of Renal Function on Anticoagulation Therapy in Asian Patients.
Topics: Creatinine; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Stroke; Warfarin | 2015 |
[New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Utilization; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombophilia; Urban Health Services | 2016 |
Dabigatran use in elderly patients with atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Databases, Factual; Drug Utilization Review; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Quebec; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2016 |
Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Brain Ischemia; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Myocardial Infarction; Patient Discharge; Prospective Studies; Stroke; Survival Analysis; Thrombosis | 2016 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Dabigatran; Dipyridamole; Female; Guideline Adherence; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Ticlopidine; Warfarin | 2015 |
Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Embolism; Greece; Health Care Costs; Humans; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Warfarin | 2015 |
Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; China; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Outcome Assessment, Health Care; Stroke; Warfarin | 2016 |
Intravenous thrombolysis in wake-up stroke in a 92-year-old patient under dabigatran.
Topics: Administration, Intravenous; Aged, 80 and over; Antithrombins; Cerebral Cortex; Dabigatran; Humans; Male; Stroke; Temporal Lobe | 2015 |
Clinical Features of Ischemic Stroke during Treatment with Dabigatran: An Association between Decreased Severity and a Favorable Prognosis.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Discharge; Prognosis; Retrospective Studies; Risk Factors; Stroke; Warfarin | 2015 |
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Disease-Free Survival; Drug Evaluation; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Insurance Coverage; Kaplan-Meier Estimate; Male; Middle Aged; Military Personnel; Mortality; Myocardial Infarction; Propensity Score; Proportional Hazards Models; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult | 2015 |
Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; Dabigatran; Databases, Factual; Drug Evaluation; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Insurance Coverage; Male; Middle Aged; Myocardial Infarction; Polypharmacy; Propensity Score; Retrospective Studies; Stroke; Thrombophilia; Treatment Outcome; Warfarin; Young Adult | 2015 |
Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Topics: Action Potentials; Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Electrophysiologic Techniques, Cardiac; Factor Xa Inhibitors; Female; Heart Rate; Humans; Male; Middle Aged; Phenprocoumon; Postoperative Complications; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2016 |
Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
Topics: Administration, Oral; Aged; Anticoagulants; Area Under Curve; Atrial Fibrillation; Brain Ischemia; Computer Simulation; Dabigatran; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Stroke; Vitamin K | 2016 |
Initial Experience With Novel Oral Anticoagulants During the First 45 Days After Left Atrial Appendage Closure With the Watchman Device.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Cardiac Surgical Procedures; Dabigatran; Echocardiography, Transesophageal; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thrombosis; Treatment Outcome | 2015 |
Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Canada; Dabigatran; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2015 |
Report questions FDA approval of controversial anticoagulant.
Topics: Anticoagulants; Dabigatran; Drug Approval; Hemorrhage; Humans; Product Surveillance, Postmarketing; Stroke; United States | 2015 |
Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Databases, Factual; Drug Prescriptions; Drug Utilization Review; Female; Health Knowledge, Attitudes, Practice; Healthcare Disparities; Hemorrhage; Humans; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Quebec; Risk Assessment; Risk Factors; Sex Factors; Stroke; Treatment Outcome; Warfarin | 2015 |
Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
Topics: Aged; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Middle Aged; Population Surveillance; Prevalence; Prospective Studies; Registries; Risk Factors; Stroke; Thromboembolism; Treatment Outcome | 2015 |
Emergency admissions for major haemorrhage associated with direct oral anticoagulants.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Gastrointestinal Hemorrhage; Hemodynamics; Hemorrhage; Hemostasis; Humans; Intracranial Hemorrhages; Male; Middle Aged; Patient Admission; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thrombosis | 2015 |
Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2015 |
Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardio-Renal Syndrome; Contraindications; Creatinine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism | 2016 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Portugal; Pyrazoles; Pyridones; Stroke; Warfarin | 2015 |
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Canada; Dabigatran; Female; Guidelines as Topic; Humans; Internship and Residency; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Surveys and Questionnaires; Treatment Outcome; Universities; Warfarin | 2016 |
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin; Young Adult | 2016 |
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Phenindione; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thromboembolism; Vitamin K; Warfarin | 2015 |
Novel oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cardiology; Dabigatran; Family; Humans; Professional-Patient Relations; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2015 |
Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Case-Control Studies; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Stroke; Taiwan; Warfarin | 2016 |
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2016 |
Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention.
Topics: Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Patient Compliance; Pyrazoles; Pyridones; Retrospective Studies; Stroke; Surveys and Questionnaires; Treatment Outcome; Warfarin | 2016 |
Dabigatran Plasma Levels in Acute Cerebrovascular Events.
Topics: Aged; Aged, 80 and over; Creatinine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Stroke | 2016 |
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Blood Coagulation; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Follow-Up Studies; Germany; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Retrospective Studies; Risk Reduction Behavior; Rivaroxaban; Stroke; Vitamin K | 2016 |
Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Disease-Free Survival; Drug Monitoring; Electronic Health Records; Female; Hemorrhage; Humans; Incidence; International Normalized Ratio; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Netherlands; Patient Safety; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2016 |
Uptake of novel oral anticoagulants in Australia.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Australia; Clinical Trials as Topic; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Veterans | 2016 |
[Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Costs; Humans; Morpholines; Portugal; Rivaroxaban; Stroke; Warfarin | 2016 |
[Anticoagulants after acute ischemic stroke with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Deglutition Disorders; Humans; Medical Records; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Time Factors; Time-to-Treatment; Treatment Outcome; Warfarin | 2016 |
Hemopericardium under dabigatran for stroke prevention in atrial fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Male; Stroke | 2017 |
[Dabigatran specific antidote: new safety level in oral anticoagulation].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Approval; Hemorrhage; Humans; Stroke | 2015 |
[First NOAK with specific antidote].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Infusions, Intravenous; Stroke | 2015 |
[First new oral anticoagulant with specific antidote].
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Cerebral Hemorrhage; Dabigatran; Humans; Infusions, Intravenous; Stroke | 2016 |
Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Health Expenditures; Humans; Insurance Benefits; Male; Medicare; Middle Aged; Rivaroxaban; Stroke; United States; Warfarin | 2016 |
[First NOAk specific antidote as additional safety factor in therapy].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Stroke | 2016 |
Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Propensity Score; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States | 2016 |
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Australia; Dabigatran; Drug Prescriptions; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Warfarin | 2016 |
Which oral anticoagulant for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Patient Selection; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
[Anticoagulation in low glomerular filtration rate].
Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Contraindications; Dabigatran; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Guideline Adherence; Humans; Kidney Failure, Chronic; Male; Stroke | 2016 |
A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Dyspepsia; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Registries; Stroke; Warfarin | 2016 |
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cost-Benefit Analysis; Dabigatran; Humans; Insurance, Health; Middle Aged; Models, Theoretical; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin | 2016 |
[Improving prevention and after-care].
Topics: Aftercare; Anticoagulants; Atrial Fibrillation; Dabigatran; Health Education; Humans; Recurrence; Stroke; Time Factors | 2016 |
Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT).
Topics: Adult; Antithrombins; Dabigatran; Epidemiologic Research Design; Female; Humans; Male; Middle Aged; Prospective Studies; Registries; Stroke; Turkey | 2016 |
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cause of Death; Dabigatran; DNA-Binding Proteins; Drosophila Proteins; Embolism; Female; Hemorrhage; Humans; Male; Medicaid; Middle Aged; Mortality; Registries; Rivaroxaban; Stroke; Transcription Factors; Treatment Outcome; United States; Warfarin | 2016 |
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood-Brain Barrier; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Inflammation; Male; Rats, Wistar; Stroke; Thrombin; Thrombosis | 2016 |
Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Dementia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab-A Case Report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Female; Humans; Stroke; Tomography Scanners, X-Ray Computed | 2016 |
Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke | 2016 |
Palmoplantar pustular eruption due to dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Biopsy; Dabigatran; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Eczema, Dyshidrotic; Female; Humans; Psoriasis; Skin; Skin Diseases, Eczematous; Stroke | 2016 |
Intracerebral Hematoma Occurring During Warfarin Versus Non-Vitamin K Antagonist Oral Anticoagulant Therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Brain; Case-Control Studies; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Female; Hematoma; Hospital Mortality; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Tomography, X-Ray Computed; Warfarin | 2016 |
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Israel; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2016 |
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Decision Trees; Female; Humans; Male; Markov Chains; Percutaneous Coronary Intervention; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Septal Occluder Device; Stroke; Survival Rate; Warfarin | 2016 |
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Denmark; Drug Administration Schedule; Embolism; Female; Hemorrhage; Humans; Male; Propensity Score; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2016 |
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Propensity Score; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin; Withholding Treatment | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Venous Thromboembolism | 2016 |
Association between Renal Function and Bleeding Risk for Dabigatran after Switching from Warfarin.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Retrospective Studies; Stroke | 2016 |
Dabigatran Versus Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Stroke; Warfarin | 2016 |
Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Partial Thromboplastin Time; Renal Insufficiency; Retrospective Studies; Risk Factors; Stroke; Thromboembolism | 2017 |
A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability.
Topics: Administration, Oral; Animals; Antithrombins; Biological Availability; Dabigatran; Emulsions; Excipients; Male; Particle Size; Pharmaceutical Vehicles; Phase Transition; Rats, Sprague-Dawley; Solubility; Stroke; Surface-Active Agents; Thromboembolism | 2016 |
Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Echocardiography, Transesophageal; Female; Heart Atria; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Regression Analysis; Retrospective Studies; Risk Factors; Severity of Illness Index; Stroke; Treatment Outcome; Warfarin | 2017 |
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin; Young Adult | 2016 |
Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Stroke; Taiwan; Warfarin | 2017 |
Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Malaysia; Male; Medication Adherence; Middle Aged; Risk Factors; Stroke | 2016 |
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Stroke; Warfarin | 2016 |
Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Creatinine; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prodrugs; Stroke | 2016 |
Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
Topics: Aged; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Denmark; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Registries; Stroke; Vitamin K | 2016 |
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles | 2016 |
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diabetes Mellitus; Female; Guideline Adherence; Heart Failure; Humans; Hypertension; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk; Risk Assessment; Stroke; Ticlopidine; United States; United States Department of Veterans Affairs; Warfarin | 2016 |
Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Insurance Claim Review; Male; Medicare Part D; Rivaroxaban; Stroke; United States | 2017 |
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thromboembolism; Warfarin | 2016 |
Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion.
Topics: Antithrombins; Brain Ischemia; Dabigatran; Humans; Stroke; Thrombectomy; Thrombolytic Therapy | 2017 |
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart Valve Diseases; Humans; Kaplan-Meier Estimate; Male; Medicare; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; United States | 2016 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Internet; Patient Education as Topic; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2016 |
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Denmark; Female; Hospitalization; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Vitamin K; Warfarin | 2017 |
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2017 |
Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.
Topics: Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Clinical Trials as Topic; Coagulants; Dabigatran; Female; Humans; Stroke; Thrombolytic Therapy | 2016 |
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Follow-Up Studies; Humans; Insurance Claim Review; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Stroke; United States | 2016 |
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Patient Readmission; Percutaneous Coronary Intervention; Postoperative Hemorrhage; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stents; Stroke; Thrombosis; Venous Thromboembolism; Warfarin | 2016 |
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pulmonary Veins; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2017 |
Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Bias; Cohort Studies; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Research Design; Stroke; Treatment Outcome; Warfarin; Young Adult | 2017 |
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
Topics: Acute Disease; Aged; Atrial Fibrillation; Coma; Dabigatran; Drug Overdose; Heart Failure; Hemodiafiltration; Hepatitis; Humans; Male; Renal Insufficiency, Chronic; Stroke | 2017 |
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Emergency Treatment; Female; Humans; Male; Medication Therapy Management; Outcome and Process Assessment, Health Care; Pyrazoles; Pyridines; Pyridones; Quality Improvement; Registries; Rivaroxaban; Stroke; Thiazoles; United States; Warfarin | 2016 |
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Propensity Score; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; United States | 2016 |
Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Taiwan; Warfarin | 2017 |
Risk of intraocular hemorrhage with new oral anticoagulants.
Topics: Anticoagulants; Dabigatran; Eye Hemorrhage; Humans; Ocular Hypertension; Odds Ratio; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2017 |
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult | 2017 |
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.
Topics: Administration, Oral; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Child; Child, Preschool; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Warfarin; World Health Organization; Young Adult | 2017 |
[Monitoring of NOAC].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Emergency Service, Hospital; Hemorrhage; Humans; Intensive Care Units; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thromboembolism; Vitamin K | 2017 |
Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Gastrointestinal Hemorrhage; Humans; Neoplasms; Stroke; Warfarin | 2017 |
Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Hospital Costs; Humans; Male; Medicare; Patient Admission; Rivaroxaban; Stroke; United States; Warfarin | 2017 |
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Hospital Mortality; Humans; International Normalized Ratio; Male; Pyrazoles; Pyridones; Recombinant Proteins; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Warfarin | 2017 |
Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Automation, Laboratory; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Female; Humans; Ischemic Attack, Transient; Male; Microfluidic Analytical Techniques; Microscopy, Fluorescence; Middle Aged; Phenprocoumon; Predictive Value of Tests; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Time Factors; Treatment Outcome; Whole Blood Coagulation Time | 2017 |
The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Health Behavior; Humans; International Normalized Ratio; Male; Middle Aged; Models, Econometric; Patient Compliance; Patient Satisfaction; Rivaroxaban; Russia; Stroke; Warfarin | 2017 |
Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Fatal Outcome; Humans; Male; Middle Aged; Stroke; Thrombolytic Therapy | 2017 |
Italian intersociety consensus on DOAC use in internal medicine.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism | 2017 |
Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Data Collection; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Observational Studies as Topic; Patient Selection; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke; Warfarin | 2017 |
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
Topics: Aged; Antithrombins; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Fibrinolytic Agents; Humans; Internationality; Male; Middle Aged; Prospective Studies; Registries; Stroke | 2017 |
Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Warfarin | 2017 |
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER
Topics: Adult; Aged; Clinical Trials as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Pulmonary Embolism; Stroke; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2017 |
Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update.
Topics: Administration, Intravenous; Antibodies, Monoclonal, Humanized; Dabigatran; Humans; Stroke; Thrombolytic Therapy | 2017 |
Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Erythrocyte Transfusion; Factor VIIa; Female; Hemorrhage; Hospital Mortality; Humans; Male; Medication Therapy Management; Ontario; Recombinant Proteins; Retrospective Studies; Stroke; Warfarin | 2017 |
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke; Warfarin | 2017 |
Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke; Warfarin | 2017 |
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Confidence Intervals; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Odds Ratio; Ontario; Risk Factors; Stroke | 2017 |
[Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Female; Humans; Male; Markov Chains; Pyrazoles; Pyridones; Rivaroxaban; Spain; Stroke; Vitamin K | 2017 |
Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Male; Ontario; Registries; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2017 |
[Real-world data on novel oral anticoagulants: the added value of registries and observational studies. Focus on apixaban].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Observational Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Registries; Rivaroxaban; Stroke | 2016 |
NOACs for Stroke Prevention in Atrial Fibrillation With Valve Disease: Filling the Gaps.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Heart Valve Diseases; Humans; Rivaroxaban; Stroke | 2017 |
[Anticoagulation in atrial fibrillation].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Female; Humans; Middle Aged; Pyridines; Risk Factors; Stroke; Vitamin K | 2008 |
Can we rely on RE-LY?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke; Warfarin | 2009 |
[Anticoagulation in atrial fibrillation. Stroke can be prevented this way].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; International Normalized Ratio; Intracranial Embolism; Pyridines; Stroke; Vitamin K | 2009 |
[Stroke prevention in atrial fibrillation. Marcumar alternative in sight].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Phenprocoumon; Pyridines; Randomized Controlled Trials as Topic; Stroke; Vitamin K | 2009 |
The year in stroke.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Humans; Pyridines; Societies; Stockings, Compression; Stroke | 2009 |
Atrial fibrillation: A promising new anticoagulant for stroke prevention.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Intracranial Hemorrhages; Pyridines; Risk Factors; Stroke; Warfarin | 2010 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Ireland; Pyridines; Stroke; Warfarin | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Hemorrhage; Humans; Incidence; International Normalized Ratio; Pyridines; Stroke; Warfarin | 2009 |
Does dabigatran improve stroke prevention in atrial fibrillation? A rebuttal.
Topics: Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke | 2010 |
Dabigatran and stroke thrombolysis.
Topics: Acute Disease; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Contraindications; Dabigatran; Drug Administration Schedule; Drug Monitoring; Humans; Pyridines; Risk Assessment; Stroke; Thrombolytic Therapy | 2010 |
Dabigatran etexilate in people with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Stroke | 2010 |
Quality of anticoagulation control in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Multicenter Studies as Topic; Pyridines; Quality of Health Care; Randomized Controlled Trials as Topic; Stroke; Thromboembolism; Treatment Outcome; Warfarin | 2010 |
Will symptomatic intracerebral hemorrhages decrease among eligible dabigatran-treated patients who receive intravenous tissue plasminogen activator for acute ischemic stroke?
Topics: Benzimidazoles; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Humans; Pyridines; Stroke; Tissue Plasminogen Activator | 2010 |
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Middle Aged; Recombinant Proteins; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2010 |
Dabigatran v warfarin. Compare with higher standard.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Pyridines; Stroke; Warfarin | 2010 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Stroke; Warfarin | 2011 |
Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk.
Topics: Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Pyridines; Stroke | 2010 |
First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Monitoring; Embolism; Humans; International Normalized Ratio; Pyridines; Stroke; Thrombin | 2010 |
Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.
Topics: Administration, Oral; Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Vitamin K; Warfarin | 2010 |
Warfarin: is the end nigh? Please?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Warfarin | 2010 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2011 |
Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Interactions; Economics, Pharmaceutical; Embolism; Humans; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Stroke | 2011 |
Anticoagulation: improve care quality or use new alternatives?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Pharmaceutical Services; Pharmacogenetics; Pyridines; Quality Assurance, Health Care; Stroke; Warfarin | 2011 |
[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Risk Assessment; Stroke; Vitamin K | 2011 |
Next generation anticoagulants may push warfarin to the wayside.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Evaluation; Humans; Medication Adherence; Stroke; Warfarin | 2011 |
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; Canada; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Embolism, Air; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Markov Chains; Pyridines; Quality-Adjusted Life Years; Stroke; Warfarin | 2011 |
Place of dabigatran in contemporary pharmacotherapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism | 2011 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Embolism; Hemorrhage; Humans; Stroke; Therapeutic Equivalency; United States; United States Food and Drug Administration; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
Topics: Aged; Antithrombins; Aphasia; Benzimidazoles; beta-Alanine; Carotid Artery Diseases; Dabigatran; Female; Fracture Fixation; Hemiplegia; Hemorrhage; Humans; Ischemia; Postoperative Complications; Practice Guidelines as Topic; Prosthesis Failure; Risk; Stroke; Thrombolytic Therapy; Thrombosis | 2011 |
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Heart Rate; Humans; Stroke | 2011 |
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Decision Trees; Hemorrhage; Humans; Markov Chains; Risk Factors; Stroke; Warfarin | 2011 |
Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabigatran; Humans; Male; Recurrence; Stroke; Ultrasonography; Warfarin | 2012 |
Atrial fibrillation: outpatient presentation and management.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Electrocardiography; Heart Rate; Humans; Male; Outpatients; Stroke; Treatment Outcome | 2011 |
The use of dabigatran in elderly patients.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Device Removal; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Pyridines; Shock, Hemorrhagic; Stroke | 2011 |
New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients".
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Hemorrhage; Humans; International Normalized Ratio; Pyridines; Risk Factors; Stroke | 2011 |
Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Embolism; Humans; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
The future of anticoagulant therapy.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Drug Approval; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Stroke; Warfarin | 2011 |
Dabigatran: will it change clinical practice?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Stroke; United States; Warfarin | 2011 |
Update on dabigatran for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2011 |
Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Fibrinolytic Agents; Humans; Injections, Intravenous; Risk Factors; Stroke; Tissue Plasminogen Activator | 2012 |
Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.
Topics: Aged; Automation; Benzimidazoles; beta-Alanine; Biomarkers; Brain Ischemia; Calibration; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Radiography; Stroke; Thrombin | 2012 |
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Stroke; Warfarin | 2011 |
Dabigatran: a new oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Thromboembolism | 2011 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2012 |
Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Cerebrovascular Circulation; Dabigatran; Electric Countershock; Fatal Outcome; Fibrinolytic Agents; Humans; Male; Middle Aged; Stroke; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2011 |
Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs.
Topics: Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Fibrinolytic Agents; Humans; Male; Stroke; Tissue Plasminogen Activator | 2011 |
Using dabigatran in patients with stroke: a practical guide for clinicians.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2012 |
Bleeding with dabigatran (Pradaxa).
Topics: Antithrombins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Hemorrhage; Humans; Pyridines; Renal Insufficiency; Stroke | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
What are the emerging therapeutic alternatives to warfarin in stroke patients? How would the results of RE-LY benefit Pakistanis?
Topics: Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Embolism; Evidence-Based Medicine; Humans; International Normalized Ratio; Pakistan; Pyridines; Stroke; Treatment Outcome; Warfarin | 2011 |
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Dabigatran; Drug Administration Schedule; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Thrombin | 2012 |
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Thrombin; Warfarin | 2012 |
Anticoagulant loses its lustre.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Stroke | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Costs; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Markov Chains; Models, Statistical; Monte Carlo Method; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electric Countershock; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Risk Factors; Societies, Medical; Stroke; Ticlopidine; Vitamin K | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Humans; Intracranial Hemorrhages; Patient Safety; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Electrocardiography; Embolism; Female; Follow-Up Studies; Heart Rate; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome; Warfarin | 2012 |
[Controversy. Dabigatran in the preventive treatment of embolic stroke: arguments in favour of its utilisation as a first-choice drug].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial Embolism; Stroke | 2012 |
[Controversy. Dabigatran in the preventive treatment of embolic stroke: arguments against its utilisation as a first-choice drug].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intracranial Embolism; Stroke | 2012 |
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; International Normalized Ratio; Male; Middle Aged; Prospective Studies; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2012 |
Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Denmark; Female; Humans; Male; Models, Theoretical; Myocardial Infarction; Pyridines; Risk Assessment; Stroke; Warfarin | 2012 |
NICE backs new oral anticoagulant for stroke prevention.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Approval; Drug Monitoring; Embolism; Humans; Prodrugs; Pyridines; Stroke | 2012 |
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Topics: Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Humans; Pyridines; Stroke; Thrombin Time | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Drug Interactions; Fibrinolytic Agents; Mice; Mice, Inbred C57BL; Stroke; Tissue Plasminogen Activator; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
Anti-stroke prophylaxis--the ethics of collateral damage.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Ethics, Medical; Humans; Male; Pyridines; Stroke | 2012 |
Avoiding adverse events with dabigatran by careful selection of eligible patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Hemorrhage; Humans; Patient Selection; Stroke; Warfarin | 2012 |
New medicines - urgent need to assess outcomes in special groups.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2012 |
Endovascular therapy after stroke in a patient treated with dabigatran.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheterization; Cerebral Angiography; Dabigatran; Endovascular Procedures; Female; Humans; Middle Cerebral Artery; Stroke; Tomography, X-Ray Computed | 2012 |
Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke | 2012 |
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Assessment; Stroke; Thrombin; United States; United States Food and Drug Administration | 2012 |
An anticoagulation option for nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Humans; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Stroke; Warfarin | 2012 |
Oral anticoagulants for atrial fibrillation: Which one to choose?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Prevention of stroke in atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Heart Rate; Humans; International Normalized Ratio; Intracranial Embolism; Myocardial Contraction; Risk Factors; Stroke; Thrombophilia | 2012 |
Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Prospective Studies; Stroke; Thromboembolism; Warfarin | 2012 |
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Guideline Adherence; Hemorrhage; Humans; Patient Selection; Practice Guidelines as Topic; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Dabigatran for stroke prevention in atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Stroke; Thrombosis; Treatment Outcome | 2012 |
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Genotype; Humans; Stroke; Warfarin | 2012 |
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Prescribing trends for dabigatran etexilate in primary care.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Ireland; Male; Off-Label Use; Postoperative Complications; Practice Patterns, Physicians'; Primary Health Care; Retrospective Studies; Stroke; Venous Thromboembolism | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Survival Rate; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Stroke; Treatment Outcome; Warfarin | 2012 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
Danger ahead: watch out for indirect comparisons!
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Male; Mice; Pyridines; Stroke; Treatment Outcome | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Spain; Stroke; Vitamin K; Warfarin | 2012 |
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2011 |
Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report.
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Brain; Dabigatran; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2012 |
Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Ischemic Attack, Transient; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests.
Topics: Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Colorimetry; Dabigatran; Factor XIII; Humans; Partial Thromboplastin Time; Prothrombin; Prothrombin Time; Pyridines; Stroke; Venous Thromboembolism | 2012 |
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hong Kong; Humans; Male; Quality of Life; Retrospective Studies; Stroke; Warfarin | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Dabigatran: beyond the RE-LY study].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Venous Thromboembolism; Warfarin | 2012 |
[Scope of the latest RE-LY substudies: clinical implications].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
[Dabigatran: transforming the management of oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Venous Thromboembolism | 2012 |
Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Blood Coagulation; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Intracranial Embolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Phenprocoumon; Pyridines; Risk Factors; Stroke; Time Factors | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Periprocedural management and approach to bleeding in patients taking dabigatran.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Half-Life; Hematemesis; Humans; Male; Melena; Plasma; Risk Factors; Stroke; Time Factors; Withholding Treatment | 2012 |
New oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Public health. Change of heart.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Humans; Public Health; State Medicine; Stroke; United Kingdom | 2012 |
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Europe; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Patient Selection; Preventive Health Services; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
South Africa enters a new era in stroke prevention.
Topics: Adult; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Dabigatran; Humans; Pyridines; South Africa; Stroke | 2012 |
Benefits of dabigatran maintained for more than two years.
Topics: American Heart Association; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain; Clinical Trials as Topic; Dabigatran; Humans; Risk Assessment; South Africa; Stroke; Time Factors; United States | 2012 |
Do ingredients make the difference?: finding the best cocktail of an anticoagulant with antiplatelets.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Embolism; Female; Humans; Male; Platelet Aggregation Inhibitors; Pyridines; Stroke; Warfarin | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clopidogrel; Dabigatran; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Thromboembolism; Ticlopidine; Warfarin | 2012 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland.
Topics: Aged; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Male; Markov Chains; Middle Aged; Models, Econometric; Quality of Life; Quality-Adjusted Life Years; Stroke; Switzerland; Vitamin K | 2013 |
Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Care Surveys; Humans; Internet; Intracranial Hemorrhages; Partial Thromboplastin Time; Physicians; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; United States | 2013 |
Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
Topics: Adult; Aged; Atrial Fibrillation; Belgium; Benzimidazoles; Confidence Intervals; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Middle Aged; Pyridines; Quality-Adjusted Life Years; Stroke | 2013 |
Australian MPs demand more data on dabigatran for atrial fibrillation.
Topics: Antithrombins; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; National Health Programs; Stroke | 2013 |
Thrombolysis in ischemic stroke patients on treatment with Dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Humans; Stroke; Thrombolytic Therapy | 2013 |
Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention.
Topics: Aged; Aged, 80 and over; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Cross-Sectional Studies; Dabigatran; Female; Humans; Kidney; Male; Middle Aged; Pyridines; Retrospective Studies; Stroke | 2013 |
[Percutaneous left atrial appendage closure after resolution of left atrial appendage thrombi with dabigatran].
Topics: Anticoagulants; Antithrombins; Atherectomy; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Echocardiography, Transesophageal; Female; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Obesity, Morbid; Risk Factors; Stroke; Thrombosis; Treatment Outcome | 2013 |
[Update in hospital internal medicine (2007): a selection].
Topics: Anti-Bacterial Agents; Anticoagulants; Benzimidazoles; Bone Density Conservation Agents; Community-Acquired Infections; Coronary Disease; Dabigatran; Defibrillators, Implantable; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Heart Neoplasms; Hip Prosthesis; Hospital Departments; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Internal Medicine; Liver Cirrhosis; Oligosaccharides; Osteoporosis; Peritonitis; Pneumonia, Bacterial; Pulmonary Embolism; Pyridines; Quality of Health Care; Risk Factors; Stroke; Teaching; Tomography, X-Ray Computed; Venous Thrombosis | 2008 |